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Inflammatory Bowel Disease (IBD) is associated with high rates of co morbid depression and 
anxiety. Corticosteroids, used commonly in IBD, are known to cause psychiatric side-effects. 
Recent studies show that depression is also associated with raised CRP and IL6. This thesis 
aims to evaluate which demographic, clinical, medication and immunological factors are 
predictors of anxiety and depression in IBD. 
The IBD, Steroids and Affective Disorder (ISA) study is a cross-sectional study of 578 IBD 
patients in Edinburgh, UK. Subjects underwent assessment including Hospital Anxiety 
Depression Scale (HADS) past psychiatric history, steroid medication history, Colitis activity 
Index (CAI) and Harvey Bradshaw Index (HBI), inflammatory markers including CRP, ESR and 
White Cell Count, the Medication Adherence Rating Scale (MARS) and Altman Self Rated 
Mania Scale (ARSM) as well as sociodemographic profile and a past history of IBD phenotype 
progression and past surgical history. 
326 patients with Crohn’s Disease and 256 with Ulcerative Colitis (72% of clinic attendees) 
were recruited. 251 (43%) patients scored 12 or above on the HADS questionnaire. 45% of 
patients had previously suffered from affective illness. Univariate predictors of affective 
disorder in IBD included female gender, unemployment, being on incapacity benefit, (all 
p<0.0001), having bowel resections (p=0.032), having oral disease (p=0.03), being diagnosed 
before age 18 (p=0.001), CAI and HBI scores (p<0.0001) and being on corticosteroid 
medication (p=0.026). Inflammatory markers were not predictive of affective disorder. 
Multivariate independent predictors were female gender, unemployment, incapacity 
benefit status, HBI, CAI and having been on corticosteroids. Subjects with Anxiety had low 
adherence scores. 
Affective illness remains common in IBD and undertreated. High risk groups can be targeted 
for screening and treatment and consideration should be given to patients on long term 
corticosteroids. Improved integrated care models may improve comorbid physical and 










The Inflammatory Bowel Disease, Steroids and Affective Disorder (ISA) study is a cross 
sectional study which looks at the relationships between the Inflammatory Bowel Diseases; 
Crohn’s Disease and Ulcerative Colitis and the Affective Disorders; Depression and Anxiety. 
The central questions in this thesis relate to which social, disease and medication factors 
(with an emphasis on corticosteroids) may predict Depression and Anxiety in this group. 
 
Inflammatory bowel diseases are severe lifelong diseases of the gut. Their age of onset may 
be as young as childhood but usually they occur in young adulthood. Due to the 
improvements in managing these conditions over the last century, they are rarely terminal 
illnesses and patients may have a normal life expectancy albeit subject to numerous periods 
of disease relapse. The main clinical features of these illnesses include severe inflammation 
of the gastrointestinal tract which leads to severe abdominal pain, diorama, rectal bleeding, 
increased bowel frequency and urgency. Presently there exist several medical and surgical 
interventions for IBD. Medical treatments primarily serve to reduce inflammation. Surgical 
interventions include bowel resection and the installation of stoma bags. One of the most 
common pharmacological treatments are corticosteroids which are the mainstay in acute 
relapse of the condition, but which may present with several side effects when used in the 
long term. 
 
Corticosteroid medications have been used in several inflammatory conditions since their 
discovery in the 1950s. These include asthma, COPD, eczema, arthritis and SLE. Due to their 
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frequency of use, a considerable literature exists documenting the side effects of these 
medications. One such side effect which has been noted is the often-sudden change in 
mental state such as a change in mood or evidence of psychotic symptoms or delirium. 
Much of the existing literature in this area suggests that this relates to a high dose of these 
medications.  
However, since corticosteroids are only prescribed to patients experiencing severe physical 
illness, it has thus far not been shown that low mood occurring in such patient groups can 
be accounted for by the corticosteroid and not by the effects of the physical illness. 
 
Inflammatory Bowel Diseases have been long shown to correlate with high levels of 
psychiatric illness. Up to 50% of patients experiencing a relapse have been noted to have 
clinical levels of anxiety or depression. This relationship has been shown in studies since the 
1920s where it was initially believed that Ulcerative colitis was itself a psychiatric condition 
which could be treated with psychoanalysis. While this idea is no longer supported, there 
remains a question about just why the levels of psychiatric illness are so high in IBD. While in 
all physical illnesses, levels of concurrent depression are high, IBD appears particularly so 
and furthermore there exists some evidence that a psychiatric illness or life stress may 
precipitate relapses of IBD. 
 
A more recent line of enquiry has related to the immunological dysfunction seen in patients 
with depression. Cytokines such as TNF alpha, IL2, IL6 and IL10 have been shown to be 
abnormal in patients with clinical depression who do not have any notable inflammatory 




Bringing these ideas together, there exists a complicated relationship between IBD, 
Affective Disorders and corticosteroid medication. Could the high levels of depression in IBD 
relate to having chronic illness; particularly a lifelong experience of pain, diarrhoea, hospital 
admissions and surgery? Could the high level of depression relate to the coincidental 
cytokine disturbance seen in both IBD and depression? Could the high level of depression be 
accounted for using corticosteroids for the treatment in IBD? 
 
Indeed, all these hypotheses are possible and, as will be seen, all may contribute to the 
presence of depression and anxiety. While much literature has been dedicated to the area 
of comorbid medical and psychiatric illness, the cohort in this thesis has been studied over 
time and thus a prospective as well as cross sectional analysis will be performed. Data from 
this study will include sociodemographic, symptom, inflammation, medication and 
psychiatric indices which extends the existing literature. 
 
This thesis is structured commencing with a narrative review about the mental disorder 
associated with corticosteroids. This will be followed by a review of IBD, its relationship with 
depression and how this has progressed historically. There will be a background account of 
Affective Disorders and discussion on their association with other physical illnesses, 
including new findings in psychoimmunology. Patients with Coeliac disease are used as a 
control group in this thesis and there will be a brief outline of this. Adherence to medication 
in this population will be studied as a separate study and act as a stand-alone chapter. 
 
Results are divided into social, disease, medication and psychiatric descriptions of the 
cohort and then univariate analysis was conducted on which of these factors predict 
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affective disorders. Finally, multivariate models were constructed to consider which factors 
acted independently.  
 
The ISA study has only been possible due to the considerable work undertaken by the 
Gastroenterology Department, University of Edinburgh and the subjects have been 














2.0 Corticosteroids and Mental Disorder 
 
 
The following chapter explores the evidence for Corticosteroid induced psychiatric illness. 
Corticosteroid medication is an essential treatment in almost all medical specialties. 
Psychiatric side effects of corticosteroids may be both common and severe and include 
psychosis, mania, depression, delirium and dependence. Only a small evidence base exists 
about susceptibility to and epidemiology of these conditions. Corticosteroid induced 
psychiatric disorder typically has an acute onset and is dose related. Manic symptoms 
predominate acutely however long-term use may be associated with depression. Steroid 
dependence and withdrawal syndromes have been documented. Case reports suggest that 
a combination of mood stabilizers and antipsychotics may be useful in management severe 















Corticosteroids were first introduced into medical practice in the late 1940s, since when 
they have been used by almost all medical specialists as effective treatment for 
autoimmune and inflammatory conditions. Over 5 million prescriptions are written for 
corticosteroids in the UK each year, at a cost of over £100 million. (1) About 1% of the 
general population and as many as 7% of hospitalized patients are receiving oral 
corticosteroid therapy at any given point in time. (1)  
 
In a community-based study published in 1996, 303 (0.5%) out of 65 786 patients received 
long-term systemic Glucocorticoids. (2) The most recent study looking at the prevalence of 
glucocorticoid prescription used The Health Improvement 
Network (THIN), a database of electronic medical records from 429 general practices (GPs) 
including 4 518 753 adult patients across the UK, which showed that an average of 0.75% 
(95% CI 0.74, 0.75) of the population was prescribed long-term oral Glucocorticoid therapy 
at any time point. (3) 
 
Importantly, over the past 20 years, long-term oral Glucocorticoid prescriptions have 
increased by 34%. (3)  
 
Whilst being renowned for important therapeutic actions they can have many adverse 
effects which must be considered in long term treatment. Physical effects such as 
osteoporosis, central obesity and immunosuppression are frequent in patients receiving 
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corticosteroids. Psychiatric effects include alterations in mood, delirium, dementia and 
psychosis.  As corticosteroids have a critical place in the management of chronic disease, 
psychiatrists should be equipped with the knowledge to recognize and manage 
corticosteroid induced mental disorder. This chapter describes the epidemiology, clinical 
presentation and management of these conditions. 
 
 
2.2 Indications and Pharmacology  
 
There are several forms of corticosteroid medication licensed in the UK, including: 
betamethasone, cortisone acetate, deflazacort, hydrocortisone, methylprednisolone 
(prednisolone) and triamcinolone. Each of these drugs has varying degrees of 
mineralocorticoid and glucocorticoid activity. All the above preparations exist in oral or 
intramuscular form. Inhaled steroid preparations will not be discussed as there is little 
evidence that they can induce mental disorder. In a study of 4 518 753 UK adult patients 
Prednisolone was the most frequently prescribed (92.3% of long-term prescriptions) 
followed by dexamethasone (3.5%), hydrocortisone (3.3%), betamethasone (0.5%) and 
prednisone (0.2%). The median daily dosage of prednisolone equivalent over the follow-up 
was 7.5 (5.0-11.3) mg and the median duration was 215 (126-490) days [vs, respectively, 30 
(15-39) mg and 9 (6-10) days for treatments 43 months]. (3) 
 
The main indications for these medications are:  
• Suppression of inflammatory and allergic bowel disease;  
• chronic or treatment resistant Asthma and COPD;  
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• Immunosuppression in Acute Lymphoblastic Leukemia, Hodgkin’s and non-Hodgkin’s 
disease, and Hormone sensitive breast cancer;  
• Palliation of symptomatic end-stage malignant disease;  
• Organ transplant rejection;  
• Auto-immune (Rheumatic) disease such as Systemic Lupus Erythematosus and 
Wegners Granulomatosis.  
 
Corticosteroids are rapidly absorbed across the gastro intestinal membrane following oral 
administration. Peak effects can be observed after 2 hours. The circulating drugs bind 
extensively to the plasma proteins Corticosteroid Binding Globulin (CBG), albumin and 
transcortin, with only the unbound portion of a dose active. Systemic prednisolone is quickly 
distributed into the kidneys, intestines, skin, liver and muscle. Corticosteroids also distribute 
into the breast milk and cross the placenta. Corticosteroids are predominantly metabolized 
by the liver to active metabolites then further metabolized to inactive compounds. These 
inactive metabolites, as well as a small portion of unchanged drug, undergo urinary 
excretion. The plasma elimination half-life is 1 hour whereas the biological half-life of 
prednisone is 18—36 hours. 
 
Corticosteroids act as glucocorticoid receptor agonists. On binding, the corticoreceptor-
ligand complex translocates itself into the cell nucleus, where it binds to Glucocorticoid 
Response Elements (GRE) in the promoter region of target genes. 
 
The DNA bound receptor then interacts with basic transcription factors, altering gene 
expression. There are high concentrations of CBG in specific brain areas such as the 
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hippocampus and pre-frontal cortex and these can therefore be thought of as a potential 
mediator of corticosteroid induced psychiatric disorder.  
 
2.3 Chronic disease and corticosteroids 
 
In parallel to the psychiatric side effects of corticosteroid therapy, most chronic medical 
conditions may be associated with considerable psychiatric morbidity. (5) A primary 
objective of the psychiatrist is to distinguish between the psychiatric effects of chronic 
illness and corticosteroids.  The 1-year prevalence for ICD-10 depressive episode alone is 
3·2% (95% CI 3·0–3·5) and an average of between about 9% and 23% of patients with one or 
more chronic physical diseases have co-morbid depression. In an international meta-
analysis, patients with a variety of chronic physical diseases and co-morbid depression had 
significantly worse health scores than those with chronic disease alone. (5) There are many 
potential reasons for this, including physical symptoms such as pain and secondary disability 
leading to loss of function.  
 
Studies of depression amongst the medically ill almost always fail however to account for 
possible corticosteroid effects. In patients with severe COPD given 30 mg of prednisolone 
for 14 days, when lung spirometry and mood state were measured, no changes in 
spirometry were detected until 7 days of active therapy. However, small but significant 
reductions in anxiety and depression were measured after 3 days of prednisolone and 
before any measurable improvement in lung function. This single study is an important part 
of a small evidence base suggesting that corticosteroids produce a mild sense of wellbeing 




2.4 Classification, Epidemiology and Clinical Features 
 
Psychiatric side effects were first described and classified by Rome and Braceland in 1952 
shortly after the initial introduction of corticosteroids into the pharmacopoeia. As can be 
noted in Table 1, the descriptions of symptoms in 1952 have an implicit hierarchy which 
places psychosis above “ego” disturbance of a neurotic nature and places these above 
euphoria. (7) 
 
Table 1: Clinical Classification of Psychological Response to Steroids  
Grade  Definition 
1 Mild euphoria, lessened fatigue, improved sensation, increased sense of 
intellectual capacity. 
2 Heightened euphoria. Patients are effusive, expansive, volatile, hypomanic, 
exhibit flight of ideas, impaired judgment, and refractory insomnia. 
3 Difference responses to reflecting the ego characteristics of the patient, such as 
anxiety, phobia, rumination, obsessional preoccupation, hypomania, or 
depression. 









The proportion of patients developing psychiatric symptoms during corticosteroid therapy 
has been reported to range from 3 to 75 percent, with a weighted average of about 28 
percent. (8) Amongst the larger studies, the Boston Collaborative Drug Surveillance Program 
(9) monitored 718 hospitalized medical patients who received prednisolone, of whom just 
21 (3%) had acute psychiatric reactions: in 6 of 463 (1%) patients receiving 40mg 
prednisolone, 8 of 175 (5%) patients receiving 41-80mg and 7 of those receiving above 
80mg (18%).  The dose-response trend was significant, but the study was conducted in 1972 
and deals with relatively small numbers of affected subjects who underwent only a basic 
psychiatric screening. Lewis and Smith reported a weighted average 5.7% incidence of 
severe psychiatric symptoms across 13 studies involving 2555 patients treated with steroids. 
A review of psychiatric symptoms in cancer patients treated with high-dose corticosteroids 
noted a 5–10% incidence. (10) Nishimura et al. reviewing treatment episodes in 135 patients 
with SLE but without overt central nervous system manifestations, observed 14 cases 
(10.1%) of new-onset DSM-IV disorders, primarily manic episodes (n = 9, 6.5%). (11) A 
review by Sirois reporting on DSM-IV steroid ‘psychosis’, found a syndromal breakdown of 
35% mania, 28% depression, 12% mixed mania and depression. (12) Recent studies have 
suggested, however, that the risk of depression increases with prolonged or chronic 
exposure. Gift et al. found significantly greater self-reported depression scores in 20 
patients with chronic obstructive pulmonary disease receiving 20–40 mg/day of prednisone 




In terms of speed of onset, symptoms appear to develop rapidly. In groups of both patients 
and healthy subjects, psychiatric symptoms occurred between 3 days and one week. (8, 14, 
15, 16) Evidence shows that significantly more women than men (P =0.009) develop 
psychiatric symptoms as a function of corticosteroid treatment. (17) 
Prednisolone is the medication most cited to cause psychiatric side effects. In case reports 
prednisolone was responsible for 37 cases, followed by methylprednisolone, 
dexamethasone betamethasone, and hydrocortisone. (8) When dose equivalences were 
calculated, ranging from 5 to 200mg prednisolone per day, a mean dose of 58.3mg per day 
or more was cited as substantially raising the risk of a psychiatric reaction. This does not 
mean that psychiatric reactions only occur at higher dosages.  
In a population study based on GP records one study identified 109 incident cases of suicide 
or suicide attempt and 10,220 incident cases of severe neuropsychiatric disorders in a 
population of 372,696 patients. The incidence of any of these outcomes was 22.2 per 100 
person-years at risk for first-course treatments. Compared to people with the same 
underlying medical disease who were not treated with glucocorticoids, the hazard ratio for 
suicide or suicide attempt in exposed patients was 6.89 (95% CI=4.52–10.50); for 
depression, 1.83 (95% CI=1.72–1.94); for mania, 4.35 (95% CI=3.67–5.16); for delirium, 
confusion, or disorientation, 5.14 (95% CI=4.54–5.82); and for panic disorder, 1.45 (95% 
CI=1.15–1.85). (3) 
 
In this study it was found that older men were at higher risk of 
delirium/confusion/disorientation and mania, while younger patients were at higher risk of 
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suicide or suicide attempt. Patients with a previous history of neuropsychiatric disorders 
and those treated with higher dosages of glucocorticoids were at greater risk of 
neuropsychiatric outcomes. (3) 
 
While dosage is not related to the risk of developing mental disturbances, neither dosage 
nor duration of treatment seem to impact upon the time of onset, duration, severity, or 
type of mental disturbances and it is unclear whether patients with a history of psychiatric 




2.6 Affective Symptoms 
 
The most common psychiatric reaction during glucocorticoid therapy is mood change, which 
accounts for almost 90 percent of the psychiatric reactions (14, 10) In a review of 56 case 
studies of psychiatric reactions to steroids, of those reporting mood symptoms (45 cases), 
mania was observed in 48%, depression in 25%, and a mixed state in 9%. (4) 
 
Reversible mood change can be seen in healthy control subjects after administration of 
prednisone and dexamethasone.  One study showed that 8/12 healthy controls experienced 
this, with manic symptoms predominating. (20) A further study which looked at 
methylprednisone in ophthalmology patients, all of whom were free of psychiatric disorder, 
found that 36% developed mania or depression during high dose steroid treatment. (16)  
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Studies examining the consequences of low dose steroid treatment have found little or no 
affective symptomatology (6).  
 
 
Regarding steroid induced mania, patients typically report sudden euphoric mood, excessive 
energy, indefatigability and some grandiosity. In addition to the rapid development of mood 
symptoms, suicidality can be associated with steroid treatment. (19). In addition to mood 
symptoms patients have been reported to experience sleep disturbances and weight gain. 
 
2.7 Recurrent affective disorder 
 
A further important consideration is whether any such affective disturbance involves one 
isolated episode or leads on to recurrent disorder. Nine patients whose initial clinical 
presentation met DSM-IV criteria for a steroid-induced mood disorder were shown in the 
long term to have a clinical course of bipolar disorder. (21) Seven patients initially developed 
a manic or hypomanic state with sub-acute onset ranging from 1 to 3 months and six 
patients had manic episodes accompanied by psychotic features. The proportion of manic 
episodes relative to total mood episodes of the 9 patients was 66%, suggesting manic 
predominance. Seven patients had future mood episodes that had no direct relationship to 
corticosteroid therapy and were preceded by various psychosocial stressors. Four of 5 
patients who received future steroids rapidly became manic or hypomanic. Recurrent cases 
of corticosteroid-induced mood disorder therefore appear to have clinical features such as 
sub-acute onset, frequent accompanying psychotic features, and similar recurrent episodes 




2.8 Psychotic Symptoms 
 
In a review of 55 case reports of steroid induced psychiatric disorder, 58% of cases 
demonstrated psychotic symptoms. (18) In 72% of the cases with psychotic symptoms, they 
were combined with an affective disorder. Similarly, in a review of 79 case reports there was 
a 71% incidence of psychotic symptoms with affective symptoms reported in over 75% of 
these. Hallucinations occurred in 58% of the cases and delusions in 74%. (8) 
 
In a more recent review of 56 case reports, psychotic symptoms were reported in 65% of 
cases. In eight of these, the development of psychotic symptoms was more clearly 
associated with the withdrawal, rather than with the administration, of steroids. (19) 
Interestingly, but perhaps coincidentally, seven of these eight cases occurred in female 
patients. All eight cases included mood disturbance; 2 with depression, 4 with mania, and 2 
with a mixed state. 
 
2.9 Cognitive effects 
 
The cognitive effects of corticosteroid therapy have been seen in patients receiving short 
term or long-term corticosteroids and relate primarily to declarative or verbal memory. (19)  
 
In one study, patients on corticosteroids had poorer performance on the Rey Auditory 
Verbal Learning Test (RAVLT), (a measure of declarative memory), the Stroop Color Word 
Test (a measure of working memory) performance, smaller hippocampal volumes and lower 
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levels of N-acetyl aspartate (a putative marker of neuronal viability in the temporal lobe 
region). (22) 
 
Deficits in declarative memory have been observed in subjects receiving as low as 4 to 5 
days of dexamethasone or prednisone. (23)  A dose-dependent impairment in declarative 
memory has been reported with high dose (160 mg/day), but not low dose (40 mg/day) 
hydrocortisone.   It appears that these cognitive impairments may be reversed with the 
reduction or withdrawal of corticosteroids. Similar results for declarative memory deficits 
are found in persons with Cushing’s disease. Such findings are consistent with reductions in 




2.10 Steroid Dependence and withdrawal 
 
Several case reports suggest that corticosteroids may be abused for their euphoric effects. 
(25) Typically, this will involve higher doses of oral systemic steroids although there is one 
report of dependence secondary to a nasal spray. (25) 
 
In a case review, 8 patients out of 11 cases of steroid dependency had a previous psychiatric 
history (predominantly depressive symptomatology), and 4 had a history of drug or alcohol 
misuse or dependence. It has been suggested that patients who may request higher steroid 





In the more recent review of case studies (19), the development of psychiatric symptoms 
was also associated with the withdrawal of steroids. Corticosteroid withdrawal symptoms 
generally include depression and fatigue, but mania and delirium have also been reported 
during dose reduction or discontinuation. Psychiatric symptoms during steroid withdrawal 
generally improve or resolve when corticosteroids are re-introduced. 
 
2.11 Cushing’s disease and psychiatric disorder 
Cushing's syndrome relates to the multi-organ over exposure of iatrogenic or endogenous 
corticosteroid and is associated with a variety of psychiatric and psychological disturbances. 
In one study examining 43 patients before and after treatment for Cushing’s, 
psychopathology was observed in a considerable number. Only 8 patients of 43 with active 
Cushing's syndrome (19%) were without psychiatric symptoms. Psychiatric diagnoses 
included: neurotic depression in 20 (46%), possible neurotic depression in 1 (2%), reactive 
depression in 6 (14%), and non-specific neurotic symptoms in 8 (19%). Psychoses were 
suspected in 3 of the patients who were depressed, but none of the 43 patients with active 
Cushing's syndrome had a definite diagnosis of Schizophrenia, Mania, Obsessive Compulsive 
Disorder or Generalised Anxiety Disorder.  
After treatment in 25 patients, when cortisol levels had been substantially reduced (to 
within normal limits in 88% of them), the percentage rated as psychiatrically asymptomatic 
increased from 19% to 68%. Scores for depression and anxiety showed significant 
improvements after treatment for Cushing's syndrome and Eysenck Personality Inventory 




2.12 Treatment of Corticosteroid induced psychiatric disorder 
 
There is a very limited literature on the treatment of corticosteroid induced mental 
disorder, although it can be noted that psychiatric symptoms generally resolve with 
discontinuation of the medication. In one review of the literature, tapering the dose of 
steroids alone appears to be effective up to 90% cases. (19) Case studies also suggest that 
switching steroids may be of value. (27)  The primary objective in managing these conditions 
is to balance the relative risk of psychiatric disturbance against the medical consequences of 
withdrawing the steroid.  
 
The management of corticosteroid induced psychiatric disorder can otherwise be largely 
divided into managing an acute psychotic/manic episode versus managing long term 
depressive symptoms and dependency. Although little evidence exists either way, it can be 
assumed that severe behavioral disturbance should be managed as per protocol - 
symptomatically with appropriate doses of benzodiazepines and antipsychotics. 
 
In terms of managing acute psychotic/manic episodes one study found that of 27 patients 
treated with lithium carbonate prophylactically, none developed severe mood symptoms 
while receiving corticosteroids. However, six out of 44 patients (14%) not receiving lithium 
developed mania or depression. (28) Antipsychotics, specifically haloperidol, risperidone 
and olanzapine, are noted from case reports to be useful in mania, mixed affective states, 
psychosis and delirium. A further case report suggested the successful use of low-dose 
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olanzapine (2.5 mg/day) for severe mood swings and suicidal ideation in a patient with 
asthma on chronic prednisolone therapy.  
 
With regard to depressive symptoms, several case reports have demonstrated some 
evidence with lithium following the onset of depressive symptoms. Carbemazepine has 
been reported to be useful in managing both manic and depressive symptoms secondary to 
corticosteroids. (29) There appears to be little benefit from the use of tricyclic 
antidepressants and in fact, a worsening of neuropsychiatric symptoms has been reported. 
(14) Case reports have been published describing the successful treatment of steroid-
induced depression with sertraline, fluvoxamine, and fluoxetine. One such report supports 
the use of a combination of an antidepressant and antipsychotic in the treatment of steroid-
induced psychotic depression (30). Case reports are noted to suggest the effectiveness of 






2.13 Conclusions  
 
Above all, the literature on the psychiatric adverse effects of corticosteroids is limited and 
larger studies on medically ill populations need to be carried out. Clinical practice continues 
to be informed by case reports despite over 50 years of awareness of these problems. There 
exists a great opportunity for future research to find predictors of steroid response including 
their genetic and neuroimaging antecedents and the literature could be enhanced with 
prospective studies and clinical trials. 
 
The ICD 10 codes steroid induced psychiatric disorder under F55.5 “Abuse of non-
dependence-producing substances “Steroids or Hormones”. No distinction is made about 
type or chronicity of symptoms. Arguably it may be more useful to classify steroids induced 
psychiatric disorder under F19.-Mental and behavioral disorders due to multiple drug use 
and use of other psychoactive substances. Corticosteroid induced psychiatric disorder can 













Table 2 Possible classificatory system for Steroid induced psychiatric illness 
Type Subtype ICD 10 Coding:  
 
F55.5 Abuse of non-dependence-producing 
substances “steroids or hormones” 
 
F19.-Mental and behavioural disorders due 






Hypomanic/Manic type with or 
without psychotic symptoms 
F19.55 Predominantly manic symptoms 
 
 
Depressive type with or without 
psychotic feature 
F19.54 Predominantly depressive 
symptoms 
 
Mixed affective type with or 
without psychotic features 
F19.56 Mixed 
Psychotic Type F19.50 Schizophrenia-like 
F19.51 Predominantly delusional 
F19.52 Predominantly hallucinatory 





Depression As F30-F39 
Mood (affective) disorders 
Recurrent affective disorder 
either depressive type or bipolar 
type 
As F30-F39 
Mood (affective) disorders 
Chronic cognitive impairment Unknown 
Corticosteroid dependence 
 
Dependence currently active use F19.24 Currently using the substance 
(active dependence) 












Regarding the acute corticosteroid syndrome, the clinical presentation can be diverse, but 
the severity of the symptoms appears to be dose dependent and they tend to occur within 
the first week of steroid administration. Affective symptoms are most common and a 
hypomanic/manic presentation is most likely. Some patients appear to have sub clinical 
hypomanic symptoms which they do not report. Symptoms resolve in most cases on 
discontinuation of the steroid. Cases are best treated with a mixture of a mood stabilizer 
(possibly prophylactically) and antipsychotic. 
 
With regards to chronic steroid syndrome, the merits of continuation of the steroid must be 
considered and a small literature suggests that depression in this group can be managed 
with an SSRI. 
 
In patients who are on long term steroids, a dependence and withdrawal syndrome may be 
seen. No evidence exists as to how this should be managed but again negotiation should 
occur between the clinicians and the patient on the need for steroids and a gradual tapering 
of dose should be considered. 
 
Presently it is not known whether individuals have idiosyncratic reaction to steroids or that, 
given a high enough dose everyone would suffer some mental disturbance. There is a 
suggestion that those with a previous affective disorder or a family history may be more 
susceptible to the adverse effects of steroids. If as many as 27% of those on high dose 
steroids suffer psychiatric symptoms, it is surprising that millions of patients do not present 




In conclusion the available literature on corticosteroid induced psychiatric illness is limited. 
There exist two important questions which have not been answered. Firstly, can anyone 
incur a psychiatric reaction to corticosteroids and secondly in chronic corticosteroid use, can 
controlling for the effect of a physical illness demonstrate an independent depressogenic 



















The following chapter will address 3 key areas with regards to Inflammatory Bowel Diseases 
and give an overview of coeliac disease. Firstly, there will be a description of the clinical 
features, aetiology and treatment of IBD. Detailing of these features is necessary to support 
the hypothesis that some of these may predict psychiatric outcomes. Secondly there will be 
an account of the historical context of IBD and associations with affective disorders and 
thirdly there will be a review of existing literature which details the relationship between 
affective disorders and IBD.  As patients with coeliac disease will be used as a control 












3.1 Clinical features, aetiology and treatment of 
Inflammatory Bowel Diseases 
 
3.1.1 Introduction 
Inflammatory Bowel Disease (IBD) consists of two principal diagnoses: Crohn’s Disease (CD) 
and Ulcerative Colitis (UC). A third, rarer, diagnosis Indeterminate Colitis lies clinically and 
histologically between these two and represents a diagnostic intermediary.   
Inflammatory bowel diseases consist of idiopathic, chronic, nonspecific inflammation of the 
gastrointestinal tract. They are persistently relapsing intestinal inflammatory conditions 
with a typical onset in young adulthood and with an unpredictable course.  
Pathogenesis of IBD is considered to involve a complex interplay between genetic, 
environmental, microbial, and immune factors. Lifelong medication has remained the basis 
of IBD management along with surgery. 
 
Here, both main diagnoses will be discussed in relation to their presentation, main 
symptoms, clinical course and prognosis as it will apply to possible consequent psychological 
or psychiatric symptoms. The immunology, genetics and treatment of both conditions will 






3.1.2 Crohn’s Disease 
 
Crohn’s disease was first described in 1932 by American gastroenterologist Burrill Bernard 
Crohn, who described a series of patients with inflammation of the terminal ileum. 
 
With regards to epidemiology, the lifetime risk of Crohn's from population studies in 
developed countries has been shown to vary from 28 to 213 per 100,000. (31) In 
international studies: north-south, east-west, and urban-rural gradients for incidence and 
prevalence of Crohn’s disease have been identified. (32, 33) 
 
Crohn's disease has a bimodal distribution in terms of age of onset; firstly, adolescents and 
young adults and then adults aged 50-70 years. Early onset can range from 0.2-9.0/100,000 
per year and late onset from 1.5-8.0/100,000 per year. (33) Males and females are equally 
affected. Early tobacco use significantly increases the risk of developing the disorder. (35) 
 
Twin studies show a concordance of greater than 55% for Crohn's disease. (34) 













Crohn’s disease may be categorized by the specific area of the gastro intestinal tract 
affected. Around 20% of cases are uniquely colonic, 30% are ileal and 50% both ileal and 
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colonic. While the disease can affect any part of the digestive tract, affected individuals 
rarely fall outside these three classifications. (37) 
 
Categorization of Crohn's disease has been both by the Vienna Classification and 
subsequently by the Montreal Classification.  (38) The Vienna classification describes 
stricturing, penetrating, and inflammatory subtypes of disease. The inability of the Vienna 
classification to allow upper gastrointestinal disease to coexist with more distal disease has 
led to the Montreal classification. The importance of this in the context of this thesis is that 





Vienna and Montreal Classification systems (38) 
 
 Vienna Montreal 
Age at Diagnosis A1 below 40y A1 Below 16y 
 A2 above 40y A2 between 17 and 40y 
  A3 above 40y 
Location L1 ileal L1 ileal 
 L2 colonic L2 colonic 
 L3 ileocolonic L3 ileocolonic 
 L4 upper L4 isolated upper disease 
Behaviour B1 non stricturing, non 
penetrating 
B1 non stricturing, non 
penetrating 
 B2 stricturing B2 stricturing 
 B3 penetrating B3 penetrating 











3.1.2.2 Clinical Presentation 
 
The hallmark of Crohn’s disease is the constellation of gastrointestinal symptoms. The main 
clinical symptoms are contained in the table below. (39) 
 
Gastrointestinal symptoms 
- Abdominal pain  
- Diarrhea and rectal bleeding. (Type of Diarrhea relates to the part of the small intestine or colon 
involved. Ileitis typically results in large-volume, watery feces. Colitis may result in a smaller 
volume of feces of higher frequency.)  
- Faecal consistency ranging from solid to watery.  
- Up to 20 bowel movements per day are reported and may need to awaken at night to defecate. 
In the setting of severe Crohn's colitis, bleeding may be copious  
- Flatulence and bloating  
- Vomiting and nausea may be present and may be a sign of small bowel obstruction due to severe 
stenosis  
- Perianal pruritis or pain which may be suggestive of inflammation, fistulization or abscess around 
the anal area or anal fissure 
- Perianal skin tags 
- Faecal incontinence  
- Aphthous ulcers in the mouth  
- Dysphagia, upper abdominal pain, and vomiting may be present when the esophagus and 
stomach are involved 
 
Extra intestinal symptoms 
 
- Pyrexia  
- Cachexia  
- Uveitis 
- Episcleritis  
- Seronegative spondyloarthropathy affecting knee, shoulder, hands, feet  
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- Ankylosing spondylitis.  
- Erythema nodosum 
- Pyoderma gangrenosum 
- Autoimmune hemolytic anemia 
- Finger clubbing  
- Osteoporosis 
- Seizures, cerebrovascular events, headaches and peripheral neuropathy reported in up to 33.2% 





The diagnosis of Crohn’s disease is based upon clinical history combined with serological 
and radiological investigations. Serological investigations include status of Erythrocyte 
Sedimentation Rate (ESR) and C-reactive protein (CRP). (39) Faecal calprotectin is a 
biochemical measurement of the protein calprotectin in the stool. Elevated faecal 
calprotectin indicates the migration of neutrophils to the intestinal mucosa, which occurs 
during intestinal inflammation and is used as a diagnostic tool and marker of severity of 
disease. (39) 
 
3.1.2.4 Surgical intervention 
 
Surgery remains an effective and often first line option in the management of Crohn’s 
Disease and may also be required for complications such as obstructions, fistulas and/or 
abscesses, or non-response to pharmacotherapy. After the first surgery, Crohn's may appear 
at the site of the resection. After a resection, strictures may form leading to obstruction. 






The clinical course of Crohn’s Disease can be variable and is difficult to predict based on the 
presentation at diagnosis. In one systematic review approximately one-third of the patients 
had ileitis, colitis, or ileocolitis at the time of diagnosis and the disease location remained 
generally stable over time. Approximately ten percent of patients have prolonged clinical 
remission. Annual incidence of hospitalizations was 20 %. Half of the patients required 
surgery within 10 years of diagnosis. Risk of postoperative recurrence was 44 – 55 % after 
10 years. (41, 42, 43) 
 
The probability of being without relapse from one study is 22 % after 5 years to 12 % after 
10 years. Risk of a continuous disease activity without clinical remissions is around 4 % after 
5 years and 1 % after 10 years. Half of the patients with active disease could expect to have 
a full year in remission within 3 years. (43) 
 
3.1.3 Ulcerative Colitis 
 
Ulcerative Colitis was first named in 1857 by Samuel Wilks but it was not till a century later 




The incidence of ulcerative colitis is approximately 10–12 cases per 100,000 per year, with a 
peak occurring between 15 and 25. Lifetime prevalence is 1 per 1000. There is thought to be 
a bimodal distribution in age of onset, with a second peak in incidence occurring in the 6th 




The geographic distribution of Ulcerative Colitis shows the highest incidences in the United 
States, Canada, the United Kingdom, and Scandinavia. Higher incidences are seen in 
northern locations compared to southern locations in Europe and the United States. (32) 
 
3.1.3.2 Gastrointestinal symptoms and classification 
 
The main symptomatic presentation is of diarrhea mixed with blood and mucus. Comorbid 
signs include weight loss and blood on rectal examination. The disease is usually 
accompanied with different degrees of abdominal pain.  
 
The disease is classified by the extent of colonic involvement: Distal colitis, Proctitis, 
Proctosigmoiditis, Left-sided colitis: Involvement of the descending colon up to the splenic 
flexure and the beginning of the transverse colon, Extensive colitis, Pancolitis: Involvement 
of the entire colon, extending from the rectum to the cecum up to small intestine 
In addition to the extent of involvement, UC patients may also be characterized by the 









Mild disease correlates with fewer than four stools daily, with or without blood, no systemic signs of 
toxicity, and a normal erythrocyte sedimentation rate (ESR). There may be mild abdominal pain or 
cramping.  
Moderate disease correlates with more than four stools daily, but with minimal signs of toxicity. Patients 
may display anemia moderate abdominal pain, and low-grade fever 
Severe disease, with more than six bloody stools a day, and evidence of toxicity as demonstrated by fever, 
tachycardia, anemia or an elevated ESR.  
Fulminant disease includes more than ten bowel movements daily, continuous bleeding, toxicity, 




3.1.3.3 Extraintestinal features 
 
In addition to gastrointestinal features, inflammation may occur in different systems 
including; aphthous ulcers of the mouth, Iritis or uveitis, Episcleritis, Primary sclerosing 




Diagnosis is based on serological and radiological evidence which would include: anaemia, 
abdominal x-ray, ESR, CRP, lymphocytic infiltration of mucosa on biopsy, colonoscopy or 




The Montreal classification assesses extent of disease and severity of symptoms, which have 
important prognostic value. The extent of disease is classified as endoscopic mucosal 
changes limited to the rectum (E1), left side of the colon, (E2) and beyond the splenic 
flexure (E3). Symptom severity score ranges from none (S0) to severe systemic 
manifestations (S3). 
 
Montreal Classification of UC (45) 
Extent/severity  Anatomy/definition 
E1 Ulcerative proctitis Involvement limited to 
rectum 
E2 Left sided UC (distal UC) Involvement limited to a 
portion of the colorectum 
distal to the splenic flexure 
E3 Extensive UC Involvement extens 
proximal to the splenic 
flexure 
S0  Clinical remission Asymptomatic 
S1 Mild UC Passage of four or fewer 
stools/day with or without 
blood, absence of systemic 
illness and normal 
inflammatory markers 
S2 Moderate UC Passage of more than 4 
stools each day with 
evidence of systemic 
toxicity 
S3 Severe UC Passage of at least 6 bloody 




3.1.3.5 Surgical intervention 
 
Unlike Crohn's disease, ulcerative colitis can be cured by colectomy. In a population-based 
study (48) extensive colitis at presentation was found to be an independent predictor of 
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colectomy at both 1 year and 10 years after diagnosis. Colectomy rates in UC patients vary 
from 6% in one year to 8.7% over 10 years. (49, 50) 
 
3.1.4 The Aetiology of Inflammatory Bowel Disease 
Inflammatory bowel diseases are of multifactorial aetiology comprising both genetic and 
environmental causative factors. While diet, breastfeeding and smoking are all cited risk 
factor for the diseases, in this thesis emphasis will be placed upon genetic and 
immunological factors in as far as they relate to pathological changes seen in depression. 
 
3.1.4.1 Immunological changes in IBD 
 
Cytokines have been directly implicated in the pathogenesis of IBD in recent genetic and 
immunological studies, and have a crucial role in controlling intestinal inflammation and the 
associated clinical symptoms of IBD (51) The role of cytokines is also highlighted by the 
blockade of tumour necrosis factor (TNF) being commonly used as a standard therapy for 
IBD (52) 
 
Interleukin‑6 (IL‑6) induces acute-phase proteins by the liver, whereas TNF is implicated in 
development of arthritis and cachexia. (53)  Further studies have identified IBD risk loci that 
contain genes which encode cytokines (e.g. IL‑2, IL‑21, interferon‑γ (IFNγ), IL‑10 and IL‑
27). IL‑6 production by lamina propria macrophages and CD4+ T cells is increased in 




The production of both membrane-bound and soluble TNF by lamina propria mononuclear 
cells is markedly augmented in patients with IBD. (55)  
 
 
3.1.4.2 The Genetics of Inflammatory Bowel Disease 
 
While IBD is likely to be caused by multiple genes of small effect size, several candidate 
genes have been shown to have a larger effect, but these contribute to a small amount of 
the genetic variance of the illness. Crohn’s disease shows high concordance for monozygotic 
twins of around 36% whereas Ulcerative Colitis has a concordance of around 16%. A family 
history of IBD may be seen in up to 30% of patients. (60) 
 
Promising candidate genes have been discovered for IBD including the NOD2/CARD15 gene 
(57)   Germline variation of NOD2/CARD15 has remained the strongest genetic determinant 










3.1.5 Treatment in Inflammatory Bowel Disease 
The main treatments for Crohn’s disease involve either medical or surgical approaches as 
well as diet and lifestyle management. Here there will be specific focus on two principal 
medical therapies; corticosteroid medication and anti TNF alpha immunoglobulin. 
The treatment for acute relapse involves aminosalicylate anti-inflammatory drugs and 
corticosteroids. Alternatives include aminosalicylates alone though many patients require 
immunosuppressive drugs. (58)  
3.1.5.1 Main Pharmacotherapy 
Below is a table outlining the main pharmacological agents for treatment in IBD and NICE 
guideline recommendations for both management of an acute episode and remission 
maintenance. (58) 
 
Class Examples (Brand Names) NICE Guidelines Recommendations 
Aminosalicylates 
 
Mesalazine, mesalamine, or 5-
ASA (Apriso, Asacol, Pentasa, 
Mezavant, Lialda, and Salofalk)  
Sulfasalazine (Azulfidine).  
Balsalazide (Colazal or 
Colazide) 
Induction of remission in acute episode 
1.2.4 In people who decline, cannot tolerate or in whom glucocorticosteroid 
treatment is contraindicated, consider 5-aminosalicylate (5-ASA) treatment for a 
first presentation or a single inflammatory exacerbation in a 12-month period.  






Induction of remission in acute episode 
1.2.2 Offer monotherapy with a conventional glucocorticosteroid (prednisolone, 
methylprednisolone or intravenous hydrocortisone) to induce remission in people 
with a first presentation or a single inflammatory exacerbation of Crohn's disease 
in a 12-month period. 
1.2.3 In people with one or more of distal ileal, ileocaecal or right-sided colonic 
disease who decline, cannot tolerate or in whom a conventional 
glucocorticosteroid is contraindicated, consider budesonide for a first presentation 
or a single inflammatory exacerbation in a 12-month period. Explain that 
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budesonide is less effective than a conventional glucocorticosteroid but may have 
fewer side effects. 
Maintenance of remission treatment 
1.3.7 Do not offer a conventional glucocorticosteroid or budesonide to maintain 
remission.  
1.2.5 Do not offer budesonide or 5-ASA treatment for severe presentations or 
exacerbations. 
1.2.6 Do not offer azathioprine, mercaptopurine or methotrexate as monotherapy 





1.2.12 Infliximab and adalimumab, are recommended as treatment options for 
adults with severe active Crohn's disease (see 1.2.17) whose disease has not 
responded to conventional therapy (including immunosuppressive and/or 
corticosteroid treatments), or who are intolerant of or have contraindications to 
conventional therapy. Infliximab or adalimumab should be given as a planned 
course of treatment until treatment failure (including the need for surgery), or until 
12 months after the start of treatment, whichever is shorter. 
Other Immunosuppressants Mercaptopurine, (6-
Mercaptopurine, 6-MP and 
Purinethol)  




Induction of remission in acute episode 
1.2.7 Consider adding azathioprine or mercaptopurine to a conventional 
glucocorticosteroid or budesonide to induce remission of Crohn's disease if: there 
are two or more inflammatory exacerbations in a 12-month period, or the 
glucocorticosteroid dose cannot be tapered. 
1.2.9 Consider adding methotrexate to a conventional glucocorticosteroid or 
budesonideto induce remission in people who cannot tolerate azathioprine or 
mercaptopurine, or in whom TPMT activity is deficient, if: there are two or more 
inflammatory exacerbations in a 12-month period, or the glucocorticosteroid dose 
cannot be tapered. 
Maintenance of remission treatment  
1.3.4 Offer azathioprine or mercaptopurine as monotherapy to maintain remission 
when previously used with a conventional glucocorticosteroid or budesonide to 
induce remission. 
1.3.5 Consider azathioprine or mercaptopurine to maintain remission in people 
who have not previously received these drugs (particularly those with adverse 
prognostic factors such as early age of onset, perianal disease, glucocorticosteroid 
use at presentation and severe presentations). 
1.3.6 Consider methotrexate to maintain remission only in people who: needed 
methotrexate to induce remission, or have tried but did not tolerate azathioprine 









3.1.5.2 Corticosteroid therapy 
 
Historically the most important treatment for an acute relapse of IBD involves use of 
corticosteroid medication.  
 
The most recent Cochrane review looking at the efficacy and safety of traditional 
corticosteroids for induction of remission in CD included RCTs with control groups receiving 
either placebo or 5-aminosalicylates (5-ASA).  (59) Comparing corticosteroids to placebo and 
comparing corticosteroids to 5-ASA; Corticosteroids were found to be significantly more 
effective than placebo at inducing remission in CD (RR 1.99; 95% CI 1.51 to 2.64; P < 
0.00001) and that Corticosteroids were found to be more effective than 5-ASA at inducing 
remission in studies with long follow-up duration (i.e. > 15 weeks; RR 1.65; 95% CI 1.33 to 
2.03; P < 0.00001). Psychiatric consequences of corticosteroid medications were not 
documented in the final review or in any of the individual studies therein. (59) 
 
The review concluded that Corticosteroids are effective for induction of remission in 
patients with CD, particularly when used for more than 15 weeks. (59) 
 
The second question which is relevant to this thesis is the Cochrane review on efficacy of 
corticosteroids for maintenance therapy and whether there is an identifiable subgroup of 
Crohn's disease patients, such as those in whom therapy cannot be successfully tapered, 




This review concluded that the use of conventional systemic corticosteroids in patients with 
clinically quiescent Crohn's disease does not appear to reduce the risk of relapse over a 24-
month period of follow-up.  
 
The natural history of response to corticosteroid therapy was specifically investigated in 
population-based studies. (60) In 196 patients over 10 years after a median follow-up of 3.4 
years, 56 % had received at least one systemic steroid treatment course, of whom 84 % 
received their first steroid course within the first year after diagnosis. The median duration 
of treatment was 84 days (range, 5 – 299). (60) Among the patients who received steroids, 
48 % achieved clinical remission, 32 % had partial clinical response, and 20 % did not 
respond to corticosteroid therapy. At the end of follow-up, 48 patients (44 %) had 
prolonged steroid response, 39 (36 %) were steroid dependent, and 22 (20 %) had steroid 
resistance. A total of 21% patients required surgical resection, including 26 % of patients 
with steroid dependency and 59 % of patients with primary non-response to steroids. (60) 
 
In a further study of 171 patients with Crohn’ s disease, 43% received corticosteroid 
therapy— 58% achieved complete remission, 26 % had partial response, and 16 % had no 
response after 30 days (59) 
 
The relevance of these studies for this thesis is that a significant number of patients will be 
treated with corticosteroid medications in any given year and that these medications 





3.1.5.3 Anti TNF immunoglobulins 
 
A more recent edition to the therapeutic arsenal in Crohn’s disease is the use of anti TNF 
alpha immunoglobulin. Anti-TNF-α agents have been shown to be effective for the induction 
of remission in Crohn's disease. In the Cochrane review on anti TNF agents in Crohn’s 
Disease, four different anti-TNF-α agents were evaluated (infliximab in 3 studies, CDP571 in 
3 studies, adalimumab in 2 studies, and certolizumab in 1 study). There is evidence from 
three randomized controlled trials that infliximab maintained clinical remission (RR 2.50; 
95% CI 1.64 to 3.80), maintains clinical response (RR 1.66; 95% CI 1.00 to 2.76), has 
corticosteroid-sparing effects (RR 3.13; 95% CI 1.25 to 7.81), and maintains fistula healing 
(RR 1.87; 95% CI 1.15 to 3.04) in patients with Crohn's disease with a response to infliximab 
induction therapy. There is evidence that adalimumab maintains clinical remission, clinical 
response, and has corticosteroid-sparing effects in patients with Crohn's disease who have 
responded or entered remission with adalimumab induction therapy. (61) 
 
In the Cochrane review, in patients with moderate to severe ulcerative colitis whose disease 
was refractory to conventional treatment using corticosteroids and/or immunosuppressive 
agents, infliximab was more effective than placebo in inducing clinical remission at 8 weeks. 
A single infusion of infliximab was also more effective than placebo in reducing the need for 
colectomy within 90 days after infusion (RR 0.44, 95% CI 0.22 to 0.87). (62) 
 
The review concluded that in patients with moderate to severe ulcerative colitis whose 
disease is refractory to conventional treatment using corticosteroids and/or 
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immunosuppressive agents, infliximab is effective in inducing clinical remission and reducing 





This section attempts to summarize the main features of IBD and its treatment. The clinical 
features of IBD can be chronic, distressing and disabling. Awareness that the life long course 
of IBD would be distressing and how the symptoms may preclude a sufferer from education 
and employment can be extrapolated. Furthermore, an awareness of the complexity of both 
surgical and medication treatment leads to an understanding of the high psychological 
burden of patients with IBD. This thesis will try and use indices to measure the severity of 
IBD in the cohort and this chapter demonstrates that this could be done by physical 











3.2 Psychiatry and Inflammatory Bowel Disease: A Historical 
Perspective 
 
Psychiatric illnesses have historically depended on varied etiological paradigms including the 
socio-cultural, psychoanalytic and bio-medical. However, the rise of pathology and 
molecular medicine has moved physical illnesses from the realms of speculation to firm 
scientific understanding.  
 
Physical and psychiatric illnesses converge in psychosomatic medicine.  
The term psychosomatic may have differing meanings but here it will be taken to mean the 
way in which mental phenomena or experience may lead to biological processes or disease. 
In the 20th Century, the rise of the biomedical model has shifted “psychosomatic” illnesses 
from more psychiatric understanding to a more medical one. An example of this is 
Inflammatory Bowel Disease (IBD) which, during the 20th century, has been a psychosomatic 
illness due to a perceived impact of social and psychological factors on the somatic disease 
process.  
Inflammatory Bowel Diseases comprising Crohn’s Disease (CD) and Ulcerative Colitis (UC) 
have a diagnosis based upon colonoscopy or endoscopy aided by biopsy and raised 




The interest in IBD as a psychosomatic illness derives from the fact that early observations 
of the condition seemed to suggest that life events, stress or personality type predisposed 
to the disease. Consequently, there is a substantial literature from both gastroenterologists 
and psychiatrists as to the basis for this apparent association. 
This chapter will review the historical influences which have shaped the understanding of 
IBD and its relationship to psychiatry. 
 
3.2.1 Early Psychosomatic Theory 
 
The 20th century has produced several important paradigms in psychiatry. Psychoanalytic 
theory provided the pre-eminent aetiological model of mental illness in general, based on 
the principles of unconscious thought and childhood development. The biomedical model 
rose with the psychopharmacological discoveries of the 1950s.  Latter-day advances in 
genetics and neuroimaging have supported the biological paradigm which predominates 
today as the model of aetiology in psychiatric illness.  
What we might call “psychosomatic” problems, now most often referred to as ‘functional’ 
or medically unexplained symptoms, appeared in the psychiatric lexicon at the time of Freud 
and Charcot 
Franz Alexander described disturbances of the vegetative functions of the body that were 
the result of a variety of etiological factors both organic and psychological in nature, noting 
that the impaired vegetative function of the body does not resolve the psychological stress 
which an individual experience. Thus, a psychosomatic symptom (a physical symptom 
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secondary to an environmental stress) is distinct from a conversion symptom which he 
argued allowed resolution of that stressor.  (63) 
The progress in physiology in the 20th century allowed the study of physical symptoms to 
gain more medical acceptance than psychiatric symptoms. Thus, the history of 
psychosomatics in the 20th century evolved differently to psychiatry with respect to major 
mental illnesses. 
3.2.2 The Brain-Gut Axis 
The so-called brain gut axis can be understood by the nervous supply of the gut. The vagus 
and splanchnic nerves supply the small intestine and proximal colon, whereas the pelvic 
nerves provide input to the colon and anal sphincter.  
The concept that the brain and the body can communicate in a bidirectional fashion is 
illustrated by early work of Henry Cotton an American psychiatrist working at the beginning 
of the 20th century. Based on the observation that patients with high fever were delusional 
or hallucinating, Cotton followed the emerging medical theory of infection-based 
psychological disorders and extrapolated this into pulling patients' teeth as they were 
suspected of harboring infections. If a cure was not achieved after these procedures, he 
would resect other organs including stomachs and especially colons. His publications tell us 
that he resected many patients’ colons and that their mental symptoms improved greatly as 
a consequence with cure rates of 85%. (64) 
A more important early study of brain gut interaction comes from the pioneering work of 
Stewart and Harold G. Wolf, who published an acclaimed work “Human Gastric Function” 
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based on their observations of a patient known as Tom. (65) As a nine-year-old boy Tom’s 
father brought home some hot soup in a beer bucket. Thinking it was beer, Tom took a swig 
and burned his oesophagus such that physicians could not keep it open as it healed. For 47 
years Tom fed himself through an opening surgeons made in his abdominal wall. As a proud 
man who had always supported his family, Drs. Wolf and Wolf asked Tom to better his lot 
and serve as an experimental subject. Wolf and Wolf were able to inform psychosomatic 
medicine in several important ways. For example, when Tom was frightened both his face 
and his stomach lining turned pale. When Tom was depressed, his stomach lining, which 
usually reddened and increased its secretion of acid after a dose of beef, hardly responded 
at all to such feeding. When Tom became angry, his face reddened and so did his stomach. 
Significantly, anxiety increased the amount of blood in the stomach membrane and the 
amount of acid secretion. (65) 
Such observations brought credibility to the idea that emotions could directly affect the gut. 
This would not be replicated in any other mental condition until the advent of functional 
neuroimaging at the end of the 20th century. However, such observations took place at a 
time when the psychoanalytic model was at a height just four years after the death of 
Freud.  
Crohn’s Disease had yet to be described but there were already many accounts of how 
stress or emotion could relate to Ulcerative Colitis. 
3.2.3 A Psychoanalytic model of Ulcerative Colitis 
Ulcerative Colitis was first described in 1859 but even a century later its aetiology was 
described as “obscure” by the American Gastroenterology Association (66) In 1930 Cecil D 
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Murray, published a paper claiming that psychological factors were important in ulcerative 
colitis. Groen and Van de Valk (67) description of this process is highly reminiscent of 
Freudian conversion theory: 
• Certain individuals have a psychological makeup that renders them more vulnerable 
to conflicts threatening their emotional security. 
• Exacerbations of colitis are brought on by an emotional conflict in which the 
individual is humiliated or defeated emotionally. 
• Such persons do not respond to the emotional stimulus by action or words. The 
resulting emotional conflict produces the changes in the colonic mucosa, which are 
responsible for the clinical and pathological signs of ulcerative colitis. 
 
Case reports by psychiatrists allude to the ‘confession’ of 'interhuman conflicts' in the 
immediate period before an attack of the disease (66). Other authors, some using the 
Rorschach test, claimed that patients with Ulcerative Colitis were “infantile, dependent, 
passive, egocentric, hesitant, and uncertain” and even suggested 'one may often recognize a 
colitis patient in the wards by the neat way he wears his pyjamas' (68, 69) 
 
When further research was conducted the limits of the psychodynamic model were 
reached. While a loose theory about the effect of stress or conflict on the gut appeared 
valuable, several important questions remained. Did specific conflicts relate to specific 
symptoms? A paper in 1955 concluded that “to lump together as causes of diarrhoea; anger, 
resentment, guilt, humiliation, anxiety, and conflict, is to reduce to relative ineffectiveness 




A second key question related to understanding the pathogenesis of symptoms. Karush et al 
sought to do so as until then “psychological descriptions of the emotional states associated 
with the physiological changes have not proven to be satisfactory psychodynamic 
formulations” (70) In this paper colonic propulsion was measured by the insertion of three 
balloons rectally, while salivary flow was measured by a suction cup placed on the buccal 
mucosa. The analysis sessions were recorded and instances of emotion were chronologically 
correlated with gut motility and salivary production. The authors noted findings from 6 
cases. In one “colonic activity of an intense, segmental, nonpropulsive nature was 
accompanied by a conscious, fearful attitude, or, more frequently, unconscious fear. The 
unconscious fear was aroused either by sexual desire inhibited by fear of sex as violence.” In 
a fifteen-year-old girl “a severe attack of abdominal cramps appeared as she told of her 
parents' threats of disaster for sexual transgression. The onset of her illness coincided with a 
tremendous increase in guilty fear because of compulsive masturbation.” The authors 
concluded that “The outstanding characteristic was dependence upon a magical, 
omnipotent authority, not merely for cure of the illness, but for resolution of conflicts about 
aggressive rage.” Unfortunately, less attention in the discussion related to the possible 
psychological effects of placing three balloons in the rectum. (70) 
 
The 1950s were also a time for major pharmacological advance and ACTH and 
Corticosteroids were both introduced successfully for the treatment of Ulcerative Colitis. 
(71) This was greeted with some scepticism by psychodynamic theorists such as Coodley 
who noted that: 
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“One of the newer and important aspects in the treatment of psychosomatic disorders 
relates to the use of specific hormonal therapy such as corticotrophin (ACTH) and cortisone. 
It is observed that cortisone and corticotropin are potent pharmacological agents which 
may deprive the patient of the keystone of his psychological defence. On the other hand, 
active therapy sometimes led to miraculous results.” 
3.2.4 The rise of the medical model 
Following the advances in treatment and histology, the perceived importance of 
psychological mechanisms in Ulcerative Colitis appears to recede from the mid-1950s.  (72) 
highlighted that psychodynamic formulations were open to question and that scientific 
evidence was not available for them. He noted that “too many factors may contribute to the 
development of this symptom (diarrhoea) to justify psychological correlations without 
further analysis of the primary changes in the bowel. When the architecture of the bowel is 
seriously deranged, or infection has developed within or outside the bowel wall, it is most 
unlikely that the psychological factors can any longer be clarified by correlative studies of 
symptoms and psychological events.”  
 
Engel noticed that in many cases rectal bleeding was the first symptom patients experienced 
and not diarrhoea. The description of a case series which Engel provides, which gives a 
detailed account of the symptoms, pathology and clinical course, shifts the understanding of 




Dick states that handling of psychological difficulties on common-sense lines is sometimes 
helpful, but formal psychotherapy is seldom indicated, and, importantly, that “the majority 
have found that A.C.T.H. and cortisone have some effect on this disease.” (73) 
 
In an early trial of cortisone, five of the six patients experienced a dramatic remission. 
Euphoria, increased appetite, disappearance of fever, and a fall in the erythrocyte 
sedimentation rate were noticed almost at once. The general conclusion reached at the 
time was that A.C.T.H. and cortisone influence appetite and produce a feeling of well-being, 
usually accompanied by a gain in weight. While it was postulated that the production of 
euphoria is an important factor in the action of A.C.T.H., it was clear that in some cases the 
physical changes, such as fall in temperature, were so dramatic in their onset and so 
coincident with the change in mental outlook that it would be difficult to argue that they 
resulted therefrom. The simpler and more probable explanation was that both resulted 
from a physical effect of the A.C.T.H., however much the euphoria may later contribute to 
the patient's recovery by assisting him to face up to and adjust to his difficulties. (73) 
 
The relationship between ulcerative colitis and psychiatric illness became more uncertain 
and the development of controlled trials and cohort studies added weight to the biomedical 
model.  
 
A series of 40 patients with schizophrenia and UC compared to 40 with just UC was followed 
over a period of years to compare the psychological and somatic course of disease, both in 
duration and severity. There remained a direct correlation between the degree of emotional 
disturbance and the severity of the colitis. However, a simultaneous increase in psychiatric 
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and physical symptoms occurred in most cases. (74) This was in direct contrast to the 
psychoanalytic model of conversion disorder where physical symptoms arose because of 
unresolved conflict. The authors noted that a simultaneous increase in psychiatric and 
physical symptoms seemed to be the rule. Furthermore, the study noted that while the 
interaction of the psychological and physical aspects of ulcerative colitis is frequently 
discussed in the literature, no assessment had been made of the basic psychiatric diagnosis 
and its relationship to the course of the disease. 
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3.2.5 Diagnostic Classification and cohort studies 
By the 1960s the psychiatric world had moved from one dominated by psychoanalysis to 
one dominated by empirical science. The emergence of the randomized controlled trials and 
controlled cohort studies gave a rational theoretical basis to psychiatric practice. In parallel 
to this was the introduction of psychiatric classification systems (the International 
Classification of Diseases or ICD) and operationalized criteria for diagnosis based upon 
standardized interviews. The discipline of psychology had also broadened beyond Freudian 
psychology as the sole paradigm. This shifted thinking from descriptions of “inner conflicts” 
to diagnosable psychiatric illnesses as possible precursors to or sequelae of physical disease. 
Personality became a dimensional and quantifiable concept and physical illness was 
correlated to psychiatric disorders such as Major Depressive Disorder or Generalised Anxiety 
Disorder.  
This coincided with the advances in gastroenterology. The diagnosis of Ulcerative Colitis and 
Crohn’s disease no longer simply depended on symptomatic description but a combination 
of colonic biopsy and histopathology. Blood markers of disease activity, latterly including C 
reactive protein (CRP), added to this greatly and allowed specific and sensitive measures of 
diagnosis and severity of disease.  
The early observations remained about the possibility that episodes of relapse could be 
triggered by stress. Studies could then be done which measured a psychiatric disorder 
objectively followed by objective measurements of bowel disease. Case control and cohort 




For example, Kurina 2001 used a retrospective case control design, assessing 12,499 
patients with IBD to see if episodes of depression or anxiety preceded a relapse of their 
bowel disease. (75)  It was found that both depression and anxiety preceded UC significantly 
more often than would be predicted from the control population’s experience but neither 
depression nor anxiety occurred excessively before CD.  On the other hand, depression and 
anxiety were significantly more common after an episode of CD; whereas UC was followed 
by anxiety, but not by depression, more often than expected by chance. The results are 
therefore compatible with the idea that the psychiatric disorders could be aetiological 
factors in some patients with UC. 
 
Evidence has also emerged for and against the view that life events may be risk factors for 
IBD relapse. In a prospective study of psychological distress and Crohn’s disease activity it 
was found that levels of depressive symptoms are positively associated with future changes 
in Crohn’s disease activity over a 2 year period (76).  In a retrospective case control design, 
Lebours 2007 showed that occurrence of a Life Event (LE) was more frequent in the 6-month 
period prior to diagnosis in CD cases than in UC cases or either control group. (77) However, 
after adjustment for depression and anxiety scores, as well as other characteristics such as 
smoking status and socio demographic features, this association appeared no longer 
significant. The authors therefore concluded that Life Events do not appear to be an 
independent risk factor for IBD onset. 
Overall, tthese studies suggest that diagnosable psychiatric disorders, irrespective of their 




The emerging field of psychoimmunology describes the communication between the 
nervous and the immune system and increasingly raises important questions about an 
interaction between psychiatric illness and IBD.  Of particular relevance here is the way in 
which the immune system is apparently suppressed in patients with depressive illnesses. 
(78) 
Major depression is accompanied by immune dysregulation and activation of the 
inflammatory response system. In a recent meta-analysis of 24 studies of cytokines in 
depression, patients with major depression had significantly higher concentrations of 
Tumour Necrosis Factor (TNF) and Interleukin 6 (IL-6) (79). These studies could partially 
explain the co-occurrence of depression and IBD beyond upset at having an illness. 
 
These interactions have been extended to mice models in which mice are given the 
depression inducing drug Reserpine. If the colons of these mice are then stimulated with a 
gastric irritant, the colons of the depressed mice show areas of greater erosion and have 
more inflammatory cell infiltration. (80) This effect can be reversed by giving the depressed 
mice an antidepressant.  Further, in mice with quiescent colitis, a relapse of inflammation 
could be induced by an episode of induced depression. 
3.2.7 Childhood trauma and adult gut problems 
Further interesting work has emerged on the effects of early life experience on the immune 
system. Disrupted infancy in mice has consequences on adult stress resilience. Mice which 
had been separated from their mothers in infancy had an exaggerated response to external 
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stressors as adults as shown by an excessive rise in cortisol. This concept was extrapolated 
to human subjects where it was shown that women with a history of child abuse had far 
greater sensitivity to stressors as adults. (81) 
Interest has grown in the last 10 years in the consequences of childhood stress on adult 
physiology. Danese (2009) showed that those who had experienced sexual or physical child 
abuse had higher levels of C reactive protein (CRP) and white blood cell count. Such work 
has led to the idea that childhood maltreatment may be a risk factor for inflammatory 
related illness in adulthood. (82) 
Lastly there is increased penetration of bacteria into the colonic of maternally separated 
mice compared to controls (83).  Maternal separation also predisposed rats to develop a 
more severe immune-driven response to chemically induced colitis (84). Furthermore, 
maternally separated rats also displayed a higher number of goblet cells and an increase of 
mucus in the colon than control animals (85). This has implications for susceptibility to 
infection, as sensitivity to the presence of bacteria in the gut may be increased, which can in 
turn result in increases in cytokine production 
The idea that infant stressors may lead to measurable biological changes in the gut has 
direct implications for psychiatric illness in inflammatory bowel disease. It therefore follows 







The main objective of this chapter was to collate examples of different paradigms explaining 
the co-occurrence of psychiatric illness and Inflammatory Bowel Disease. 
From the outset both psychoanalytic and bio medical paradigms play an important historical 
role in describing this association. The main thread of observation, that mental experience 
can lead to altered bowel habit, appears to ring true through both paradigms. Each 
paradigm has attempted to give its own explanation for this observation. Both paradigms 
have attempted to look at the observation in a cross sectional and developmental fashion. 
Difficulties have existed when attempting to define the mental events: conflicts, stressors, 
distress, major depressive disorder or generalized anxiety are all terms which have been 
used to qualify the mental troubles which may precipitate the gastroenterological problem. 
Psychoanalysis concentrated on childhood development, the influence of which appears to 
have been ignored during the rise of biological psychiatry only to be revisited as the 
biological models became more sophisticated. 
During this time, Inflammatory Bowel Disease has become associated with objective 
evidence of measurable pathology in the gut. While approaches to psychiatric illnesses have 
been influenced by the fall of the psychoanalytical and the rise of the biological model, 
neither neuroimaging nor genetics have been able to objectify pathology as 
gastroenterological histology has. Medically unexplained syndromes such as Irritable Bowel 
Syndrome or Chronic Fatigue Syndrome have yet to be explained biologically. Thus, 
inflammatory bowel disease provides a fascinating model of multi conceptual influence. 
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Studies of IBD today include those which suggest that psychotherapy may again be useful in 
preventing relapses. A historical perspective appears appropriate for IBD as it can highlight 
how a central theme can be interpreted by different paradigms. The concluding similarity of 
approach: that childhood can influence the adult gut, should be humbling for both 
















3.3 Inflammatory Bowel Disease and Affective 
Disorders 
The following section will look at existing literature regarding the direct relationship 
between Inflammatory Bowel Disease and Affective Disorder.  
 
The relationship between psychiatric illness and IBD is a complex one and as discussed, has 
been discussed at length using many different paradigms since the initial descriptions of 
both IBD and depression and anxiety. 
 
This section will concentrate on three main areas regarding the relationship between 
psychiatric illness and IBD.  
 
1. What is the prevalence of psychiatric illness in IBD?  
2. Do depression or anxiety affect the prognosis of IBD?  










3.3.1 Prevalence of psychiatric illness in IBD 
 
Several studies have sought to describe the prevalence of psychiatric illness, anxiety, stress, 
psychological distress and quality of life in patients with IBD. The following studies are case 
control or cross-sectional studies which look at concurrent IBD and psychiatric illness. Below 
are studies listed when the terms IBD OR Crohn’s Disease OR Ulcerative Colitis AND 
Depression OR Anxiety were entered Medline search in 2009. Studies were excluded if they 
were not in English, were reviews, were case reports, had lower than 30 subjects or did not 
quantitatively assess depression or anxiety for patients with IBD. The studies are reported in 
chronological order in the table below. A systematic review was published in June 2016 on 
Depression and Anxiety in Inflammatory Bowel Disease and reviewed 171 papers totalling 
158,371 participants. Pooled estimate of depression in this group was 15.2% and anxiety 
was 20.7%. The most used measure was the HADS scale of which the pooled mean score for 
depression was 5.4 and for anxiety was 7.5 in the disease group. The prevalence in Crohn’s 
disease was higher in than Ulcerative Colitis and higher in active disease compared to 
remission. Measurement scales included the use of Hospital Anxiety Depression Scale, HADS 
(37 studies, 7589 participants) Beck Depression Inventory, BDI (17 studies, 761 participants) 







Paper Clinical setting Patient group Control 
group 
Measure Main findings 















CD patients had significantly higher levels of depression, 
obsessive compulsive disorder, obsessive symptoms and 
lifetime psychiatric disorder 
Helzer 1984 (87) Gastroenterology Out 
patients 





No significant difference between UC patients  and controls. 










Prevalence of psychiatric illness in UC and CD was 34% and 
33% 
Robertson et al 
1989(89)  
Medical Out patients 80 consecutive IBD  




HADS Depression occurring only in patients with active chronic 
disease. 











 CD patients increased prevalence of anxiety, depression and 
panic disorder occurring at any time in their life. Panic 
disorder higher in CD prior to disease onset. UC no increased 
prevalence of psychiatric disorder before or after disease 
onset 
Drossman et al 1991 
(91) 
Postal questionnaire  997 members of 
the Crohn’s and 
Colitis Foundation 





SCL-90, and the 
Ways of 
Coping-Revised. 
Crohn's disease had more psychosocial difficulties, which 
were related to greater symptom severity. 




50 consecutive UC 
patients 







Psychiatric disturbance found in 11 UC patients (22%) and 8 
controls (16%). at interview a psychiatric disturbance was 
present in 31 UC patients (62%) and four controls (8%). 








 Symptomatic patients had higher level of perceived stress, 
trait and state anxiety and depression. 




IBD Out patients 
with IBS 
 65% of patients with IBD had some kind of psychiatric illness 
compared to 42% of controls. 




79 consecutive IBD 
patients  




rates of the rates of anxiety were as high as 80% for anxiety 
and 60% for depression during relapse using CD and UC 







 HADS  30 (25.9%) had probable psychological disorder and fifty five 
patients (47.4%) had possible psychological. No significant 
differences between CD and UC in depression scores and 
health-related quality of life. 





492 IBD patients  HADS. Here, patients with UC reported higher levels in all 
dimensions of health-related and disease-specific quality of 
life than did patients with CD. CD patients reported more 
anxiety and depression than did patients with UC. 








no controls BDI, STAI and 
PSQ. 
At baseline, depression was found in 17 of 60 (28%) patients. 




77 UC consecutive 
out patients 




Scale and the 
Emotional 
Support 
Network Scale   
A large number of patients perceived a “decline of vitality or 
vigor” despite being in the remission phase. 
Fuller-Thomson et al 
2006, (100) 
Population based study in a Canadian 
population based 
study compared 




 Prevalence of depressive disorder was 14% over 1 year, 
three times higher than the general 




















Crohn’s disease had significantly higher scores on BDI when 
compared to ASLC and BD controls. 61% of Crohn’s disease 
patients had BD>4 compared to 38% of blood donor controls 
and 45% of ASLC. Ulcerative Colitis patients significantly 
higher BDI scores compared to BD controls but no significant 
differences with ASLC group. There were no differences on 
BATE anxiety scores between the UC, ALSC and blood donor 
groups. 




IBD out patients Patients 
diagnosed 


















anxiety and mood 
disorders in 
subjects with IBD 
No controls  found a higher lifetime prevalence of mood disorders (27%) 
in IBD subjects compared to 12% in the control population. 




422 IBD patients  140 controls 
with chronic 
liver diseases 






of the HADS 
Mental disorders were more frequent in IBD patients with 
slight (27.7%) and moderate/severe disease activity (49.3%) 
compared to GP (10.4%) (P < 0.001), but not in IBD patients 
in remission (11.3%). No difference in levels of anxiety and 
depression or in the frequency of a probable mental 
disorder. The levels of anxiety and depression of IBD 
patients with active disease were higher than that of the GP, 
but not of the IBD patients in remission. The depression 
score of the CLD sample was higher than that of the IBD 
sample (P < 0.001), but not the anxiety score 












HADS HADS scores in the control, celiac, UC and CD groups were: 
HADS-A =5.3, 7.3, 6.0, 8.0 and HADS-D = 5.5, 7.5, 7.0, 9.0 
(both p<0.0001). The HADS A and D were higher in Coeliac 
than UC patients. 
      
 
 
In the 19 studies described above, 14 were samples of diagnosed out patients and 5 were 
postal questionnaires sent to community patients; 12 studies were controlled, 2 had both 
medically ill and healthy population controls, 5 had only medically ill control groups and 6 
had only healthy controls. Psychiatric illness was found to be higher in 11 of the 13 
controlled studies but lower in 2 studies. Psychiatric interviews were used as the method of 





3.3.2 Psychiatric illness and IBD prognosis 
 
It has been reported that the presence of co morbid depression and physical illness may 
lead to increased symptom reporting, pain, health care usage, surgery, disability, sick leave, 
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hospital stay and decreased productivity. (107, 108, 109, 110) This relationship may exist 
across many diseases including Diabetes, coronary heart disease and asthma. While the 
literature on IBD is slender it is reasonable to presume that this is also the case. In regards 
to this area there are two important questions. Firstly does co morbid depression 
exacerbate the disease process and secondly what other healthcare measures may be 
impaired by co morbid depression. 
 
Two studies noted a clear association between disease activity and levels of symptoms. In 
25 UC clinic patients, one study (111) found higher levels of depression and anxiety during 
an active disease phase, with diminishing symptoms during remission. In a clinical sample of 
104 CD and UC patients followed for 6 months, Disease activity paralleled anxiety and 
depression levels. (112) In a third study, 56 assessed 59 CD and UC patients at 2 time points, 
reporting similar levels of anxiety and depression at baseline and 12 months later. (113) 
 
There are three prospective studies which provide support for a more direct negative 
impact of depression on IBD. A 2-year study that assessed CD patients at 2–3-month 
intervals found that higher depression scores were associated with higher Crohn’s Disease 
Activity Index (CDAI) scores in the subsequent time. (114) A further study assessed 60 IBD 
patients with clinically inactive disease and assessed them every 3 months for 18 months. 
Here, Depression level at baseline was significantly correlated with total number of relapses 
and the median time until first relapse was much shorter for patients with depression (md = 
97 days) compared to the group who were not depressed at baseline (md = 362 days; P 





A prospective study of the relationship between depression and treatment response tracked 
100 CD clinic patients who were refractory to usual treatments who were given infliximab. 
(116) 
 
After 9 months until the next flare or the end of the observation period, those with major 
depressive disorder or higher anxiety symptoms at baseline were 
less likely to achieve remission with the infliximab. Multivariate regression analyses 
confirming depression was an independent determinant of failure to achieve remission in 
these patients. The presence of a major depressive disorder at baseline was significantly 
associated with a shorter time to initiating treatment. (116) 
 
With regards to other health measures, Guthrie et al report that co-occurrence of 
depression or anxiety predicts low health related quality of life in IBD patients.  In 222 
consecutive patients with IBD, depression was a predictor of increased health care 
utilization including visits to the gastroenterologist and GP. (117) 
 
3.3.3 What specific aspects of IBD may predict higher likelihood of depression or anxiety?  
 
Many factors can predict depression in a healthy population such as gender, unemployment 
and age. To date very little literature has focussed on which factors in patients with IBD are 
likely to predict depressive illness. Three main areas have been highlighted in studies though 
often they focus on quality of life rather than depressive illness: demographic factors, IBS 
symptoms and presence of stomas or anastomoses. In terms of demographic factors one 
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paper suggests that family and peer support is a significant factor leading to fewer 
psychiatric symptoms in patients with IBD (118). 
 
Many papers look at co morbid IBS like symptoms in IBD. Barratt et al 2011 find that the 
presence of reflux and IBS like symptoms is associated with reduced QoL and increasing 
likelihood of anxiety and depression.  (107) 
 
Bryant et al report that in 162 patients with IBD, 66% met criteria for at least one Functional 
Gastrointestinal Disorder (FGID). Those with significant (Hospital Anxiety and Depression 
Scale ≥ 8) anxiety and/or depression were more likely to meet criteria for coexistent FGID 
(78% vs 22% and 89% vs 11%, respectively; each P < 0.001). It was concluded that Symptoms 
consistent with FGID correlate with greater psychological comorbidity and poorer HRQoL in 
a "load-dependent" fashion. (119) 
 
With regards to ileostomy, in 492 Swedish IBD patients, having an ileostomy does not seem 
to affect patients' quality of life, while having ileoanal anastomosis appears to reduce QoL 
and affects the HADS score. Having ileoanal anastomosis may lead to more anxiety and 
depression, while having an ileostomy does not.  
 
In an earlier study the psychiatric morbidity of the 68 subjects seen at 12 months after 
stoma surgery showed that eleven subjects reported both anxiety and depression at 
moderate or severe levels and the overall psychiatric morbidity was 15 subjects (22%) This 
study indicated that a significant minority of patients following stoma surgery have 






The literature on IBD and psychiatric illness suggests several important conclusions. 
Depression and anxiety disorders are common in IBD ranging from 30-80% during relapses 
of the condition. However, depression is a common co morbidity in all medical illnesses and 
sadly only a few studies have included healthy controls or control groups with other medical 
illnesses in this work. Depression and Anxiety appear to be higher in clinical populations 
than community samples. The larger studies to address the prevalence have used 
questionnaires rather than clinical interviews and thus the diagnosis of MDD nor in fact IBD 
can be totally certain. Despite this depression remains common co morbidity in IBD and is at 
least as common as in other medial illnesses.  
 
While there has been historical interest on whether psychological symptoms may be 
precipitants for relapse, there are only a few studies which have been able to answer this 
question. Life events, perceived stress, diagnoses of anxiety and depression have all been 
used as the psychological phenotype which could be used as a model. A large prospective 
study which includes clinical interviews and avoids retrospective bias is lacking. Broadly the 
literature points towards life events and a depressive episode preceding relapse. 
 
It can also be concluded that both depressive and anxiety symptoms are more common 
during the active rather than quiescent phase of the illness. This has suggested that 
psychiatric illness may worsen the prognosis of the illness and the prospective studies do 
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suggest that likelihood of relapse and time-to-relapse may both be modified by an affective 
disorder. 
 
In terms of predicting Affective disorders in IBD, the presence of a stoma/pouch appears to 
increase this likelihood. In other research the presence of IBS like symptoms predicts a 
worse quality of life in patients with IBD. However, one can question the direction of 
causality in this relationship. 
 
Lastly the recent use of mouse models of depression in IBD provides an important insight 
into the co morbidity. One question which can always be levelled at clinical studies is 
whether IBD symptoms, Depressive disorders and quality of life are being accurately 
measured or whether propensity to report symptoms in any domain drives the correlations. 
This weakness in the literature is elegantly combated by mouse modelling which can clearly 
show a biological relationship between behavioural and intestinal pathology. 
 
The mouse models can be seen as the most convincing evidence that psychiatric factors may 
well precipitate and worsen colitis and can well explain a high level of comorbidity of 







3.4 Coeliac Disease 
 
The following section will outline the main features of Coeliac Disease as patients with 
Coeliac Disease will be used as a control group for the ISA study. 
 
Coeliac Disease is an inflammatory disorder of the small intestine caused by ingestion of 
cereal prolamins including gliadins in wheat, hordeins in barley, and secalins in rye. (118) 
Coeliac disease (CD) affects up to 1% of all individuals in developed countries. (119) Affected 
individuals experience a gastrointestinal inflammation. Like Inflammatory Bowel Diseases, 
sufferers suffer from a variety of gastrointestinal symptoms, require adherence to a 
treatment plan and have the potential of a lifelong autoimmune related illness. Unlike IBD 
patients, Coeliac Disease may be limited by a regulated diet, there is little place for 
pharmacotherapy (corticosteroids are generally not prescribed) and patients are unlikely to 
require hospital admission or surgery. Patients also routinely attend Gastroenterological 
Outpatient clinics and are often seen by the same physicians treating IBD. The 
immunological pathways seen in IBD and Coeliac Disease are different. Hence it is these 
similarities and differences which make Coeliac Disease a choice of comparison group for 







The symptoms of Coeliac Disease were first recognized as malabsorbtion and steatorrhoea. 
Coeliac disease causes variable mucosal inflammation of the small intestine. The 
characteristic histology is loss of villous height such that, mucosa appears completely flat 
and there may be subtotal villous atrophy. There is little sex difference. About 10 per cent 
of first-degree relatives are affected, and twin studies of have shown a concordance of 
70 per cent for monozygotic twins.  
3.4.2 Clinical features 
Coeliac Disease presents at the point that cereals are introduced. Babies show failure to 
thrive, food refusal and weight loss. Further, clinical features include abdominal distention, 
muscle wasting, diarrhea with steatorrhoea and vomiting.  
In adults, the most common presentations are anemia and abdominal symptoms of 
discomfort, bloating, flatulence, and an altered bowel habit.  
3.4.3 Diagnosis 
The gold standard diagnostic test is a small-intestinal biopsy.  Serological tests have been 
developed which include antibodies to gliadin (IgA or IgG isotype), IgA antibodies to 
reticulin, and IgA antibodies to endomysium. The endomysial antibody is the most useful 
with a specificity and sensitivity of 90 to 95 per cent.  
 
3.4.4 Clinical Course and Prognosis 
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Once the diagnosis by a small-intestinal biopsy is known, patients should be started on a 
Gluten Free Diet (GFD). Nutritional supplements may be necessary if there are low serum 
concentrations of iron and folate, or biochemical evidence of osteomalacia. After 3 to 4 
months, a repeat small-intestinal biopsy is recommended for histological recovery. Dietary 
compliance may be checked by measuring antiendomysial antibody titre.  
The prognosis is excellent if patients adhere to a strict diet. A small group fail to respond to 
a gluten-free diet. These patients are often not classified as Coeliac but may be referred to 
as ‘non-responsive Coeliac’. Here Corticosteroids with or without Azathioprine has some 
evidence for treatment. 
 
3.4.5 Coeliac Disease and Affective Disorders 
 
Several studies point to the higher prevalence of Affective Disorders in patients with Coeliac 
Disease compared to healthy controls. The presence of affective disorders has been 
described in Coeliac Disease patients since the 1980s. (120, 121) 
 
The prevalence of depression in cross sectional studies of Coeliac patients has been shown 
to range between 6–57% (122-125) with the lowest prevalence occurring among individuals 
on a Gluten-Free Diet (GFD).  Furthermore, in prospective cohort studies, individuals with 





Coeliac Disease patients also exhibited high levels of other affective disorders such as 
dysthymic disorder (8.3%), adjustment disorders (30.5%), and panic disorder (13.9%) The 
life-time prevalence rate of self-reported depressive symptoms was 39.0% in a study of 883 
patients, of whom 270 (11.9%) suffered from current depressive symptoms. (127) 
 
In cross sectional work looking at all gastrointestinal illnesses state anxiety was present in a 
higher percentage of CD patients with respect to controls, while trait anxiety was not 
significantly different indicating that anxiety could be related to the physical symptoms 
present. (128) 
 
Depressive symptoms do not appear to be influenced by age, age at the time of diagnosis, 
gender, socioeconomic variables, Gluten Free Diet (GFD) duration and GFD referred 
compliance, which suggests that depressive symptoms may be considered a common 
feature of Coeliac.(129) Furthermore anxiety disorder in Coeliac patients was related to a 
sense of being different from the ordinary population and, particularly in women, to a low 
level of general well-being. (129) 
 
Roos et al. found no increased risk of depressed mood in treated Coeliac Disease when 
there was objective evidence of remission (return of villous structure at repeat biopsy or 
absence of IgA endomysial/gliadin autoantibodies) after the institution of GFD. Coeliac 
patients evaluated before and after 12 months of GFD were shown to have an improvement 




In studies on Quality of Life (QoL), Coeliac Disease patients demonstrated lower QoL than 
controls and this was mediated by physical symptoms and depression.19, 20 Other factors 
cited as leading to poor QoL include an unsatisfactory sex life and difficulty in adapting to 
the chronic nature of Coeliac Disease (121,122) 
 
3.4.6 Aetiology of Comorbidity 
 
Several factors have been hypothesized to explain the high prevalence of 
Affective Disorders in Coeliac Disease patients. Reduced cerebral monoamine production is 
consistently implicated in affective disorder. One study showed a significant reduction of 
serotonin metabolites in cerebral spinal fluid of Coeliac Disease patients. (131) Further work 
showed an improvement in mood after GFD and a subsequent elevation in plasma 
concentrations of tryptophan. (132) 
Folate and homocysteine may play important roles in the pathogenesis of depression. It is 
possible that due to malabsorbtion these will be lower in patients with active Coeliac 
Disease and could lead to low mood. (133, 134) 
 
3.4.7 Treatment of Comorbidity 
 
In one study an improvement of state anxiety was found after GFD, while depression was 
still present and was related to the limitation of GFD in daily life. While a reduction of 
anxiety disorders after GFD could be related to the improvement of physical symptoms, it is 
thought that depression is sustained by the reduction in the quality of life (QoL). This may 
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be due in part to the decreased sense of well-being, and in part to dietary restrictions that 
lead to difficulties in daily social relationships. (135) 
 
One trialled psychological support for Coeliac Disease patients and showed that in those 
with affective disorders, psychological support can reduce depression and increase GFD 
compliance. (136) 
Importantly, treatment of co morbid psychological difficulties can lead to improved dietary 




Patients with Coeliac disease experience a dietary related autoimmune activation leading to 
several gastrointestinal symptoms. They appear to experience a higher level of affective 
disorder symptoms than the general population, yet the affective symptoms reduce when 
patients are treated. The use of Coeliac disease as a control group will be to evaluate 
whether IBD patients have a significantly higher level of affective disorder. If so it may be 
possible to suggest that this higher rate could be due to the differences from coeliac 
disease. Importantly it will be interesting to see whether coeliac patients have a similar 
sociodemographic profile as IBD patients as this will allow sociodemographic factors to be 








Below is a table summarising similarities and differences between IBD and Coeliac disease 




 Inflammatory Bowel Disease Coeliac Disease 
Socio demographic profile Social class I-V 
Male: Female ratio 1:1 
Social class I-V 
Male: Female ratio 1:1 
Symptoms Diarrhea, bowel frequency, urgency, 
abdominal pain 
Diarrhea, bowel frequency, urgency, 
abdominal pain 
Age of Onset Child or young adult Child or young adult 
 
Diagnosis and investigations 
 
Diagnostic biopsy, regular serology, 
serum inflammatory markers, radiology 
 
One diagnostic biopsy, infrequent 
serology if complications 
Diet Evidence that dietary factors may 
improve course 
Strict diet as main therapeutic measure 
Treatment Several pharmacotherapy’s, many with 
significant side effects 
In general, no pharmacotherapy 
Corticosteroids Used as mainstay of treatment Used rarely in treatment resistance 
Health service usage Frequent outpatient appointments, 
hospital admissions  
Rare outpatient appointments, 
admission generally unlikely 
Inflammation Known immunological pathways 
including crp, interleukins, tnf  
IgA serology 
Complications/comorbid conditions Uveitis, Arthritis, Renal Caliculi, 
Infertility, Bowel Cancer, Iritis 
Thyroiditis, Addison’s disease, Fibrosing 
alveolitis, systemic lupus 
erythematosus, and polyarteritis, 
Lymphoma 
Treatment Complications Stoma, Cushings Disease No major complications 
Prognosis Probably lifelong relapsing remitting 
illness 
Remission if diet maintained 
Mortality Increased mortality associated with 
complications, treatment 
No change in mortality 
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4.0 Affective Disorders 
 
 
The following chapter will focus on Affective Disorders, how they relate to chronic medical 
illness and their relationship to immunology.  
 
4.1 Clinical features and management of affective disorders 
This thesis will focus on three main diagnoses of Affective Disorder: Depression, Bipolar 
Disorder and Anxiety Disorders. The Anxiety disorders relevant to this thesis are Generalized 




Depression is a major cause of morbidity worldwide with lifetime prevalence up to 17%. 
(141) It affects 298 million people worldwide (4.3% of global population) and is the leading 
cause of disability as measured by Years Lived with Disability (YLDs). (142) Diagnosis of 





The box below outlines the ICD-10 diagnostic criteria  
F32 Depressive episode 
 
The depressive episode should last for at least 2 weeks. 
There have been no hypomanic or manic symptoms sufficient to 
meet the criteria for hypomanic or manic episode  
The episode is not attributable to psychoactive substance use  
F32.0 Mild depressive episode 
 
A. The general criteria for depressive episode (F32) must be met. 
 
B. At least two of the following three symptoms must be present: 
 
(1) Depressed mood to a degree that is definitely abnormal for the 
individual 
(2) loss of interest or pleasure in activities that are normally 
pleasurable; 
(3) decreased energy or increased fatigability. 
 
C. An additional symptom or symptoms from the following list 
should be present, to give a total of at least 
four: 
 
(1) loss of confidence and self-esteem; 
(2) unreasonable feelings of self-reproach or excessive and 
inappropriate guilt; 
(3) recurrent thoughts of death or suicide, or any suicidal 
behaviour; 
(4) complaints or evidence of diminished ability to think or 
concentrate, such as indecisiveness or vacillation; 
(5) change in psychomotor activity, with agitation or retardation 
(either subjective or objective); 
(6) sleep disturbance of any type; 
(7) change in appetite (decrease or increase) with corresponding 
weight change). 
(8) Marked loss of libido. 
 
F32.1 Moderate depressive episode 
 
A. The general criteria for depressive episode (F32) must be met. 
 
B. At least two of the three symptoms listed for F32.0, criterion B, 
must be present. 
 
C. Additional symptoms from F32.0, criterion C, must be present, 
to give a total of at least six. 
 
F32.2 Severe depressive episode All three of the typical symptoms noted for mild and moderate 
depressive episodes (F32.0, F32.1) should be present, plus at least 
four other symptoms, some of which should be of severe intensity.  
 
In the UK, around 3.4% of people with major depression commit suicide and up to 60% of 
people who commit suicide had depression or another mood disorder. (143) 
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In addition to psychological features, patients with depression often experience physical 
symptoms including increased physical pain and fatigue. One or more pain symptoms are 
present in 65% of depressed patients, and anywhere from 5 to 85% of patients with pain will 
be suffering from depression, depending on the context. The diagnosis of depression is 
often delayed or missed, which leads to worse prognosis. (144) 
Onset is most commonly between the ages of 30 and 40, and there is a second, peak of 
incidence between ages 50 and 60.  (145) Fifty-one percent of those with major depression 
also suffer from lifetime anxiety. It has been suggested that up to 80% of those suffering 
from their first major depressive episode will suffer from at least 1 more during their life, 
with a lifetime average of 4 episodes. (146) 
Depression in a medically ill population is complicated as fatigue, appetite disturbance and 
sleep disturbance may be caused by the physical illness rather than depression.  (147) 
4.1.1.2 Aetiology of depression 
The aetiology of depression is best understood by a biopsychosocial model.  Biological 
factors include a heritability estimate of 40% and a number of candidate genes implicated 
including polymorphisms in the 5HTT and BDNF genes. (148) Neuroimaging changes have 
been consistently noted in the anterior cingulate, hippocampus and amygdala (149, 150)  
Lack of neurogenesis in the hippocampus has been more recently implicated (151) Here 
hippocampal neuronal loss correlates with impaired memory and dysthymic mood and 
Antidepressants which stimulate neurogenesis can increase hippocampal volume. (151) 
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Multiple social factors have been shown to predict depressive illness. In women, lack of a 
confiding relationship, responsibility for the care of several young children at home, and 
unemployment can increase the risk of depression. (152) In older adults, health problems, 
the death of a significant other, or a change in social relationships because of their own 
health-related life changes have been cited as factors. (153) Depression is often associated 
with unemployment, poverty and stressful life events (154, 155)  
4.1.1.3 Management of depression 
The NICE guidelines on management of depression in adults suggest a stepwise model of 
treatment. Of relevance to this thesis there exists specific guidance in relation to those with 







































NICE Guidelines for people with Depression and a chronic physical health problem 
 
For patients with persistent sub threshold depressive symptoms or mild to moderate depression and a chronic physical health 
problem, and for patients with sub threshold depressive symptoms that complicate the care of the chronic physical health 
problem, consider offering one or more of the following interventions, guided by the patient's preference: 
 
• a structured group physical activity programme 
• a group-based peer support (self-help) programme 
• individual guided self-help based on the principles of cognitive behavioural therapy (CBT) 
• computerised cognitive behavioural therapy (CCBT)[5] 
 
Do not use antidepressants routinely to treat sub threshold depressive symptoms or      mild depression, but consider them for 
people with: 
 
• mild depression that complicates the care of the physical health problem or 
• a past history of moderate or severe depression 
• initial presentation of sub threshold depressive symptoms present for at least 2 years  
• sub threshold depressive symptoms or mild depression persisting after other interventions 
 
For patients with initial presentation of moderate depression and a chronic physical health problem, offer the following choice 
of high-intensity psychological interventions: 
 
• group-based CBT 
• individual CBT for patients who decline group-based CBT or for whom it is not appropriate, or where a group is not 
available  
• behavioural couples therapy for people who have a regular partner and where the relationship may contribute to the 
development or maintenance of depression, or where involving the partner is considered to be of potential therapeutic 
benefit. 
 
When an antidepressant is to be prescribed for a patient with depression and a chronic 
physical health problem, take into account the following:  
 
• the presence of additional physical health disorders  
• the side effects of antidepressants, which may impact on the underlying physical disease (in particular, SSRIs may 
result in or exacerbate hyponatraemia, especially in older people) 
• that there is no evidence as yet supporting the use of specific antidepressants for patients with particular chronic 
physical health problems 
• interactions with other medications 
 
Consider collaborative care for patients with moderate to severe depression and a chronic physical health problem with 
associated functional impairment whose depression has not responded to initial high-intensity psychological interventions, 





4.1.2 Bipolar disorder 
Bipolar disorder is a severe lifelong psychiatric illness characterized by episodes of both low 
and high mood. Its importance in this thesis relates to whether bipolar disorder may be seen 
more commonly in patients with Inflammatory Bowel Disease and whether patients 
receiving corticosteroid medication are more likely demonstrate a bipolar mood disorder 
episode. The relationship between corticosteroid medication and mood disorder has already 
been described in chapter 2. There is little evidence that Bipolar Disorder is likely to be more 
common in chronic medical conditions. National Epidemiological Catchment Area survey 
suggested that 0.8% of the population experience a manic episode at least once and a 
further 0.5% have a hypomanic episode. (157,158) 
The incidence of bipolar disorder is similar in men and women. Bipolar illness has higher 
heritability estimates than unipolar depression (up to 80%).  
To gain a diagnosis of bipolar illness, patients must experience a hypomanic or manic 















A. The mood is elevated or irritable to a degree that is definitely abnormal for the individual concerned 
and sustained for at least four consecutive days. 
 
B. At least three of the following must be present, leading to some interference with personal functioning 
in daily living: 
(1) increased activity or physical restlessness; 
(2) increased talkativeness; 
(3) difficulty in concentration or distractibility; 
(4) decreased need for sleep; 
(5) increased sexual energy; 
(6) mild spending sprees, or other types of reckless or irresponsible 
behaviour; 
(7) increased sociability or over-familiarity. 
 
C. The episode does not meet the criteria for mania (F30.1 and F30.2), bipolar affective disorder (F31.-), 
depressive episode (F32.-), cyclothymia (F34.0) or anorexia nervosa (F50.0). 
 
D. Most commonly used exclusion criteria: the episode is not attributable to psychoactive substance use 
(F1) or any organic mental disorder, in the sense of F0. 
F30.2 Mania A mood which is predominantly elevated, expansive or irritable and definitely abnormal for the individual 
concerned. This mood change must be prominent and sustained for at least a week (unless it is severe 
enough to require hospital admission) 
 
B. At least three of the main symptoms must be present (four if the mood is merely irritable), leading to 
severe interference with personal functioning in daily living: 
 
C. The absence of hallucinations or delusions, although perceptual disorders may occur (e.g. subjective 
hyperacusis, appreciation of colours as specially vivid, etc.).D.  
 
 
For research purposes symptom scales have been used which include the Young Mania 
Rating Scale and the Altman self-rating mania scale. The usage of these will be discussed 
further in the methodology section.  
 
4.1.3 Anxiety Disorders 
 
Anxiety is noted to co-exist in 50% of cases of Depression and can be sometimes seen as 
part of the phenotypic continuum of depressive illness. A significant component of research 
on depression in medical illness includes anxiety dimensions. Anxiety symptoms have been 
shown to have specific clinical implications in medical illness. Anxiety Disorders have 
emotional, cognitive and somatic symptoms. The cardinal somatic symptoms of Anxiety 
90 
 
include tachycardia, dry mouth, dyspnoea or tachypnoea, urinary urgency, rash, tremor.  
Cognitive symptoms include fear of dying, need to escape and worry. 
 
In this thesis, Anxiety will be defined as both categorical diagnosis and dimensional levels of 
anxiety. Four categorical diagnoses will be briefly outlined below: Generalized Anxiety 
Disorder, Panic Disorder, Simple Phobia and Obsessive-Compulsive Disorder.  
 
Somatic Symptoms of Anxiety (1) Palpitations or pounding heart, or accelerated heart rate. 
(2) Sweating. 
(3) Trembling or shaking. 
(4) Dry mouth (not due to medication or dehydration). 
Symptoms concerning chest and abdomen 
(5) Difficulty breathing. 
(6) Feeling of choking. 
(7) Chest pain or discomfort. 
(8) Nausea or abdominal distress (e.g. churning in stomach). 
Symptoms concerning brain and mind 
(9) Feeling dizzy, unsteady, faint or light-headed. 
(10) Feelings that objects are unreal (derealization), or that one's self is distant or "not really here" 
(depersonalization). 
(11) Fear of losing control, going crazy, or passing out. 
(12) Fear of dying 
(13) Hot flushes or cold chills. 
(14) Numbness or tingling sensations. 
(15) Muscle tension or aches and pains. 
(16) Restlessness and inability to relax. 
(17) Feeling keyed up, or on edge, or of mental tension. 
(18) A sensation of a lump in the throat, or difficulty with swallowing. 
Generalized Anxiety Disorder A. A period of at least six months with prominent tension, worry and feelings of apprehension, about every-day 
events and problems. 
B. At least four symptoms out of the above list of items must be present, of which at least one from items (1) to 
(4) 
F40.2 Specific (isolated) phobias 
 
A. Either (1) or (2): 
(1) marked fear of a specific object or situation not included in agoraphobia (F40.0) or social phobia (F40.1); 
(2) marked avoidance of such objects or situations. Among the most common objects or situations are animals, 
birds, insects, heights, thunder, flying, small enclosed spaces, sight of blood or injury, injections, dentists and 
hospitals Symptoms of anxiety in the feared situation at some time since the onset of the disorder, as defined in 
criterion B for F40.0 (Agoraphobia). 
C. Significant emotional distress due to the symptoms or the avoidance, and a recognition that these are excessive 
or unreasonable. 
D. Symptoms are restricted to the feared situation, or when thinking about it. 
 
Panic Disorder 
F41.0 Panic disorder [episodic 
paroxysmal anxiety] 
 
A. Recurrent panic attacks, that are not consistently associated with a specific situation or object, 
and often occurring spontaneously (i.e. the episodes are unpredictable). The panic attacks are not 
associated with marked exertion or with exposure to dangerous or life-threatening situations. 
B. A panic attack is characterized by all of the following: 
(a) it is a discrete episode of intense fear or discomfort; 
(b) it starts abruptly; 
(c) it reaches a crescendo within a few minutes and lasts at least some minutes; 
(d) at least four symptoms must be present from the list above, one of which must be from items (1) to (4): 
F42 Obsessive Compulsive 
disorder 
 
A. Either obsessions or compulsions (or both), present on most days for a period of at least two weeks. 
B. Obsessions (thoughts, ideas or images) and compulsions (acts) share the following features, all of which must 
be present: 
(1) They are acknowledged as originating in the mind of the patient, and are not imposed by 
outside persons or influences. 
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(2) They are repetitive and unpleasant, and at least one obsession or compulsion must 
be present that is acknowledged as excessive or unreasonable. 
(3) The subject tries to resist them (but if very long-standing, resistance to some obsessions or compulsions may 
be minimal). At least one obsession or compulsion must be present which 
is unsuccessfully resisted. 
(4) Carrying out the obsessive thought or compulsive act is not in itself pleasurable. (This should be distinguished 
from the temporary relief of tension or anxiety). 
C. The obsessions or compulsions cause distress or interfere with the subject's social or individual functioning, 
usually by wasting time. 
D. Most commonly used exclusion criteria: not due to other mental disorders, such as schizophrenia and related 






4.2.0 Depression in medical illness 
 
There exists extensive literature about depression in medical illness, a significant amount of 
which could relate to, but is not covered by the work on depression in IBD. There are three 
central themes which will be discussed here. Firstly, what is the epidemiology of affective 
disorder in a medically ill population? Secondly what is the relationship between physical 
and mental illness? Thirdly, what are the consequences of a co morbid affective disorder? 
 
 
4.2.1 Epidemiology  
 
With a globally ageing population, individuals are increasingly likely to spend more of their 
lifetime with a chronic illness associated with age and those with a chronic medical 
condition are likely to live longer. Due in part to co morbid medical illness, when moving 
from the community to primary-care, to inpatient medical settings, the prevalence of major 




In earlier epidemiological work in the USA, in the Epidemiologic Catchment Area Study 
found that people suffering from one of eight medical disorders had a 41% increase in the 
risk of having any recent psychiatric disorder (anxiety, affective, substance abuse disorders) 
compared with people without chronic medical disorders. (163) 
 
In a further US study there was a 4% risk of developing major depression with any long-term 
medical condition compared with 2.8% of those without medical conditions. (164) 
 
With regards to case-controlled studies in specific illnesses the odds of major depression in 
diabetes patients was twice that of a non-diabetic group (165) and when using structured 
psychiatric interviews, 11%–15% of diabetics were found to meet criteria for major 
depressive disorder (165) 
 
In an international epidemiological study carried out by the WHO in 60 countries, including 
subjects from Europe, Asia, Africa and the Americas the point prevalence of Depression 
alone stood at 3·2% (3·0–3·5) when using the Composite International Diagnostic Interview. 
(9) In those who had several co morbid chronic medical illnesses the rates of depression 
were higher. For patients with diabetes, at a worldwide level, 9·3% (7·3–11·3), 10·7% (9·1–
12·3) with arthritis, 15·0% (12·9–17·2) with angina, and respondents with asthma at 18·1% 
(15·9–20·3). (166) 
 
For the 7·1% (6·6–7·6) of subjects who had two or more chronic physical conditions, nearly a 
quarter (23%) also had depression in addition to their existing medical illnesses. The study 
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concluded that the prevalence of depression in respondents with chronic diseases is 
significantly higher than in respondents without chronic diseases (3·2%, p<0·0001). (166) 
 
Less literature is available for a Scottish population but in a study of out patients with cancer 
and depression one quarter of the cancer outpatients 674 out of 3071 (22%; 95% 
confidence interval (CI) 20–23%) met criteria for clinically significant emotional distress 
(total HADS score 15 or more). A diagnosis of depression as made by telephone SCID was 
made in 13% of this population. (167) 
 
 
4.2.2 Why does depression co-exist with physical illness? 
 
Katon states five postulates for why depression may occur in physical illness. (168)  These 
are:  
 
1) Depression is a risk factor for the development of some specific diseases 
2) Depression is a secondary psychological reaction to the development of the disease 
3) Depression is secondary to the complications or aversive symptoms of that disease 
4)  Depression is secondary to the side effects from medication used to treat these  
5)  The chronic medical illness has a direct pathophysiologic effect on the brain or has 
indirect physiologic effects (such as via cytokines)  
 
A sixth point which has not been raised by Katon is that sociodemographic factors may be 




4.2.3. What are the consequences of comorbid affective disorder? 
 
In considering the relationship between affective disorder and inflammatory bowel 
diseases, the consequences of comorbidity are important. Comorbidity will be looked at in 
terms of adverse health behaviours, social role change, symptom reporting and health 
service usage.  
 
Patients with depression may exhibit poorer self-care or hygiene, have unhealthier diets or 
may do less exercise. All these simple behaviours may understandably lead to poorer 
physical health. Anxiety and depression are associated with poor adherence to self-care 
regimens (diet, exercise, cessation of smoking, medication regimens) and increased medical 
complications in patients with chronic medical illness, which should lead to increased 
symptom burden (29, 30) Studies have reported that patients with major depression have 
higher rates of adverse health-risk behaviours, such as sedentary lifestyle, smoking, and 
over-eating. These may lead to a higher incidence of diabetes and heart disease (170) 
Subjects with major depression were shown in the Epidemiologic Catchment Area Study to 
have a significantly higher rate of smoking compared with non-depressed respondents (165) 
 
With regards to social functioning, data from the Medical Outcomes Study showed that 
patients with major depression perceived their vocational and social functioning and 
general health to be more impaired than patients with one of seven other medical 
conditions (171). When major depression was co morbid with chronic medical illness, there 
was additive functional impairment (171). Longitudinal studies have shown that affective 
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disorders are more predictive of functional impairment over time than severity of physical 
illness. For example, Sullivan and colleagues demonstrated that symptoms of affective 
disorder at initial diagnosis of coronary disease by angiogram were more highly correlated 
with functional impairment at both 1- and 5-year follow ups than was any physiologic 
measure (172) 
 
Data from both mixed-aged and elderly samples of primary-care patients have found 
significantly higher medical costs in patients with either depressive symptoms or major 
depression compared with patients without depression. 
The increase in costs is a consequence of increased primary care visits, specialty visits, 
mental health visits, emergency room visits, pharmacy costs, laboratory and x-ray 
examinations, and inpatient costs. (167) It has also been noted that there is an Increase in 
length of hospital stay (173) in patients with both benign and malignant illness in those with 
co morbid depression compared with those without depression. (174) 
 
After adjusting for sociodemographic characteristics, alcohol dependence and chronic 
physical illness burden, the presence of co-morbid depression was associated with 
significantly greater (approximately double the) likelihood of health-care utilization and 
increased functional disability and work absence compared to the presence of a chronic 
physical illness without co-morbid depression. The impact of depression was seen across 
many illnesses with the strongest associations seen for work absence. Depression was 





Patients with co morbid depression were seen to report more physical symptoms. 
There appears to be an amplification of chronic disease symptoms in patients with chronic 
medical illness who have comorbid anxiety or depressive disorders. (175) 
 
Furthermore, patients with chronic medical illness and comorbid depression or anxiety 
compared to those with chronic medical illness alone reported significantly higher numbers 
of medical symptoms when controlling for severity of disease. (175) 
 
A systematic review looking at associations between depression and mortality found 44 
studies (72%) reporting a positive association and 17 (28%) reporting no association. Here 
positive studies had a longer median length of follow-up and were more likely to use 
structured psychiatric interviews to define major depression rather than depression self-
rating scales. (176) 
 
The co-occurrence of affective disorder and physical illness has been studied across many 
physical illnesses. It can be concluded that depression is common in physical illness and is 
associated with many social and medical complications such as role impairment and disease 
severity. The relationship may itself be bidirectional as psychiatric symptoms as seen above 
may be a cause and consequence of these complications. The inclusion of this section in the 







4.3.0 Psychoimmunology: Depression and Immunological Function 
 
The relationship between chronic medical illness is and affective disorder, prime facie, a 
simple one. Patients suffering from chronic pain, disability, loss of role, difficulties in 
relationships and loss of employment are understandable reasons for onset of a depressive 
illness. One of the central themes of this thesis, however, is that depressive illness in the 
context of chronic medical illness can be understood through a biological paradigm.  The 
immunological changes seen in medical illnesses may themselves lead to depressive 
symptoms. This section will concentrate on immunological seen in depression as it is these 
changes are seen in both the pathophysiology and treatment of Inflammatory Bowel 
Disease. 
 
4.3.1 Cytokines in Depression 
 
A significant literature suggests that depressive illness is accompanied by immune 
dysregulation. Activation of the inflammatory response system has been demonstrated by 
increased production of Pro inflammatory cytokines such as interleukin IL-1, IL-2, IL-6, 
interferon (IFN), tumor necrosis factor (TNF), the soluble IL-6 receptor (IL-6R), and the IL-1 
receptor antagonist (IL-1RA) (177-186).  
 
Proinflammatory cytokines may cause the development of depressive symptoms (187). 
Furthermore, evidence in the context of chronic inflammatory disease demonstrates that an 
improvement of mood and cognitive symptoms can be seen with anti-inflammatory 
treatment. Cytokines have been shown to induce neuroendocrine and central 
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neurotransmitter changes like those in depression (187), and it has been demonstrated that 
treatment with IFN-gamma can precipitate depression (188). 
 
However, the association between cytokines and depression is not consistently significant in 
all studies or for all cytokines (188, 189, 190) 
 
In studies of TNF alpha measurements were made in 438 depressed and 350 non-depressed 
subjects extracted from 13 studies. The meta-analysis noted that there were significantly 
higher concentrations of TNF-alpha in depressed subjects compared with control subjects. 
(191)  
 
In studies of IL-6, measurements were made in 492 depressed and 400 non-depressed 
subjects extracted from 16 studies. Depressed patients had significantly higher 
concentrations of IL-6. (192) In four studies of IFN-gamma, for 131 depressed and 107 
nondepressed subjects. Concentrations of IFN-gamma did not differ between groups.  
 
IL-6 and TNF-alpha are thought to either decrease levels of serotonin in the brain or activate 
the HPA axis (193, 194). Other studies found that pro-inflammatory cytokines activate 
serotonin degrading enzymes (195). There have be many articles published which report a 
decrease in depressive symptoms in patients receiving Infliximab (IFX), a monoclonal 
antibody against TNF-alpha, which antagonises the effects of TNF-alpha. In 2009, Soczynska 
et al. (196) reviewed the effect of anti-TNF-alpha drugs on depressive symptoms related to 
bipolar disorder in patients suffering from autoimmune diseases and advanced cancer. This 
literature review looked at six papers which studied the effect of TNF-alpha antagonists 
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Adalimumab, Etanercept and Infliximab on the depressive symptoms. The authors suggest 
that infliximab as well as other TNF-alpha antagonists may be therapeutic for somatic, 
cognitive and affective symptoms associated with the depressive symptoms. However, it 
remains unclear whether infliximab is having a direct therapeutic effect on depressive 




Results from a 2-year, randomized, comparator-controlled trial evaluating anti TNF therapy 
with in patients with rheumatoid arthritis reported significant improvements in quality of 
life and somatic symptom measures (197) 
 
In one randomized, double-blind, placebo-controlled trial of patients with psoriasis (198) 
subjects receiving Etanercept had a 47% reduction in psoriatic measures and at least a 50% 
improvement in HAMD and BDI at 12 weeks. However, significant improvement in 
depressive symptoms was less correlated with objective measures of skin clearance or joint 
pain (198). 
 
Two studies looked specifically at the change in affective symptoms in patients with Crohn’s 
disease treated with Infliximab. Persoons et al. reported that the prevalence of depressive 
disorder at baseline predicted significantly lower remission rates (29% vs. 70%) at 4 weeks 
as compared to subjects without depression. A significant decrease in time to retreatment 
was also reported for subjects with depression. A significantly smaller proportion of subjects 
met criteria for depression at 4 weeks (16% vs. 24%) as compared to baseline (199) 
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Minderhoud et al. in a single blinded study enrolled patients with Crohn’s disease (n = 14), 
each of whom received placebo at baseline, followed by infliximab at 2 weeks. (200) A 
significant effect of Infliximab was observed on the Centre of Epidemiological Studies 
Depression scale (CES-D) at 4 weeks, which was not seen in the placebo group. (200) 
 
This evidence concludes that, the results of these studies provide support that TNF-a 
antagonists may offer therapeutic benefit for somatic, cognitive, and affective symptoms 
associated with mood disorders. 
 
4.3.2 C-Reactive Protein 
 
C-reactive protein (CRP) is an acute-phase protein which is a member of the class of acute-
phase reactants, as its levels rise dramatically during inflammatory processes and this is due 
to a rise in the plasma concentration of IL-6. CRP rises to 50,000-fold in acute inflammation, 
such as infection. It rises above normal limits within 6 hours, and peaks at 48 hours. 
Emerging literature has supported the notion that CRP is elevated in depression. Results 
from a prospective cohort study demonstrated significant interaction between C-reactive 
protein and depression, such that moderately increased C-reactive protein in depressed 
men was predictive of a subsequent first coronary event (201) When men were assessed 2 
months after acute coronary syndrome, it was found that depression and C-reactive protein 
were overlapping prognostic risks. 
 
Other studies showed that current depression diagnosis alone is less likely to be related to 
inflammation risk as measured by HS CRP, but current depression and maltreatment history 
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combined seem to be good predictors of inflammation levels. Moreover, even in the 
absence of a current diagnosis of depression, maltreatment history alone still confers 


















The following section on methodology will outline patient population, measurement scales, 
statistical methods and ethical approval 
 
5.1 Patient population 
 
Of many studies on the prevalence of psychiatric and psychological comorbidities in 
Inflammatory Bowel Disease, many different clinical populations have been used as can be 
seen in Chapter 3. From the literature these can be divided into two main groups. However, 
both main populations used come with important selection and observer biases.  
 
Firstly, there are large population cohorts who have been recruited via postal surveys or 
patient membership organisations. This methodology carries the advantage of increased 
study power allowing assessment of multiple clinical variables. However, there are three 
principle drawbacks. As many of these studies have been conducted on patients who are 
members of patient organisations, their histological diagnosis cannot be confirmed. It is 
possible that some of this group may carry a diagnosis of IBS rather than IBD. Secondly a 
major weakness in postal surveys is that failure to get good phenotypic psychiatric 
assessment. There exists an inherent methodological weakness in self-report of psychiatric 
symptoms which may be unconfirmed by clinical assessment, GP records or record of 
medication. A third drawback in these studies is response bias. At best 60% of the 
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populations have responded and are either more likely to be those who have lower rates of 
psychiatric illness or those who have possible higher levels of health anxiety. (see chapter 3) 
 
The second type of study population is drawn from in-patient and out-patient clinical 
populations. A disadvantage of this group relates to the opportunity to power the studies as 
well. Rarely do these studies exceed a few hundred subjects. It is possible that patients with 
co morbid psychiatric illness may be either more or less likely to access health services. 
Furthermore, the out-patient and in-patient population are likely to be those with more 
severe disease. (see chapter 3) 
 
The main objective of this thesis is to determine which inflammatory, disease, treatment 
and socio demographic factors predict affective disorder in IBD. It is therefore a prerequisite 
that subjects have a histological diagnosis of IBD, that it is sufficiently powered to measure 
predictors but also that potential predictors exist in the study population i.e. to assess the 
impact of corticosteroid medication as a risk factor, many patients taking this medication 
will be required. It is possible that a community sample may not have sufficiently severe 
disease to study treatment or disease variables. A further advantage of clinical compared to 
community samples will be the opportunity to perform more extensive psychiatric 
phenotyping. 
 
A secondary question will be to address the prevalence of affective disorder in clinical 
populations. Even if clinical populations are unrepresentative of IBD patients, this group are 
having direct contact with gastroenterologists and thus there is the potential to shape 
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services around this population. The ISA study population is therefore taken from outpatient 




The city of Edinburgh and surrounding area has an approximate population of 468,000 as of 
2010. The city includes both affluent and deprived areas but has less ethnic diversity 
compared to other UK cities. Socio demographically Edinburgh may be unrepresentative of 
all UK cities due to a large affluent population centred on the universities and financial 
sector institutions.  
 
The city hosts two University teaching hospitals, the Western General Hospital and The 
Royal Infirmary of Edinburgh. With an approximate lifetime prevalence of 1/250, it can be 
estimated that there are around 1900 IBD patients in the city. 
 
Regarding service configuration in Edinburgh, all IBD patients attend the Department of 
Gastroenterology outpatient clinic at the Western General Hospital. Some patients requiring 
complex surgery or other medical and surgical co morbidity additionally attend the Royal 
Infirmary of Edinburgh. The importance of this service configuration is that all patients with 
a histological diagnosis of IBD are likely to be known to one clinical site and attend one 









Patients with Inflammatory Bowel Disease were recruited into prospective cohort and 
genetic studies in Edinburgh from 1995. Patients were recruited from in patient and out 
patient populations and their clinical phenotype; treatment and genotype were followed 
over the subsequent 20 years. Existing data includes disease extent, severity, surgery, socio 
demographic variables, smoking and treatment. Methodology from these studies is 
documented elsewhere. (203) 
 
Ulcerative Colitis phenotype at baseline was classified by disease extent, disease severity, and 
need for surgery. The extent of disease has been documented at the time of latest follow-up. 
(203) Disease extent has been defined as disease extending beyond the splenic flexure, left-
sided colitis as disease extending to the splenic flexure, and proctitis as disease limited to the 
rectum as determined by histologic and macroscopic evidence. Other phenotypic details such 
as smoking, family history, presence of primary sclerosing cholangitis, and other extra 
intestinal manifestations were also recorded.  
 
Crohn’s Disease patients were described according to the Vienna Classifications. Previous 
work has shown that disease behaviour is consistent over time and therefore disease 
behaviour was analysed only at time of diagnosis and at latest follow-up. (203) 
In one study previously published by the gastroenterology group, two hundred thirty-one 
patients with well-characterized CD were categorized according to the Vienna classification 
and were further assessed at 5-, 10-, 15-, and 20-year stages. 
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In this study additional clinical and biologic parameter that may relate to the progression of 
disease type had been also collected which comprised gender, smoking history, family 
history of IBD, surgical history, the presence of joint problems, azathioprine use, ASCA 
status, and NOD2/CARD15 status. Their median length of follow-up was 138 months. (203) 
 
The data from other studies on the same cohort shows that the behaviour of disease 
predicts location of disease and ASCA status significantly but shows no difference with 
regards to age and gender of patient, smoking status or family history. (204) 
 
After 5 years, disease behaviour, in this cohort, continues to significantly predict disease 
location. Furthermore, there is a significant relationship between disease behaviour and 
gender. (204) 
 
Disease behaviour at 10 years shows that there continues to be a relationship between 




The importance of this data for the ISA study is that, in looking for predictors of affective 
illness in this population, both disease behaviour and disease location may be predictors. If 
subsets of disease behaviour are predictors of subsequent affective illness, this could allow 
targeted screening of IBD phenotypes for psychiatric illness. The relationship between 
disease behaviour or location may impact on affective illness through several mechanisms 
which would include disease behaviour relating to a more severe subtype of disease, 
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symptom experience or causal mechanism (e.g. could certain disease subtypes have related 
to smoking, poor diet or family history – each of which may be separately related to an 
affective illness). 
 
5.4 Cross Sectional Study Assessment  
 
Data was collected from the subjects as part of the cross-sectional part of the study as 




5.5 Medical Diagnosis and Physical Symptom Scales 
 
Diagnosis of Crohn’s Disease and Ulcerative colitis was made based on histological samples 
and all subjects in the ISA study had a confirmed diagnosis of IBD. 








Colitis Activity Index (UC) 







Altman Self Rated Mania 



















Patients with Crohn’s Disease had symptoms measured by the Harvey Bradshaw Index 
which is a 12 question self-reported scale of GI symptomatology which is widely used and 
well validated.  (205)  
 
Patients with Ulcerative Colitis, similarly had their physical symptoms measured through the 




5.6 Psychiatric Phenotype 
 
Psychiatric Phenotype was assessed through self-reported symptom scores and self-reports 
of past psychiatric history, contact with mental health professionals and psychiatric 
treatment. The HADS scale was chosen due to it being used many times in IBD populations 
and its clinical utility. 
 
5.7 Mania scales 
 
Mania rating scales can be divided into those used for diagnosis and those used for severity 
rating. As the main purpose of this study was to capture a range of manic symptoms a scale 
with a dimensional range of scores was necessary. A study comparing the performance of 
three self-rating mania scales, The Internal State Scale (ISS), the Self- Report Manic 
Inventory (SRMI), and the Altman Self- 
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Rating Mania Scale (ASRM), in a group of patients with acute mania was conducted at 
different stages of treatment for a group of patients exhibiting mania. In this study patients 
also were rated by clinicians on the Clinician-Administered Rating Scale for Mania (CARS-M) 
as a gold standard comparator. At baseline, scores on the 
ASRM and the ISS well-being subscale were significantly correlated with CARS-M scores. The 
sensitivities for each scale to correctly identify patients with acute symptoms were 45% for 
ISS, 86% for SRMI, and 93% for ASRM. 
Specificities were 73%, 46.6%, and 33%. Hence ASRM and SRMI were more sensitive than 
the ISS in screening patients with acute mania and all three measures appeared sensitive to 
treatment effects. The ARSM is notably a short scale which was piloted on several out 
patients and found to be both useable and acceptable. (214) 
 
 
5.8 Background Psychiatric Data 
 
Psychiatric History was gathered by self-report. Although this is likely to show 
underreporting, given the constraints and ethical scope of the study it was impossible to 
gain confirmatory data from primary or secondary care case notes. Below is the form which 











5.9 Medication history 
 
Medication history was taken from self-report and patient case records. All patients who 
described being on medication had case records checked for type and dose. 
 
5.10 Inflammatory markers 
 
Patients had routine serology completed while attending the out-patient clinic. Samples 
were not collected systematically; 466 patients had a Full Blood Count taken of which White 
Cell Count and Haemoglobin were recorded for this study; 196 had ESR, 364 had CRP and 56 
gave samples for Faecal Calprotectin. Patients who completed these tests were more likely 
to be those experiencing relapse or whose remission was being closely monitored.  
 
 
5.11 Ethics and R&D 
 
Ethical permission was sought from the Lothian Research and Ethics Committee and R&D 
approval was sanctioned by NHS Lothian. 08/S1101/58. Below is a flow chart for 








The aim of the ISA study was to find predictors of depression and anxiety in a population of 
out patients with Inflammatory Bowel Disease.  
 
The main hypotheses were that the following factors would predict likelihood of depression 
and anxiety: 
Demographic factors (e.g. age, gender and social class)  
Clinical factors (e.g. duration of disease, disease phenotype previous surgery) 
Medication (e.g. dose and duration of corticosteroids, infliximab) 
Past Psychiatric illness (e.g. previously diagnosed or treated depression) 
Inflammatory markers (e.g. CRP, ESR, WCC or calprotectin) 
 




Data was analysed using SPSS statistical package v19.  
 
Statistical Plan 
Demographic information (gender, marital status, employment status), Medical history 
(disease type, surgery), prescription of medication, past psychiatric illnesses (diagnosis and 
treatments) were all considered as categorical variables. Dose of corticosteroids, 
inflammatory markers were continuous variables. Inflammatory markers were normally 
distributed. Social class was considered as ordinal data. Psychiatric rating scales were 




The cohort is described according to frequencies of demographic and clinical information in 
their respective categories. Comparison of diagnoses and demographic data is performed 
using Kruksal wallis test and Chi squared tests. 
Range of inflammatory markers will be described using means and standard deviations. 
Demographic, clinical and medication data will be correlated against psychiatric rating scales 
using Mann Whitney U tests (binary) and Kruksal Wallis tests (multiple categories). 
Predictors of psychiatric scale outcomes will be measured by Independent T tests (binary 
categories such as gender), Pearson correlations (for continuous measures) such as age) and 
one-way ANOVAs (multiple categories such as Vienna classification). 
Pearson correlations are then used to consider correlations between two sets of continuous 
variables such as inflammatory markers, psychiatric symptom scales and gastrointestinal 
symptom scales. 
Multivariate linear regression analysis was used to identify the most important independent 
predictors of HADS anxiety and depression. All significant predictors were entered into the 
regression model for Crohn’s Disease or Ulcerative Colitis and HADS Anxiety or Depression. 














The following chapter will report the results of the thesis. This will be divided into three main 
sections. Firstly, there will be a description of the cohort in terms of sociodemographic, psychiatric, 
medical and other clinical variables. (6.1) Secondly there will be the sociodemographic, clinical and 
medication predictors of affective disorder including multivariable analysis. (6.2) Thirdly there will be 



















6.1 Cohort Description 
6.1.1 Sociodemographic Characteristics of ISA Cohort 
The following section will describe the sociodemographic characteristics of the cohort by 
diagnosis. This will be a comparison of subjects with Ulcerative Colitis, Crohn’s Disease and 
Coeliac Disease. 
6.1.1.1 Gender of Subjects by Diagnosis 
 








Male (%) 115 (45.2) 132 (40.1) 23 (29.4) 270 
Female (%) 139 (54.8) 191 (59.9) 55 (60.6) 385 
                                                          
Total  
254(100) 323(100) 78(100) 655 
     
 
 






















Married (%) 137 (54.8) 133 (41.8) 43 (55.1) 313 
Single (%) 86 (34.4) 153 (48.8) 23 (29.5) 262 
Divorced (%) 18 (7.2) 25 (7.9) 8 (10.2) 51 
Widowed (%) 9 (3.6) 7 (2.2) 4 (5.1) 20 
Total 250(100) 318(100) 78(100) 646 
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6.1.1.6.1.1.3 Household Composition of subjects by Diagnosis 
 










 Parents 16(6.4) 42(13.2) 4(5.1) 62 
Spouse/Partner 
 
103(41.2) 101(31.8) 30(38.5) 234 
Spouse/Partner and Children 
 
75(30.0) 83(26.1) 22(28.2) 180 
Children Alone 
 
15 (6.0) 21(6.6) 3(3.8) 39 
Flatmate (s) 
 
9(3.6) 17(5.3) 3(3.8) 29 
Alone 
 
32(12.8) 54(16.9) 16(20.5) 102 



















6.1.1.4 Employment Status by Diagnosis 
 
 































     37 (14.9)      50 (16.7)      20 (26.7) 107 
Total 
 




6.1.1.5 Incapacity Benefit status by Diagnosis 
 








Presently on ICB (%) 
 
Previously on ICB but not now (%) 
 
Never been on ICB (%) 
 
18 (7.7) 36 (12) 6 (8.2) 60 
19 (8.2) 39 (13) 3 (4.1) 61 
196(84.1)  225 (75.0) 65 (87.7) 486 
















Presently Smoking (%) 
Past Smoker (%) 
Never Smoked (%) 
48(18.9) 115(35.6) 19(24.4) 182 
71(27.9) 57(17.6) 10(12.8) 138 
135(53.1) 151(46.7) 49(62.8) 335 




6.1.1.7 Alcohol Consumption by Diagnosis 
 
 








Presently drinking alcohol 
 
Not drinking alcohol 
 
189(74.4) 223(69.0) 57(73.0) 469 
65(25.6) 100(31.0) 21(26.9) 186 















6.1.1.8 Number of Units of Alcohol Consumed each week by diagnosis 
 










No Alcohol 71(28.0) 127(39.3) 27(34.6) 225 
1-5 Units (%) 
 
64(25.2) 107(33.1) 23(29.5) 194 
6-15 Units (%) 
 
101(39.8) 77(23.8) 25(32.1) 203 
15+ Units (%) 
 
18(7.1) 12(3.7) 3(3.8) 33 






















6.1.1.9 Comparison of Sociodemographic variables by Diagnosis 
 
Using the Kruksal Wallis test, at a significance level of p<0.05, marital status, gender, 
Incapacity Benefit status and smoking status are significantly different between diagnoses. 
Patients with Crohn’s Disease appear less likely to be married and more likely to be single. 
More patients with Crohn’s are female. There appears to be no significant differences in 
terms of household composition, though the numbers are low in some cell counts. Patients 
with Crohn’s disease are more likely to be or have been on Income Capacity Benefit.  
Patients with Crohn’s disease are more likely to smoke (almost twice as likely 35.6% vs 











































Using a one-way Anova test, units of alcohol per week were compared between diagnoses. 















333.676 2 166.838 3.847 
0.022 Within Groups 28276.040 652 43.368  
     





When Ulcerative Colitis is compared with Crohn’s Disease subjects with UC drink 



























6.1.2 Disease characteristics of the ISA cohort 
 
 
The following subsection of results will describe the disease characteristics of patients in the 
ISA cohort. This will be done separately for those with Crohn’s disease and Ulcerative Colitis. 
Of 577 patients in the ISA cohort, 293 had been assessed continuously prior to their 
psychiatric assessment. Patients had gastroenterological phenotyping at diagnosis and at 
subsequent follow ups. 
 
The follow up assessments occurred between 2000 and 2010. These assessments do not 
represent specific time points during IBD. 
 
The data will be presented in 2 categories:  
 
6.1.2.1 Clinical and surgical features of IBD subjects 
 












6.1.2.1.1 Clinical features of Crohn’s Disease subjects 
 
Of the 323 patients with Crohn’s disease who were assessed in 2010-2011, 172 were 
followed from their original diagnosis which was made between 2001-2003. During this time 
their IBD phenotype may have altered. The rational here is to consider whether early 
disease phenotype may predict later psychiatric phenotype. 
These 172 patients will be described according to their initial presentation of Crohn’s 
disease and subsequent GI phenotyping. There exist two classification systems of Crohn’s 
disease; Vienna classification and Montreal Classification as described in previous chapters. 
Below is a table summarising how such classification is performed. Subjects from the ISA 
cohort were classified according to both systems. 
 
 
 Vienna Montreal 
Age at 
diagnosis 
A1 below 40 y A1 below 16 y 
 A2 above 40 y A2 between 17 and 40 y 
  A3 above 40 y 
   
Location L1 ileal L1 ileal 
 L2 colonic L2 colonic 
 L3 ileocolonic L3 ileocolonic 
 L4 upper L4 isolated upper disease* 
   




 B2 stricturing B2 stricturing 
 B3 penetrating B3 penetrating 








6.1.2.1.2 Disease onset, family history and age at psychiatric assessment of Crohn’s 
Disease subjects 
 
The following table shows age at diagnosis and at the time of psychiatric assessment 
 
 
 N Minimum Maximum Mean 
Std. 
Deviation 
Age at time of ISA 
Assessment 
172 21.2 65.6 44.4 13.392 






The following table shows age at Diagnosis by age category 
 
Age at diagnosis Frequency Percent 
 
<12 years 6 3.4 
12-18 years 29 16.9 
19-29 years 74 43.0 
30-39 years 24 14.0 
40-49 years 16 9.3 
>50 23 13.3 




The following shows whether subjects had a family history of Crohn’s disease. 
 
Family history Frequency Percent 
 
No 132 76.7 
Yes 40 23.3 










6.1.2.1.3 Disease phenotype by site of disease at diagnosis and follow up 
 
The following table shows anatomical site of disease in patients at diagnosis and follow up.  
 
 
Site of Disease 
At Diagnosis At Follow Up 
Percentage 
change % 
Present (%) Absent (%) Present (%) Absent (%) 
Oral 8 (4.7) 164 (95.3) 9 (5.2) 163 (94.8) +0.5 
Oesophageal/Gastric 7 (4.1) 165 (95.9) 14 (8.1) 158 (91.9) +4.0 
Jejunum 6 (3.5) 166 (96.5) 18 (10.5) 154 (89.5) +7.0 
Ileum 99 (57.6) 73 (42.4) 125 (72.5) 47 (27.3) +14.9 
Colon 80 (46.5) 92 (53.5) 100 (58.1) 72 (41.9) +11.6 
Rectum 48 (27.9) 124 (72.1) 69 (40.1) 103 (59.9) +12.2 




6.1.2.1.4 Classification of patients with Crohn’s Disease  
 

























































Age at Diagnosis 
A1 133 (77.3) A1 13 (7.6) A1 133 (77.3) A1 13 (7.6) 
 A2 120 (69.7)  A2 120 (69.7) 
A2 39 (22.7) A3 39 (22.7) A2 39 (22.7) A3 39 (22.7) 
    
Location 
L1 ileal L1 53 (30.8) 
L1+L4 10 (5.8) 
L1 ileal L1 ileal 
L2 colonic L2 46 (26.7) 
L2+L4  2 (1.2) 
L2 colonic L2 colonic 
L3 ileocolonic L3 41 (23.8) L3 ileocolonic L3 ileocolonic 
L4 upper L4 7 (4.1) L4 upper L4 isolated upper 
disease* 
    
Behaviour 
B1 114 (66.3)  
B1 116 (67.4) 
B1p 14 (8.1) 
B1 58 (33.7) 
B1 60 (34.9) 
B1p 25 (14.5) 
B2 20 (11.6) B2 19 (11.0) B2 40 (23.3) 
B2 35 (20.3) 
B2p 9 (5.2) 
B3 23 (13.4) B3 8 (4.7) B3 70 (40.7) 
B3 30 (17.4) 





6.1.2.1.5 Surgical History of patients with Crohn’s Disease 
 
The following two tables show the surgical history of Crohn’s disease patients. This includes 
a first table showing those with Stomas and a second table showing all procedures. 
 
 
 Ileal Stoma (%) Colonic Stoma 
(%) 
Any stoma (%) 
Yes 17 (9.9) 1 (0.6) 18 (10.5) 
No 155 (90.1) 171 (99.4) 154 (89.5) 




Procedure  Yes (%) No (%) Unknown Total 
Bowel Resection  97 (56.4) 75 (43.6)  172 
Number of Bowel 
Resections 
1 57 (33.1)    
2 21 (12.2)    
3 12 (7.0)    
>3 6 (3.5)    
Stricturoplasty  16 (9.3) 154 (89.5) 2 (1.2) 172 
Number of 
Stricturoplasties 
1 7 (4.1)    
2 5 (2.9)    
3 1 (0.6)    
>3 3 (1.8)    
Abscess/Fistulae 
Operation 
 33 (19.2) 111(64.5) 28 (16.3) 172 
Diversion Surgery  10 (5.8) 164 (94.2)  172 
Non-Perianal 
Operations 
 98 (57.0) 74 (43.0)  172 
Number of Non-
Perianal Operations 
1 48 (27.9)    
2 18 (10.5)    
128 
 
3 15 (8.7)    
>3 17 (10.0)    
Perianal drainage 
operations 
 31 (18.2) 138 (80.2) 3 (1.7) 172 
Number of Perianal 
drainage operations 
1 10 (5.8)    
2 
5 (2.9)    
    
 
     
3 4 (2.3)    
>3 12 (7.0)    
Therapeutic Surgery  74 (43.0) 98 (57.0)  172 
Number of Therapeutic 
Surgeries 
1 55 (32.0)    
2 22 (12.8)    
3 14 (8.1)    






















6.1.2.1.6 Clinical features of subjects with Ulcerative Colitis 
 
The following section relates to patients with Ulcerative Colitis. Of 245 patients in the ISA 
study with Ulcerative colitis, 121 have been followed up from the original cohort.  
 
6.1.2.1.7 Disease onset and family history of Ulcerative Colitis 
 
Below is a table showing age at diagnosis and age at ISA assessment followed by a table 
showing presence of family history. 
 
 N Minimum Maximum Mean 
Std. 
Deviation 
Age at time of ISA 
Assessment 
121 18.5 63.2 47.3 9.4 














Family history Frequency Percent 
 
No 103 85.1 
Yes 18 14.9 











6.1.2.1.10 Surgical and Medical History of patients with Ulcerative Colitis 
 
Below is a table showing surgical history of patients with Ulcerative colitis. Patients with UC 
frequently have other medical co morbidities which are shown below. 
 
 
Procedure  Yes N (%) No N (%) 
Missing N 
(%) 
Total N (%) 
Colectomy  9 (7.4) 112 (92.6)  121 (100) 
Ileo-Anal 
Pouch 
 6 (5.0) 115 (95.0)  121 (100) 
Pouchitis  2 (1.7) 117 (96.7) 2 (1.7) 121 (100) 
Tonsillectomy  28 (23.1) 93 (76.9)  121 (100) 
Appendectomy  6 (5.0) 115 (95.0)  121 (100) 
Joint Problems  43 (35.5) 78 (64.5)  121 (100) 
























6.1.2.2.1 Disease phenotyping at ISA assessment 
 
 
The following section will describe the disease phenotype performed at the time of the ISA 












Minimum Maximum Mean Std. Deviation 
Colitis Activity 
Index 
254 0 13 3.8386 2.91133 
Harvey Bradshaw 
Index 
323 0 10 3.8824 2.68971 
C-Reactive Protein 
(CRP) 




196 0 84 14.75 12.849 
White Cell Count 461 0 16 7.31 2.407 
Faecal Calprotectin 56 0 2500 652.84 717.910 













6.1.3 Psychiatric Phenotype 
 
 
The following results subsection shows the psychiatric phenotype of the ISA cohort. Subjects 
were asked about previous psychiatric diagnoses, previous psychiatric medication and 
previous contact with psychiatric services. Subjects were asked to complete the Hospital 
Anxiety Depression Scale and the Altman Self Rated Mania Scale.  
 
The following table shows numbers and percentages of patients who report a past history of 
psychiatric diagnosis, previous psychiatric medication usage and previous contact with 
psychiatric services. These results are categorised by gastrointestinal diagnosis (Ulcerative 

























Have you ever 
suffered 
from? 
Depression 83 (32.7) 102 (31.6) 26 (33.3) 0.93 
Anxiety Disorder 53 (20.9) 59 (18.3) 19 (24.4) 0.44 
Panic Disorder 36 (14.2) 32 (9.9) 7 (9.0) 0.21 
Phobias 10 (3.9) 18 (5.6) 3 (3.8) 0.61 
Obsessive 
Compulsive disorder 
14 (5.5) 17 (5.3) 3 (3.8) 0.84 
Bipolar Disorder 1 (0.3) 5 (1.5) 0 (0.0) 0.23 





67 (26.4) 80 (24.8) 17 (22.0) 0.71 
Anxiety Medication 36 (14.1) 37 (11.5) 12 (15.4) 0.50 
Bipolar medication 0 (0.0) 3 (0.9) 0 (0.0) 0.21 
Have you ever 
seen? 
Counsellor 56 (22.0) 67 (20.7) 19 (24.4) 0.77 
Psychologist 25 (9.8) 38 (11.8) 7 (9.0) 0.66 
Psychotherapist 12 (4.7) 13 (4.0) 4 (5.1) 0.86 
Psychiatrist 22 (8.7) 31(9.6) 3 (3.8) 0.26 
Been a patient in a 
Psychiatric Hospital 
5 (2.0) 4 (1.2) 2 (2.6) 0.65 




The table below compares mean scores on the Hospital Anxiety Depression Scale (HADS) 
and Altman Self Rated Mania Scale (ARSM) by gastrointestinal diagnosis. These are 





























































































(3.72) 0.160 0.865 0.466 0.358 
 
 
Almost one third of patients with these gastrointestinal diagnoses report a previous history 
of depression. Up to one quarter of these patients have received a psychological 
intervention or antidepressant medication. There are, however, significant differences in 
the rates between patients with Coeliac Disease or either inflammatory bowel disease with 
regards to past psychiatric diagnoses, psychiatric treatments or contact with psychiatric 
services. 
 
With regards to present psychiatric symptoms, there are no differences between 
gastrointestinal diagnoses in terms of anxiety symptoms nor mania symptoms. There exists 
a significant difference with regards to depressive symptoms between Crohn’s Disease and 
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The following results subsection describes the medication taken by the cohort both 




























The following table shows the dose and duration of Prednisolone used. 
 
 
 Minimum Maximum Mean SD 
Dose of 
Prednisolone 
1mg 50mg 18.11 13.63 
Weeks of 
Prednisolone 
1 week 1820 weeks 175 weeks 372.4 
Medication 




What medication were 
you taking in the last 
year (but not now)? 
N (%) 
Prednisolone 85 (14.6) 113 (19.6) 




271 (46.4) 243 (40.2) 
Azathioprine 139 (24.1) 48 (8.3) 
Mecaptopurine 35 (6.0) 12 (2.1) 
Methotrexate 12 (2.1) 7 (1.2) 
Infliximab 17 (2.9) 11 (1.9) 
Adulimamab 25 (4.3) 7 (1.2) 
TOTAL 578 (100) 578 (100) 
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6.2 Predictors of Affective disorder in subjects 
with Crohn’s disease and Ulcerative colitis 
 
The following section will look at domains of predicting affective disorder. These will be: 
6.2.1 Sociodemographic predictors of HADS 
6.2.2 Disease predictors  
6.2.3 Medication Predictors 











6.2.1 Sociodemographic predictors of Anxiety and Depression from Hospital Anxiety 
Depression Score (HADS)  
 
The following subsection will look at how socio demographic variables predict affective 
disorder in this population. Here all IBD patients will be considered as one group and will be 
analysed by Anxiety and Depression separately. 
 
6.2.1.1 HADS Anxiety  
 
6.2.1.1.1 Gender by HADS anxiety scale 
 



















6.2.1.1.2 Marital status by HADS Anxiety 
 






6.2.1.1.3 HADS Anxiety Scores by Household composition 








6.2.1.1.4 HADS Anxiety Scores by Employment Status 





6.2.1.1.5 HADS Anxiety scores by Incapacity Benefit status 
Kruskal Wallis Test  







6.2.1.1.6 HADS Anxiety scores by smoking status 




6.2.1.1.7 HADS Anxiety scores by total alcohol intake 
Kruskal Wallis Test Chi-Square=1.985 P=0.575 
 
No alcohol 225 (34.2%) 
0-5 Units per week 195 (29.7%) 
5-15 Units per week 203 (30.9%) 







6.2.1.1.8 HADS Anxiety by social class 





























6.2.1.2 HADS Depression scores by sociodemographic variables 
 
The following section will look at HADS depression scores by demographic variables 
 
6.2.1.2.1 HADS Depression scores by Gender 




6.2.1.2.2 Depression by marital status 








6.2.1.2.3 Depression by household composition 
Kruskal Wallis Test 4.297, P=0.507 
 
 
6.2.1.2.4 Depression by Employment status 






6.2.1.2.5 Depression by Incapacity Benefit Status 




6.2.1.2.6 Depression by Alcohol Units per week  
Kruskal Wallis Test, Chi=8.569 p=0.036 
 
No alcohol 225 (34.2%) 
0-5 Units per week 195 (29.7%) 
5-15 Units per week 203 (30.9%) 




6.2.1.2.7 Depression by Smoking Status 






6.2.1.2.9 Depression by social class 









In summary the significant predictors of Anxiety are: 
 
Gender*, Marital Status, Smoking, Incapacity Benefit*, Employment Status*, Social class 
 
The Significant predictors of Depression are: 
 
Smoking, Alcohol Consumption, Incapacity Benefit*, Employment Status*, Social Class 
 
 

























6.2.2 Disease predictors of affective disorders 
 
The following subsection of results will relate to whether disease phenotype may predict 




6.2.2.1 Crohn’s Disease 
 
 
Disease phenotype will be described by several factors. These are; age at which the subject 
was diagnosed with the disease, whether the subject was diagnosed before or after the age 
of 18, whether the subject has suffered from the illness for than 10 years and whether there 
is a family history of Crohn’s Disease. The second component of the phenotyping will relate 
to the site of disease at diagnosis and follow up and the Vienna Classification of the disease 
at diagnosis and follow up. 
 
The psychiatric phenotype will be defined in three ways. Firstly, the present level of 
affective disorder symptoms as measured by the HADS. Secondly, the past psychiatric 
history and thirdly by the reported use of psychiatric/psychological therapies. 
 
The psychiatric phenotype will then be correlated with the surgical history of the subjects. 
Finally, the psychiatric phenotype will be compared with the present inflammatory markers; 
White Cell Count, Erythrocyte Sedimentation Rate, C-Reactive Protein and Haemoglobin. 
These will all be correlated with the present gastroenterological symptoms of the subjects 
as measured by the Harvey Bradshaw Index. 
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6.2.2.1.1 Crohn’s Disease features and classification and psychiatric phenotype (HADS and 
self-report) 
 
The first table below shows Crohn’s phenotype and present affective symptoms as 


































Age at Diagnosis 
Pearson 
Correlation 
172 P=0.620 P=0.019 







Duration of years of 
illness </> 10 years 
Independent T-
test 
62 > 10years 





Family History of IBD 
Independent T-
test 
132 No FH 
40 with FH 
P=0.312 P=0.312 

























Classification of Illness 



































Classification of Illness 














6.2.2.1.2 The following boxplot shows HADS scores against Vienna Classification of Crohn’s 















Does the Subject have a Past History of 

























40 with FH 
132 without 
FH 
P=0.875 P=0.339 P=0.239 P=0.138 p=0.681 








99 no P=0.920 P=0.956 P=0.531 P=0.423 P=0.835 
Colon 
92 yes 
80 no P=0.492 P=0.785 P=0.962 P=0.566 P=0.942 
Rectum 
48 yes 
124 no P=0.915 P=0.604 P=0.322 P=0.968 P=0.459 
Anal/Perianal 
30 yes 




172 P=0.034 P=0.453 P=0.740 P=0.986 P=0.480 
Site of Illness 
at Follow Up 
                                    
Ileum   
47 yes 
125 no P=0.277 P=0.811 P=0.347 P=0.348 P=0.488 
Colon 
72 yes 
100 no P=0.760 P=0.606 P=0.564 P=0.468 P=0.803 
Rectum 
103 yes 
63 no P=0.778 P=0.712 P=0.540 P=0.349 P=0.794 
Anal/Perianal 
115 yes 
57 no P=0.409 P=0.574 P=0.068 P=0.281 P=0.371 
Classification 
at Follow Up 
(Vienna) 
172 P=0.175 P=0.280 P=0.817 P=0.959 P=0.885 
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Has the subject received the following treatments 
Antidepressant 
medication 





































40 with FH 
132 without 
FH 










99 no P=0.310 P=0.468 P=0.259  P=0.842 
Colon 
92 yes 
80 no P=0.711 P=0.079 P=0.447  P=0.580 
Rectum 
48 yes 
124 no P=0.548 P=0.759 P=0.162  P=0.476 
Anal/Perianal 
30 yes 




172 P=0.125 P=0.313 P=0.331  P=0.322 
Site at Follow 
Up                                                                                 
Oral 
9 yes 
163 no P=0.067 P=0.265 P=0.617  P=0.141 
                                    
Ileum   
47 yes 
125 no P=0.151 P=0.414 P=0.727  P=0.506 
Colon 
72 yes 
100 no P=0.769 P=0.509 P=0.258  P=0.213 
Rectum 
103 yes 
63 no P=0.469 P=0.620 P=0.026  P=0.589 
Anal/Perianal 
115 yes 
57 no P=0.443 P=0.489 P=0.001  P=0.021 
Classification 
at Follow Up 
(Vienna) 
172 P=0.108 P=0.396 P=0.491  P=0.337 
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97/172 172 16/172 17/172 98/172 172 74/172 
HADS A P=0.232 P=0.237 P=0.147 P=0.783 P=0.148 P=0.854 P=0.098 
HADS D P=0.032 P=0.044 P=0.410 P=0.045 P=0.033 P=0.118 P=0.017 
Depression P=0.991 P=0.262 P=0.558 P=0.550 P=0.513 P=0.385 P=0.218 
Anxiety P=0.164 P=0.326 P=0.859 P=0.673 P=0.726 P=0.042 P=0.056 
Antidepress
ants 
P=0.572 P=0.850 P=0.317 P=0.798 P=0.325 P=0.605 P=0.715 
Anti-Anxiety P=0.730 P=0.684 P=0.037 P=0.438 P=0.750 P=0.767 P=0.266 
Psychologic
al therapy 
P=0.354 P=0.600 P=0.584 P=0.274 P=0.418 P=0.316 P=0.370 




















6.2.2.1.2 Symptoms and inflammatory markers as predictors of psychiatric phenotype in 
subjects with Crohn’s disease 
 
 
The following section will look at self-reported symptom measures (Harvey Bradshaw 
Index), Inflammatory Markers (CRP, ESR, WCC, Calprotectin and Hb) and Psychiatric 
phenotype (HADS, past psychiatric history). 
 
6.2.2.1.2.1 The following graphs show correlation of HBI against HADS depression and 
anxiety for 323 subjects with Crohn’s disease 
 
Depression: Pearson correlation 0.482, Significance P<0.0001, Anxiety: Pearson Correlation 





6.2.2.1.2.2 Harvey Bradshaw Index against Inflammatory Markers 
 
 

















CRP ESR WCC Faecal Calprotectin 
Pearson Correlation 0.131 0.132 0.286** -0.431* 
Significance (P) 0.081 0.162 0.000 0.011 




`                           
 
 









Pearson Correlation 0.016 -0.078 -0.002 -0.120 -0.029 
Sig. (2-tailed) 0.828 0.415 0.973 0.498 0.663 
Number of subjects 180 113 225 34 229 
6.2.2.1.2.3 The following 
graphs show the relationship 
between HADS Anxiety and 
inflammatory markers. Here 



















Pearson Correlation 0.042 -0.035 0.041 -0.209 -0.043 
Sig. (2-tailed) 0.579 0.716 0.538 0.235 0.517 
Number of subjects 180 113 225 34 229 
6.2.2.1.2.4 The following 
graphs show the relationship 
between HADS Depression 
and inflammatory markers. 
























6.2.2.2 Ulcerative Colitis 
 
Disease phenotype will be described by several factors. These are; age at which the subject 
was diagnosed with the disease, duration of illness in years and whether there is a family 
history of Crohn’s Disease. The second component of the phenotyping will relate to the site 
of disease at diagnosis and follow up and the Montreal Classification of the disease at 
diagnosis and follow up. 
 
The psychiatric phenotype will be defined in three ways. Firstly, the present level of 
affective disorder symptoms as measured by the HADS. Secondly the past psychiatric history 
and thirdly by the reported use of psychiatric/psychological therapies. 
 
The psychiatric phenotype will then be correlated with the surgical history of the subjects. 
Finally, the psychiatric phenotype will be compared with the present inflammatory markers; 
White Cell Count, Erythrocyte Sedimentation Rate, C-Reactive Protein and Haemoglobin. 
These will all be correlated with the present gastroenterological symptoms of the subjects 


















6.2.2.2.1 Ulcerative Colitis features and psychiatric phenotype 
 
6.2.2.2.1.1 The first table below shows Colitis phenotype and present affective symptoms as 
















Age at Diagnosis 
Pearson 
Correlation 
121 0.016 0.959 




         121 0.986 0.436 
Family History of IBD 
Independent T-
test 
121 0.410 0.583 





121 0.268 0.064 
Classification of Illness 










































Does the Subject have a Past History of 















121 0.505 0.615 0.275 0.699 0.334 0.245 
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6.2.2.2.1.3 The following chart shows how surgical history may predict psychiatric 














Colectomy 0.175 0.030 0.453 0.525 0.085 0.231 0.837 
Ileo-Anal 
Pouch 
0.521 0.136 0.545 0.422 0.165 0.202 0.510 
Pouchitis 0.767 0.310 0.913 0.692 0.508 0.933 0.522 
Tonsillectomy 0.452 0.251 0.791 0.899 0.510 0.759 0.277 
Appendectomy 0.222 0.166 0.545 0.942 0.165 0.733 0.429 















6.2.2.2.2 Symptoms and inflammatory markers as predictors of psychiatric phenotype in 
UC 
 
The following section looks at the relationship between gastrointestinal symptom scores on 
the Colitis activity index, psychiatric phenotype on the HADS and inflammatory markers. 
 














6.2.2.2.2.2 The following section shows the relationship between Colitis activity index and 














Pearson Correlation 0.127 0.268* 0.237** 0.470* 
Sig. (2-tailed) 0.151 0.016 0.002 0.027 






















-0.014 0.084 0.033 -0.012 0.096 
Significance 0.873 0.460 0.662 0.958 0.207 
Number 130 80 173 22 174 
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0.002 0.104 0.076 0.049 0.149 
Significance 0.978 0.357 0.320 0.829 0.050 




6.2.2.2.2.5 The following section compares past psychiatric history with present 

















The following section of the results looks at univariate analysis of the effect of specific 
medications on current affective symptoms. Table below compares patients who are/are 
not taking each of the medications and their score on HADS anxiety and HADS depression. 
Many patients will be on more than one medication; as the number of permutations of 
different medication regimens is high, analysis will be performed on simple comparison of 
those who are/are not on one of each group. As HADS scores are normally distributed, 














































Here it can be seen that those on a corticosteroid medication (either prednisolone or 
budesonide) are have significantly higher scores on the HADS depression but not anxiety. 
Subjects on Anti TNF immunoglobulin, Adalimumab score significantly lower on both HADS 





6.2.3.1 Corticosteroid medication 
As it has been suggested that the depressogenic effects of corticosteroid medication are a 
consequence of long-term use, below are three results detailing the effects of this.   
In terms of prescription of Prednisolone in the last year (but not now), 113 patients have 
been compared with 465 who have not been taking this medication.  The 85 patients who 
presently take prednisolone are then compared with those who do not in terms of their 
current dose and duration of their prednisolone. Dose is based on self-report of daily dose. 
 





































Here it can be seen that those patients who have been on prednisolone in the last year have 
significantly higher depression scores than those who have not. Secondly it can be seen that 
the duration of prednisolone prescription is significantly correlated with both HADS Anxiety 
and Depression scores. Thirdly it can be seen that dose of prednisolone does not correlate 










































There appears to be no significant difference between those who are presently on or have been on 
prednisolone in the last year in terms of their ASRM score. The duration of prednisolone appears to 
















The following section of results will look at how socio demographic factors can predict 
aspects of the phenotype of inflammatory bowel disease. 
 
Here basic demographic factors will include gender, age, social class, employment status, 
alcohol usage, income capacity benefit status. 
 
The phenotype of inflammatory bowel disease will be represented by symptom scores on 
the HBI and CAI, inflammatory markers, past phenotype and past surgical history. 
 

























6.3.1 Crohn’s disease 
 
This section will look at how GI symptoms are reported by HBI in relation to demographic 
factors. 
 








t df Significance (P value) 
Crohn’s Harvey 
Bradshaw Index 
60/171 -2.703 169 0.008 
CRP 52/144 -.343 142 0.732 
ESR 43/106 -1.604 104 0.112 
WCC 59/167 -1.664 162 0.098 
Faecal Calprotectin 23/65 -.622 63 0.536 
Haemoglobin 59/165 .375 165 0.708 
 












The following chart shows one-way ANOVA for social class and symptom scores and 
inflammatory markers. Symptom scores on the HBI are significantly correlated with 

























 F Sig. 
Crohn’s Harvey Bradshaw 
Index 
 4.396 0.001 
CRP  1.163 0.332 
ESR  0.781 0.566 
White Cell Count  1.236 0.296 
Faecal Calprotectin  2.002 0.095 
Haemoglobin  .947 0.453 
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6.3.1.3 Marital Status 
 
The following shows how marital status relates to HBI symptoms and levels of inflammation 
 
 
Below is a chart of a one-way ANOVA showing that neither HBI nor inflammatory markers 
























 F Sig. 
Crohn’s Harvey Bradshaw 
Index 
 1.090 0.355 
CRP  1.475 0.224 
ESR  0.134 0.940 
White Cell Count  0.408 0.778 
Faecal Calprotectin  0.521 0.669 
Haemoglobin  0.572 0.634 
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6.3.1.4 Incapacity Benefit 
 





















 F Sig. 
Crohn’s Harvey Bradshaw 
Index 
 8.108 <0.0001 
CRP  3.662 0.028 
ESR  0.320 0.727 
White Cell Count  0.987 0.375 
Faecal Calprotectin  0.454 0.637 
Haemoglobin  0.773 0.464 
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6.3.1.5 Employment status 




The following chart shows that HBI correlates strongly with Employment status, but 














 F Sig. 
Crohn’s Harvey Bradshaw 
Index 
 7.337 <0.0001 
CRP  1.978 0.120 
ESR  0.101 0.959 
White Cell Count  1.849 0.141 
Faecal Calprotectin  0.904 0.444 





The following chart shows Pearson correlation between age and HBI and inflammatory 





































0.102 -0.075 -0.041 -0.014 -0.065 -0.045 
Sig. (2-tailed) 0.186 0.370 0.676 0.856 0.607 0.564 





The table below compares smokers with non-smokers in terms of scores on HBI and 
Inflammatory markers. There are no significant differences between groups. 
 
 
 T df Significance (P) 
Crohn’s Harvey Bradshaw Index 
-1.704 169 0.090 
   
CRP 
1.041 142 0.300 
   
ESR 
-.243 104 0.808 
   
WCC 
-1.148 162 0.253 
   
Faecal Calprotectin 
.870 63 0.388 
   
Haemoglobin 
.433 165 0.666 



















6.3.1.8 Alcohol Consumption 
 
The following table compares subjects who drink alcohol with those who do not in terms of 
HBI and inflammatory markers. There are no significant differences between groups on any 
of these measures.  
 
 T df Significance 
Crohn’s Harvey Bradshaw Index 1.696 169 0.092 
   
CRP .393 142 0.695 
   
ESR .276 104 0.783 
   
WCC -.093 162 0.926 
   
Faecal Calprotectin -1.480 63 0.144 
   
Haemoglobin -.954 165 0.342 




















6.3.2 Ulcerative Colitis 
 
The following section shows sociodemographic predictors of symptoms and inflammatory 







t df Sig. (2-tailed) 
Colitis Activity Index 
 -2.514 117 0.013 
 -2.609 116.089 0.010 
CRP 
 .068 89 0.946 
 .068 88.535 0.946 
ESR 
 -1.629 74 0.108 
 -1.683 73.969 0.097 
WCC 
 -1.510 116 0.134 
 -1.484 96.744 0.141 
Faecal Calprotectin 
 -1.232 36 0.226 
 -1.373 20.000 0.185 
Haemoglobin 
 -.516 116 0.607 




From the above it can be seen that females have significantly higher on the Colitis Activity 








Below is a Pearson correlation between age and CAI and Inflammatory markers. There are 









Pearson -.040 .153 .177 .090 -.096 .114 
Significance 0.665 0.148 0.126 0.332 0.568 0.219 
number 119 91 76 118 38 118 
 
6.3.2.3 Marital status 
Below is a boxplot and chart showing the association between marital status and symptom 




 F Sig. 
Colitis Activity Index  0.776 0.510 
CRP  0.502 0.682 
ESR  1.373 0.258 
WCC  1.190 0.317 
Faecal Calprotectin  0.382 0.767 




6.3.2.4 Incapacity Benefit 
 
Below can be seen the correlations between Incapacity Benefit and CAI and Inflammatory 
markers. Here ICB is correlated with CAI and CRP. 
 
 
 F Sig. 
Colitis Activity Index  5.374 0.006 
CRP  3.316 0.041 
ESR  0.818 0.446 
WCC  1.156 0.319 
Faecal Calprotectin  0.234 0.632 














6.3.2.5 Employment status 
 
Below is shown the correlation between employment status and CAI/Inflammatory Markers. 
There are no significant associations to be seen.  
 
 
 F Sig. 
Colitis Activity Index  1.851 0.142 
CRP  .054 0.983 
ESR  .179 0.911 
WCC  1.617 0.189 
Faecal Calprotectin  .967 0.419 





















 t-test for Equality of Means 
t df Sig. (2-tailed) 
Colitis Activity Index  -1.132 117 .260 
CRP  -1.220 89 .226 
ESR  -1.397 74 .167 
WCC  -1.744 116 .084 
Faecal Calprotectin  -.863 36 .394 


















6.3.2.7 Alcohol consumption 
 
Below are the correlations between alcohol consumption and CAI/Inflammatory markers. 




t-test for Equality of Means 
t df Sig. (2-tailed) 
Colitis Activity Index  -2.343 117 0.021 
CRP  -1.692 89 0.094 
ESR  -.372 74 0.711 
WCC  .290 116 0.772 
Faecal Calprotectin  .659 36 0.514 














Below is a scatter plot showing units of alcohol against CAI. There appears some suggestion 
of a “J” shaped relationship in which those who do not drink and those who drink 
















6.4 Multivariate Analysis 
 
The following section of the results will be the multivariate analysis. Multivariate linear 
regression analysis was used to identify the most important independent predictors of HADS 
anxiety and depression. All significant predictors were entered into the regression model for 
Crohn’s Disease or Ulcerative Colitis and HADS Anxiety or Depression. A forward stepwise 































 Harvey Bradshaw Index, CRP, ESR, WCC, 
Prednisolone now, Prednisolone in last 
year, Gender, Marital Status, Household 
composition, Smoking, Alcohol, 
Employment status, Incapacity Benefit 
Status, Disease duration, Disease Site, 



























 Simple Colitis Activity Index, CRP, ESR, 
WCC, Prednisolone now, Prednisolone in 
last year, Gender, Marital Status, 
Household composition, Smoking, 
Alcohol, Employment status, Incapacity 
Benefit Status, Disease duration, Disease 
























Here it can be seen that Gender, Incapacity benefit status, employment status, prednisolone 
in the last year and physical symptom indices represent independent predictors of Anxiety 
and Depression in this population. 
Below is multivariate analysis for predictors of physical symptoms: Harvey Bradshaw Index 
for Crohn’s Disease and Colitis Activity Index for Ulcerative Colitis. A forward stepwise 
model was then used to assess significance of independent variables. 
 












 HADS Depression & Anxiety, CRP, ESR, 
WCC, Prednisolone now, Prednisolone in 
last year, Gender, Marital Status, 
Household composition, Smoking, 
Alcohol, Employment status, Incapacity 
Benefit Status, Disease duration, Disease 








Colitis Activity Index 
  
0.172  
 HADS Depression & Anxiety, WCC, CRP, 
ESR, WCC, Gender, Marital Status, 
Household composition, Smoking, 
Alcohol, Employment status, Incapacity 
Benefit Status, Disease duration, Disease 







   
 
 
These results show that higher levels of reported physical symptoms are predicted by Gender, WCC 
and HADS Depression. 
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The discussion for this thesis will be divided into four main sections. These will be a 
description and discussion of the main results, critique of the methodology, implications of 




















7.1 Main results 
 
In total 655 patients were recruited to the ISA study of whom 254 had Ulcerative Colitis, 323 
had Crohn’s Disease and 78 had Coeliac disease. Of 752 patients attending the outpatient 
IBD clinic during the study, 578 (76.8%) were recruited. Of the IBD sample 293/578 (50.6%), 
were part of the original IBD cohort assessed between 2001-2004. Below is a flowchart 










The subjects recruited into the ISA study were compared to those recruited into the original 
sample. Below is a table showing a comparison of these groups which shows that there are 
no significant differences between them other than age. 
Variable Original sample 
not included in ISA 
ISA sample Statistical 
significance 
 
Year of birth 1958.85 1966.62 P=0.001 
Independent T test 
Gender 37.9% male 35.3% male P=0.535 Mann 
Whitney U 
Age at Diagnosis 33.4yrs 31.7yrs P=0.343 
Independent T test 
Family History 
Positive 
22.1% 24.2% P=0.647 
Independent T test 
Vienna 
Classification of 
illness at diagnosis 
  P=0.312 Mann 
Whitney U 
Number of Surgical 
procedures 
0.86 0.94 P=0.444 
Independent T test 









7.1.1 Socio Demographic Characteristics of IBD and Coeliac Patients 
 
Consistent with the epidemiology of IBD, the ISA cohort show a female preponderance 
(57.1%). However, when comparing Crohn’s Disease patients with UC and Coeliac disease 
with regards to other demographic variables many differences exist. Crohn’s patients are 
younger. Nearly half (48.8%) are martially single unlike UC (29%) and Coeliac Disease (34%). 
Crohn’s disease patients are also twice as likely to live with their parents. In other studies, 
55% of patients at diagnosis were married and 30% were single. (232)  
 
With regards to employment status, some 19% of Crohn’s Disease patients are unemployed 
compared to 10-11% UC and Coeliac disease. Furthermore 25% of Crohn’s Disease patients 
have been on ICB compared with 12% Coeliac and 16% UC. In other studies, when compared 
with the general population, patients with IBD were more likely to be unemployed. (232) 
Crohn’s disease appeared to affect employment more than ulcerative colitis. Here around 
10% of those with Crohn’s were unemployed at the time of diagnosis compared with 6% of 
UC. (232) This shows that the ISA population were different to other populations. 
 
In summary, Crohn’s disease patients are more likely to be unemployed, on ICB and living 
with parents than the other two groups. Some of these differences may be accounted for by 
age, but the increased use of ICB suggests that Crohn’s patients will have a far more socially 





7.1.2 Disease Characteristics 
 
In terms of disease characteristics, 43% of patients with Crohn’s disease are diagnosed 
between the ages of 20 and 29. The mean age of diagnosis is 27.1 years. In a meta-analysis, 
incidence rates for both CD and UC were highest among the second to the fourth decade of 
life. Therefore, IBD affects individuals in the most formidable and productive years of life, 
resulting in long-term cost to the patient, health care system, and society. (233) 
 
Twenty three percent of patients with Crohn’s Disease have a family history of the illness. 
The rates of familial IBD in probands ranges between 1.25% and 20% in other studies. (234) 
 
At diagnosis, patients present with disease in the Ilium (57%) and Colon (46.5%). These 
areas remain as the principally diseased areas. The prevalence of anal and rectal disease 
increases as the disease progresses. From other studies, at the time of diagnosis, 35-45 % 
had pure ileitis, 36-40 % had colitis alone, and 29-35 % had ileocolitis. (235) 
 
 
According to Vienna classification, the most common type of disease in this group is A2L1B1. 
Just 9% of patients are given an Ileal stoma for treatment of their disease. Fifty-six percent 
of patients have a bowel operation; 3.5% of patients have more than 3 operations. From 
systematic review of outcome in IBD, approximately half of the patients require surgery 10 
years after diagnosis. (235) This suggests that the patient group used in the ISA study may 




In Ulcerative colitis the mean age of diagnosis is 32.3 years, and 14.9% of patients have a 
family history of the illness. The most common site of disease at diagnosis is the hepatic 
flexure (81.2%). The most common type of disease at diagnosis is E2: Left sided UC (distal 
UC): Involvement limited to a proportion of the colo-rectum distal to the Splenic flexure. 
Just 7.5% of patients receive a Colectomy as part of the treatment. These findings are 
consistent with existent literature on the clinical phenotype of UC. (236) 
 
CRP is presently the most popular marker of measuring disease activity in IBD. Of 180 
patients with Crohn’s disease 85 (47.2%) had normal CRP and of 130 patients with UC, 72 
(55.4%) had a normal CRP. (236) While just 12.5% of patients had a normal Faecal 
Calprotectin, these were taken from just 56 patients of 315 who had immune markers 
available and are likely to represent those with more severe illness. This may be a sample 
bias as those who had this test were likely to be relapsing. It is therefore likely that around 
half of the patients in the ISA study had increased inflammation and consequently were 
likely to have active disease. Importantly those who had inflammatory markers in the 
normal range had all histological diagnoses of IBD. This is important as many population 
studies of IBD are unable to ensure subjects had prior histological diagnoses. 
 
 
7.1.3 Psychiatric phenotype 
 
Psychiatric phenotype has been defined by symptom scales, self-reported past psychiatric 





When considering psychiatric phenotype, there are several similarities and differences 
between IBD and Coeliac disease group. IBD patients reported the same rate of past 
psychiatric diagnoses as those with Coeliac. (There were no significant differences with 
regards to depression, anxiety, panic disorder, OCD and Bipolar illness). This may relate to 
the fact that patients with Coeliac Disease who presented to outpatient clinics for follow up 
were a more complex group or required more health service usage.  
 
Of note the rate of Bipolar illness in the IBD cohort is around 1% (6/657) which is what 
would be expected in community samples. The inclusion of self-reports of psychiatric 
medication or contact with mental health professionals is a measure of past psychiatric 
history which may not be accounted for by psychiatric diagnosis alone. Here, Coeliac Disease 
patients are very similar to IBD patients other than with regards to contact with a 
psychiatrist where the rate in IBD is twice that of coeliac disease. This may well represent 
the fact that patients with IBD have more severe psychiatric illness. 
 
There are several important findings with regards to the HADS scores of IBD and Coeliac 
Disease patients. There are no significant differences between mean scores for the three 
groups or between each pair of groups with regards to HADS total or HADS anxiety. There 
exists a significant difference between Crohn’s disease and the UC/Coeliac with regards to 
HADS depression scores. Patients with Crohn’s disease have higher depression scores than 
these other illnesses. There are many reasons which could account for this. As above, 
patients with Crohn’s have higher levels of unemployment and ICB. Patients are also more 
likely to be unmarried and younger. Patients with Crohn’s may have had earlier onset of 
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illness and have had greater adversity as a consequence. Crohn’s disease may simply be a 
more symptomatic and disabling illness. Crohn’s patients have had several surgical 
procedures compared with UC but surprisingly UC (by this argument) should have higher 
levels of depression compared with Coeliac disease.  
 
There are no differences between diagnoses with regards to Manic symptoms as measured 
by the ASRM. This suggests that the likelihood of bipolar affective illness is not mediated by 
presence of bowel illness. 
 
Of 578 patients with IBD, 148 patients (25.6%) had HADS Depression scores of 7 or over 
which is suggestive of current depressive illness. This is consistent with findings from other 
studies in chapter 3 in which rates of depression ranged from 22-62% in IBD outpatients. Of 
the 148 patients, 87 (58.7%) had never received either an antidepressant or any 
psychological intervention in the past. (Eighty-six, {58.1%} had never received any 
psychological intervention and 72 {48.6%} had never received an antidepressant).  
This finding suggests that around 15% of patients attending a GI outpatient clinic suffer from 
a depressive illness and are currently not receiving any treatment.  
 
This contrasts with 185 patients with IBD who report a past history of depression. Of these 
patients, 155 (83.8%) have received an intervention.  Those who have not received an 
intervention would be subjects who have erroneously reported depressive illness, those 
who had such a mild illness as to not warrant an intervention and those who refused or 
failed to comply with an intervention. As 83% of those who reported having depression 
received an intervention, it would suggest that the self-reporting in this instance may be 
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quite accurate. Furthermore, it would suggest that when patients attend the local services 
with depression, most are able to receive an intervention. 
 
Similarly, 330/655 (50.2%) patients report HADS anxiety scores of 7 or above suggestive of 
anxiety disorder. This is consistent with previous literature which shows that 33-65% of 
patients with IBD have clinical levels of anxiety as seen in chapter 3. Of 330 patients, just 
114 (34.5%) have received either a psychological or pharmacological intervention. This 
means that 32.9% of patients attending a GI clinic have clinical levels of anxiety and are 
presently receiving no intervention. This does not mean they have necessarily a diagnosable 
anxiety disorder such as Generalised Anxiety Disorder – indeed their primary diagnosis may 
be Major Depressive Disorder as part of which anxiety is a strong feature. Notwithstanding 
this caveat, there is clearly a high level of untreated (and largely undiagnosed) anxiety 
symptoms in this population. 
 
These findings represent an unmet need in the out-patient population. Such findings apply 
for both IBD and Coeliac disease patients.  
 
 
7.1.4 Medication usage 
 
 
With regards to medication, 85 (14.9%) patients are presently on prednisolone and 20 
(3.5%) were on budesonide. 113 (19.6%) were on prednisolone and 5 (1.0%) were on 
budesonide in the last year but no longer are. The range of prescription duration is likely to 
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represent several different clinical situations. Amongst these patients there will be those 
experiencing acute relapse who are likely to be on >20mg for a short period of time. 
Secondly there are those who are on a low dose of around 1mg for many years who are 
unable to stop taking this medication. Thirdly there are those who are undergoing a process 
of reduction of steroids following a resolving relapse. Other studies suggest that half of the 
patients receive steroids during disease course. (235) 
 
At the time of the study 17 (2.9%) patients were on Infliximab and 25 (4.5%) of patients 
were on Adalimumab. These anti TNF medications represent a small but significant group of 
patients who are likely to be suffering from severe disease. The use of Anti TNF medications 




7.1.5 Socio demographic predictors of Affective illness 
 
 
The first part of the univariate analysis has concentrated on socio demographic predictors of 
affective illness. When looking solely at the IBD cohort; gender, marital status, smoking, ICB 





Significant predictors of Depression include smoking, alcohol consumption, ICB and 
Employment Status but not marital status. Household composition appears to have no 
effect on either depression or anxiety.  
 
Female gender has been consistently associated with higher levels of affective symptoms. 
Similarly, being married is consistently associated with lower levels of affective symptoms 
compared with being single, widowed and divorced. The fact that marital status and 
household composition does not correlate with depression in this study may relate to a 
ceiling effect i.e. the presence of a disease is a more important modifier in this group. This is 
consistent with one other study in which marital status does not predict depression in this 
group (237). 
 
With regards to employment, those employed have lower levels of anxiety and depression. 
Those who are self-employed have the lowest levels. The direction of causality is unknown 
here. Are subjects more depressed or anxious because they are unemployed or have co 
morbid depression or anxiety illness prevented subjects from working? The choice to be 
self-employed may reflect either flexibility of working pattern leading to less 
depression/anxiety or a more self-reliant personality which has less tendency to 
depression/anxiety. ICB is likely to be a secondary index of unemployment. This is again 
consistent with other literature in which unemployment predicts depression in IBD (237) 
 
Alcohol usage and smoking may relate to affective illness in this study in several ways. High 
alcohol consumption may precede or follow affective illness. Alternatively, both smoking 
and alcohol consumption may be indices for low social class and multiple social adversities. 
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Hence these act as predictors of both affective illness and predictors of IBD. These represent 
well known sociodemographic associations in literature of depression. 
 
Of note there appears to be a trend for both anxiety and depression with regards to an 
association with social class. HADS depression and anxiety scores both increase from social 
class 1 through to social class 6. This is consistent with the body of literature on the social 
determinants of depression.  (237) 
 
In the context of the ISA study the socio demographic predictors of affective illness are 
important in that, given a high level of depression in the out patient population, social 




7.1.6 Disease predictors of depression 
 
 
In considering disease factors which would predict affective illness in this population, it may 
have been assumed that those with younger onset, longer duration of disease and more 
surgical procedures would experience more psychiatric illness. The picture presented in the 
results from this study is however more complicated. In most of the findings relating to 
severity of disease, depression is the most noticeable psychiatric phenotype whereas 




Age above 18 rather than below appears to predict depression as evidenced by past 
depression diagnosis, contact with mental health professional and current HADS depression. 
This finding may relate to a powering effect as only 36 patients with data were diagnosed 
below the age of 18. Notably those who have been diagnosed above the age of 18 are more 
likely to have seen a psychiatrist (whereas there are no differences in terms of contact with 
other mental health professionals). This may suggest that those diagnosed above the age of 
18 have more severe depression. This may also relate to the fact that the psychiatric 
sequelae of medical illness happen later in life. At the time of assessment in this study, early 
onset patients may not have developed their psychiatric presentations. 
 
Additional interpretations may relate to the fact that age of onset of depression is likely to 
be later in life or that young people may adapt to their illness at an earlier stage. Subjects 
diagnosed above the age of 50 may be experiencing other physical illness or have more 
financial or family responsibilities. As expected, duration of illness remains important and is 
correlated with depression but not anxiety. Indeed, the older age predictor may simply 
relate to duration of illness. 
 
There is no relationship between a family history of IBD and present or past psychiatric 
illness. It has been suggested that those with familial illness may have a more severe 
phenotype or younger onset. (233) Additionally, from a psychological perspective, 
witnessing IBD in a parent or other family member may lead to higher levels of distress. 
There is no evidence of this however from this study. Reasons may relate to a definition of 
“family history” being any blood relative and therefore negating an environmental and 





Although only pertaining to a small number of subjects, the presence of oral Crohn’s Disease 
appears to significantly relate to HADS Depression, past history of depression and 
experience of psychiatric treatments.  If this is a true relationship, there could be several 
explanations for this. Oral illness may be an index of severe disease or indeed a specific 
clinical subtype. Oral disease itself may be more distressing and disabling in terms of daily 
activities. As will be discussed later, oral disease may be an index of a possible cerebral 
pattern of inflammation. Conversely do patients with depression behave differently (for 
example, they smoke more or have worse dentition) and are more susceptible to oral 
disease. With either direction of causality, it may be noted that patients presenting with oral 
disease may well have depression and oral disease could be a useful index for screening. 
Similarly, there appears to be an association between joint problems in Ulcerative Colitis 
and depression. There appears to be no previous literature on these findings. 
 
 
Current HADS depression in Crohn’s Disease is significantly associated with having had a 
bowel resection, the number of bowel resections, having an ileal stoma and the total 
number of therapeutic surgeries. Similarly having a colectomy is associated with higher 
HADS in patients with Ulcerative Colitis. This is consistent with other work on depression in 
IBD where surgery is known to be a predictive factor for depression. (238) 
 
 It makes great sense that suffering incurred from severe illness as measured by extensive 
surgical treatment would be a predictor of current depressive symptomatology. However, 
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there are several other implications of this finding. Firstly, there is no relationship between 
HADS anxiety and any surgical history. Why should depression be the predominant 
psychiatric phenotype? From the time course of the study, the surgical history relates to 
interventions which have taken place over many years. It is possible that anxiety symptoms 
relate more to present difficulties rather than past ones. 
 
A second question which may relate to this association is about whether those with a prior 
depressive illness are more likely to have surgical treatment. Here depression may have led 
immunologically to a more severe disease. Alternatively, those who suffer from depression 
are more likely to use health services and have more surgery. It is beyond the scope of this 
study to be able to demonstrate a temporal association between onset of depression and 
subsequent need for surgery. However, it is possible, and consistent with literature, that 
those with depression undergo more surgical procedures as it has been shown that 
depressed patients have greater healthcare utilisation. (237) Irrespective of the direction of 
causality, patients who have a significant surgical history represent a high-risk group for 











7.1.7 Symptom and Inflammatory predictors of affective illness 
 
 
Thus far the results have focussed on categorical data which relates to current and past 
affective illness. We have seen that duration of illness and extent of surgical treatment 
predicts both past and present depressive illness. We will now turn to how 
contemporaneous levels of inflammation may relate to both affective illness and physical 
symptoms. There exist three hypotheses for this component of the study. Inflammatory 
markers CRP, ESR, WCC and Faecal Calprotectin are indicators of disease severity. 
Concurrently self-reported symptom measures Harvey Bradshaw Index (HBI) for Crohn’s 
Disease and Colitis Activity Index (CAI) for ulcerative colitis are also well validated measures 
of disease activity.  Psychiatric symptoms (HADS) should correlate with severity of disease 
measured by symptom reports. This may be due to depressive or anxiety symptoms arising 
due to the presence of physical symptoms (or physical symptoms being more noticeable in 
the context of a depressive illness). Psychiatric symptoms should also correlate with the 
level of inflammation, given what has already been discussed about common inflammatory 
disruption in both depression and IBD such as raised TNF and IL 2,6,10. 
 
In terms of hypotheses; HADS should correlate positively with physical symptom scores and 
inflammatory markers; physical symptom scores should correlate positively with 
inflammatory markers. 
 
In patients with Crohn’s disease, the results show that HBI correlates with WCC and Faecal 
Calprotectin but not CRP nor ESR. Similarly, in UC, CAI correlates with ESR, WCC and Faecal 
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Calprotectin but not CRP. It should be the case that symptom scores correlate with severity 
of disease. Given the sample size, the lack of correlation is unlikely to be a powering issue. It 
is therefore curious that this correlation is not very strong. The strongest marker is Faecal 
Calprotectin which, as a marker of intestinal disease, is the best predictor of disease 
severity. The lack of association between CRP and physical symptoms is difficult to 
understand but may relate to many asymptomatic patients.  
 
The second component of these results is the relationship between HADS and physical 
symptom scores HBI and CAI. Here we find that both HADS anxiety and HADS depression 
scales correlate strongly (p<0.00001) with HBI in Crohn’s Disease and CAI in Ulcerative 
Colitis. This is further supported by the fact that a past history of depression or anxiety 
illness and experience of psychiatric treatment leads to an increase in present reporting of 
physical symptoms for both Ulcerative Colitis and Crohn’s Disease. Why should physical 
symptom scores correspond strongly with psychiatric symptoms but only variably with 
disease severity? 
 
There are several possible explanations for these findings.  
 
i) HADS and physical symptom scores may be measuring similar things 
In a literal sense, HADS scales include questions about low energy and malaise as do CAI and 
HBI. Alternatively, it may well be that patients who are likely to report lots of symptoms on 





ii) There exists a common biology implicated in both gastroenterological and 
psychiatric symptoms. Nervous innervation of the gut from the 
parasympathetic and sympathetic nervous system is likely to be affected by 
anxiety through noradrenergic and adrenergic pathways. The presence of 
bowel frequency and urgency are likely to be related to sympathetic nervous 
system and anxiety. This connection may exist irrespective of the level of 
inflammation. Vagus innervation of the gut is partly moderated by Serotonin 
which is implicated in depression. (Although serotonin does not cross the 
blood brain barrier, such an explanation cannot easily be given.) Thus, it 
would be possible to separate the physical symptoms of pain, urgency, 
nocturnal defaecation and frequency from a quantitative level of 
inflammation. 
 
iii) Physical symptom reporting is accentuated in depression. Patients may 
notice physical symptoms more. Pain scores are higher in depressed subjects.  
 
iv) The most distressing aspect of having IBD is presence of symptoms.  Waking 
to pass stool, frequency and urgency could be the most distressing aspects of 
having this illness. Quantitative levels of inflammation may be less important 
in terms of quality of life than disability caused by symptoms. 
 
The third component of these associations is that there appears to be no correlation 
between psychiatric symptoms and any inflammatory markers. HADS Anxiety and 
Depression scales do not correspond with CRP, ESR, WCC and Faecal Calprotectin in both 
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Ulcerative Colitis and Crohn’s Disease. (Of incidental interest is the finding that low Hb in 
both illnesses corresponds with higher depression scores which is consistent with anaemia 
being a well understood cause of depressive syndrome. This is reassuring as it suggests that 
serology can in fact be associated with psychiatric symptoms consistently with previous 
literature). 
This finding is perplexing in the context of the thesis. 
 
i) Depression is associated with changes in IL 2, IL6 and IL 10 and TNF alpha. These 
cytokines are on the pathway for CRP levels. Depression should associate with 
CRP and consequently ESR. 
ii) Faecal Calprotectin is a strong marker of intestinal disease. Depression (or 
anxiety) should be likely to correlate to severity of disease even indirectly via 
symptoms. 
 
The possible explanations for this are 
 
i) The relationship between depression and inflammatory changes has been based 
on patient populations without acute inflammation. Patients with known 
autoimmune illness are generally excluded from studies of depression and 
inflammation.  
ii) The literature on psychoimmunology does not include severe levels of 
inflammation. It could be possible that above a ceiling level of inflammation the 
relationship does not exist 
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iii) CRP and ESR are poor markers. In much of the literature, HS CRP is used rather 
than normal CRP. It is possible that if cytokines were measured these would be 
altered. 
iv) The contribution of inflammation to depressive symptoms is small. This 
contribution is superseded by distress incurred by physical symptoms. 
 
In summary the relationship between affective symptoms, physical symptoms and 
inflammation is complicated. Results from this study go against the literature on 
psychoimmunology but are consistent with findings from clinical studies about a strong 




7.1.8 The role of corticosteroids in affective disorder in the IBD population 
 
 
A primary hypothesis of this study is that corticosteroids are an independent predictor of 
affective illness in this population. The results showed that in patients with Ulcerative Colitis 
or Crohn’s disease by univariate analysis 85 patients who are presently on Prednisolone 
compared with 578 who are not have significantly higher HADS Depression scores (p=0.026) 
but no difference in HADS Anxiety Scores (p=0.959). This supports the hypothesis that being 
on Corticosteroid medication predicts higher levels of depression symptoms but not anxiety 
symptoms. Secondly, having been on Prednisolone in the past year (but no longer being on 
the medication) is significantly associated with higher HADS Depression (p=0.033) but not 
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HADS Anxiety (p=0.081). Thirdly increased duration of prescription is related to higher 
depression scores, but dose is not. A fourth finding is that neither being on prednisolone nor 
having been on prednisolone is not significantly related to an increase in ASRM mania 
symptoms (p=0.172, p=0.501). Similarly, neither dose nor duration has any effect on the 
presence of manic symptoms. 
 
 
The finding that usage of corticosteroid medication is a predictor of depression is consistent 
with a large body of literature suggesting that this should be the case. As described in 
chapter 2, high levels of corticosteroid affect amygdala and hippocampus and are analogous 
to a chronic stress state. The finding that those who have been on corticosteroids but are no 
longer, is also consistent with a chronic stress model of depression. Furthermore, those who 
have ceased corticosteroids often report dependency symptoms. The finding that duration 
of prescription is associated with depression is also consistent with neuro endocrinological 
literature. The main difference from other studies is that dose of steroid does not appear to 
play a role. Early work into the psychiatric side effects of steroids pointed to the observation 
that patients would experience noticeable mood swings in the first days to weeks of starting 
a medication but that this effect would lessen over time.  In looking at subjects in this study 
who have been on corticosteroid for a week we do not find this. This may be due to the fact 
that the experience of physical illness or other factors play a larger role in depressive 
symptomatology. Furthermore, in earlier work the presence, nature or severity of the 
physical illness is not measured. Thus, the depressive symptoms observed at the time of 
steroid prescription are attributed to the steroids alone. As this part of the discussion is 
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focussing on univariate analysis, we will not concentrate here on the effect of disease 
symptoms or severity of inflammation as confounding factors yet. 
It would be important to conclude however that patients with IBD who are on or who have 
been on steroids for a long time are more likely to experience depressive symptoms. These 
patients would be a target group for screening.  
 
HADS anxiety does not correlate with corticosteroid usage. It would be imagined that this 
should do. The omission from the literature about anxiety may relate more to a publication 
bias rather than an absence of anxiety not relating to the HPA axis. Is there a separate 
biology underpinning anxiety and depressive illness which can be highlighted through the 
HPA axis dysfunction? 
 
An important finding is the lack of relationship between corticosteroid usage and ASRM 
manic symptomatology. Previous literature would suggest that a high dose of 
corticosteroids would cause an acute manic/psychotic reaction. The likelihood of this 
reaction would be determined by dose of the steroid and that potentially everyone could 
have such a reaction given a high enough dose. The findings from this study contradict this. 
Unlike other studies, ISA measures manic symptoms as a continuous measure rather than 
categorical diagnosis. As such it is possible to detect that some patients may notice some 
affective symptoms suggestive of mania (such as poor sleep, higher energy etc) but who do 
not have a full syndrome. It is clear that while many patients acknowledge some of these 
symptoms, they do not appear to correlate to corticosteroid medication. Furthermore, 
there is no effect of corticosteroids on the onset of manic symptoms. The literature reports 
that corticosteroid induced mania/psychosis occurs between 3-7 days of starting the 
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medication. We can show that that there is no increase in these symptoms in this time 
frame. The conclusion here is that a manic/psychotic episode caused by corticosteroid 
medication is likely to be an idiosyncratic response in predisposed patient rather than a 
dose effect. This is important as it suggests that, by analogy, environmental stress may only 
precipitate psychosis or mania in some individuals rather than it being a risk factor for all 
given a sufficiently major stressor.  
 
The limitations of these findings may derive from the measures used in the study. The ASRM 
has not been used in a medically ill population. Typically, it is used more for measuring 
change in a patient with diagnosed mania. The lack of categorical diagnosis could also be 
questioned but the main premise has been that manic side effects are dose dependent on 
corticosteroid and thus a dimensional measure appears more appropriate. Of note 
psychotic symptoms were not measured and thus no conclusion can be reached about a 





7.1.9 Role of anti TNF immune modulators in depression 
 
 A number of studies have pointed to a higher level of TNF alpha in patients with depression. 
Other studies, from work on patients with autoimmune illness, have shown an increase in 
mood prior to any change in physical health indicators, when these patients have been 




There have been three main hypotheses for the involvement of pro-inflammatory cytokines 
in the activation of depression.  As discussed in chapter 4, IL-6 and TNF-alpha are thought to 
either decrease levels of serotonin in the brain or activate the HPA axis (239, 240). One 
study describes an activation of the neuronal serotonin uptake transporters by these 
cytokines. (241) Other studies found that pro-inflammatory cytokines activate serotonin 
degrading enzymes (242). Both of these theories suggest that certain pro-inflammatory 
cytokines cause a decrease in synaptic serotonin which contributes to the developing 
depression. Another theory suggests that these cytokines have a role in depression related 
activation of the HPA system (243, 244). 
 
There have be many articles published which report a decrease in depressive symptoms in 
patients receiving Infliximab (IFX). As described in Chapter 4, it has been suggested that 
infliximab as well as other TNF-alpha antagonists may be therapeutic for somatic, cognitive 
and affective symptoms associated with the depressive symptoms in BD. It has remained 
unclear whether infliximab is having a direct therapeutic effect on depressive symptoms or 
whether it acts indirectly through relieving the autoimmune symptoms.  
 
 
One study looked at 6 Crohn’s disease patients on infliximab and showed that on Day 7 and 
56, when plasma levels of IFX decrease following last injection there was an increase in 
HADS, CDAI and CRP scores overtime.  (229) There was a correlation between physical 
symptoms and HADS. A further study looked at 23 CD and UC patients and showed that IFX 
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treatment was associated with a decrease in depressive score on IBDQ, and an increase in 
QoL. (247) 
 
In a study of 92 CD patients and IFX treatment was associated with more anxiety at time of 
injection but fewer depressive symptoms compared to other treatments. (248) One study 
followed 14 CD patients and IFX treatment showed a significant effect in reducing 
depression scores on CES-D. (249) Persoons et al. 2005 studied 100 CD patients and IFX 
treatment decreased the risk of earlier retreatment, improved CDAI and CRP scores. (250) 
Importantly there was a correlation in depression score and well-being in total group. 
However, it can be noted that it is impossible to determine in most of these studies whether 
the reduction in depressive symptoms relates to the IFX directly or whether this is a 
consequence of increased quality of life, decreased inflammation or decreased symptoms. 
Interestingly those with a high baseline serum CRP show a significant improvement in 
depression compared to control, whereas patients with normal CRP show no difference. 
 
The ISA study lacks longitudinal dimension which would allow a clearer understanding of the 
relationship between anti TNF medication and depression. However, it is powered to be 
able to control for the effects of inflammation and symptoms on the relationship between 
medication and affective disorder. The results from ISA show that patients on infliximab 
have lower levels of depressive symptoms (HADS-D) than those who are not on infliximab. 
These patients have no significant differences between their levels of symptoms, CPR, ESR, 
WCC and faecal Calprotectin. If anything, it is likely that those receiving infliximab are more 
likely to have (of have had) severe disease. Therefore, infliximab is probably associated with 
lower depressive symptoms and this reduction is not likely to be due to lower inflammation 
216 
 
or physical symptoms. The same is not true for Adulimamab but this may be due to 
powering effects. Just 12 patients were on Adulimamab at the time of study. There are two 
potential questions related to this finding. Firstly, it is possible that the reverse direction of 
causality is possible. Patients who report more symptoms due to their depression may be 
offered Infliximab. Lastly there may be a non-pharmacological benefit of Infliximab. 
Infliximab is offered by infusions and is generally delivered by specialist nursing staff. It is 




7.1.10 Socio Demographic predictors of GI symptoms 
 
 
There exists a widespread literature on the social determinants of health. General 
consensus exists that poverty and social inequality lead to increased levels of disease across 
the world. The ISA study includes data pertaining to social class, unemployment and other 
variables that facilitate the opportunity to look at this in an IBD population.  
 
Importantly, unlike many larger studies, data exists which includes physical symptoms, 
disease activity and sociodemographic variables. 
 
Gender is a common factor which has been looked at in terms of relationship to physical 
health measures. In the ISA cohort, consistent with other literature it can be seen that 
female gender is associated with higher levels of physical symptoms although there is no 
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relationship between gender and inflammation markers. This, as discussed above may be 
due to higher levels of depressive symptoms but also may represent sociological factors 
relating to socially derived gender differences and differences in health seeking behaviour. 
(237) 
 
When social class is addressed, we can see a significant trend towards higher physical 
symptom reporting in lower social classes. A trend towards a lower social class is 
represented by a higher level of symptoms. Concurrently there is no change in any 
inflammatory marker between social classes. This means that disease activity is non-
significantly differentiated by social class, but symptom reporting is. It is perhaps unusual 
that quantitative levels of disease are not, in fact, higher in lower social class.  
 
There are a number of ways this could be explained. Firstly, lower social class could be 
causative of higher levels of physical symptom reporting. This could be due to the 
experience of more social adversity of which disease was one of many difficulties causing 
more distress. Those in lower social classes may be experiencing higher levels of depression 
and anxiety and thus physical symptoms (as can be seen above) reflect this. Higher 
symptom reporting may also reflect style of engagement with health services. Are patients 
likely to be taken more seriously if they mention more symptoms? 
 
Secondly more physical symptoms may be causative of occupational situation and 
consequently social class by the terms used in this study. Those who had previous severe 
disease (but not now) may have lost jobs or not attempted nor succeeded in job promotion. 
Those who experience more symptoms may struggle to perform at work or may be less 
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likely to seek promotion. Those who experience more symptoms may be less likely to have 
completed education.  
 
There exists a literature which considers the role of social class and post code in relation to 
IBD. To date there is no evidence that IBD is differentially represented by social class. 
Furthermore, geographical living situation does not reflect this. Much public health 
literature is dedicated towards social determinants of health. However, this work often does 
not have both subjective symptoms and objective inflammatory markers. 
 
A third possibility would include confounders relating to both symptom reporting and social 
class. Here personality features and psychiatric illness may play a role. Patients with higher 
levels of external locus of control may be more likely to report symptoms and may be less 
able to attain higher skilled jobs.  Patients with aspects of certain personality disorders may 
be more help seeking and equally may struggle to progress in workplace environments.  
 
Following on from this, perceived stress (not measured) may be higher in lower social 
classes. This may be expressed in this study in terms of physical symptoms.  
 
In terms of multiple adversities leading to higher symptom reporting, it can be noted that 
neither marital status nor household composition predict change in symptom reporting for 
either Crohn’s disease nor Ulcerative Colitis. Age, smoking nor alcohol consumption status is 
predictive of symptom reporting variation. Importantly employment status and consequent 
incapacity benefit status do predict symptoms but not disease activity. This suggests that of 
factors associated with social adversity and deprivation, it is work above all others which 
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relate to reporting symptom irrespective of level of disease. Consistent with this, is the fact 
that those who have been previously on incapacity benefit (but no longer are), have higher 
symptom scores than those who are but lower scores than those who have never been on 
ICB. This would suggest that it could relate to level of meaningful activity which predicts 
symptom reports irrespective of disease activity. 
 
Another finding consistent with this is that those who are self-employed have lower levels 
of symptoms compared to those who are employed. Self-employment by definition requires 
strong internal locus of control. In the absence of sick pay, those who are self-employed 
should have higher need to dismiss symptoms.  
 
 
One further finding in this group is that those who drink alcohol have higher levels of 
symptom reporting in spite of no differences in disease activity. There is an arguable “J” 
shaped curve relating to physical symptoms and units of alcohol consumption. Here those 
who drink large amounts and those who do not drink at all have higher levels of symptoms. 
This may relate to background levels of mental illness – those who are able to drink 
moderately may be the most mentally healthy.  
 
An initial hypothesis could be that symptoms relate to a social function. The experience of a 
symptom and the need to voice this could relate in some way to there being someone to 
voice this to. However, this section of the results shows that neither marital situation nor 




We will see in the discussion of multivariate analysis the role depression may play in 
mediating some of these associations. However, from what can be seen here, meaningful 
activity as measured by social class and employment status appears to be a predictor of 
physical symptoms in the absence of variance in inflammation. 
 
 
7.1.11 Multivariate analysis 
 
Thus far the results discussed have related to univariate analysis. Both psychiatric and 
physical symptom measures have been associated with social, clinical and pharmacological 
predictors. There is a clear association between gender, employment, incapacity benefit 
status, marital status, physical symptoms, corticosteroid medication, infliximab, surgery and 
disease phenotype and depression and anxiety. There is also a clear association between 
socio demographic factors and physical symptoms. 
 
The multivariate analysis was conducted using forward stepwise regression. In patients with 
Crohn’s disease employment status, incapacity benefit status, and Harvey Bradshaw index 
were independent variables predicting both HADS anxiety and HADS depression. 
 
There are several important interpretations of this finding for Crohn’s disease. Firstly, this 
shows that physical symptoms are independently correlated with depression and anxiety. 
This correlation is independent of disease severity (as measured by inflammation), historical 
disease severity (as measured by surgical history, presence of stoma, duration of disease or 
age of onset) or prescribed medication as a proxy for disease relapse. This can be taken to 
221 
 
mean that those reporting high levels of physical symptoms have a stronger likelihood of 
depression than those with “worse” disease. This could mean that whatever the medical 
history of a patient with Crohn’s disease, it is reporting of physical symptoms which is most 
likely to indicate a raised likelihood of a depressive or anxiety illness.  
 
Secondly the presence of both employment status and incapacity benefit status as 
independent variables from each other is interesting. The fact that employment, or lack 
thereof, relates to the presence of depression and anxiety is not surprising. However, the 
fact that both employment status and in addition the present or past receipt of incapacity 
benefit is curious. This may represent two different mechanisms leading to depression. This 
follows a previous study wherein both unemployment and social deprivation are 
independent risk factors for affective disorder in IBD. (238) 
 
Before discussing this point further, it is important to note that while gender, marital status, 
smoking and alcohol are predictive of mental state in univariate analysis, these effects are 
not independent of employment and benefits. Thus, the social determinants of mental 
health appear, in this population, to derive from meaningful activity. This appears to be 
more important than severity of disease (as measured by the factors listed above). Thus, it is 
not the fact that a patient may have undergone several surgical procedures, nor that they 
have active disease but how they are able to subsequently return to work or role which 
predicts whether they will become depressed. 
 
The independence of employment status and incapacity benefit status is interesting. This 
would suggest that having a job is important but that when unemployed the decision to 
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receive incapacity benefit is also important. The decision to receive benefits may represent 
a series of psychological processes. From the data in this study, it would seem that such a 
decision and its ramifications for subsequent depressive illness, does not depend on severity 
of illness. If a patient with Crohn’s disease receives incapacity benefits, their likelihood of 
depression does not derive from severity of illness even if it is that severity of illness which 
may have led them to receiving these benefits. Thus, it may be perceived loss of long-term 
role which may be the most important element predicting depression or anxiety. 
 
The findings in Ulcerative Colitis differ from those in Crohn’s disease. Independent 
predictors of anxiety are incapacity benefit status, prednisolone in the last year and the 
colitis activity index. Independent predictors of depression Ulcerative Colitis are incapacity 
benefit status, prednisolone in the last year and gender. 
 
The presence of incapacity benefit status in both illnesses supports the hypothesis that the 
lack of meaningful activity irrespective of disease severity is a pathway into depression and 
anxiety. Here the absence of employment status is curious. As there is less unemployment 
in the UC group it may be that those who are unemployed are not so because of their 
illness. Whereas those on incapacity benefit are likely to be either the worse affected by 
illness or those who have other reasons for needing these benefits.  
 
Unlike with Crohn’s disease, gender is an independent risk factor for depression in UC. This 
is an unusual finding as other literature has shown that there are many characteristics of 
Crohn’s including infertility, obstetric complications and body dysmorphia secondary to 
higher rates of stomas which might suggest that women are more likely to be depressed. 
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Univariate analysis clearly shows that female gender remains a predictor of depression in 
Crohn’s, but this appears to be accounted for by other more depressogenic factors. The 
finding that female gender is a risk factor for depression at all is completely consistent with 
a large body of evidence. 
 
Finally, the finding that being on Prednisolone in the last year is an independent risk factor 
for depression in UC is an important finding from this study. While there exists good rational 
for the finding that corticosteroids should cause depression, this is the first study to find 
that this is the case when controlling for severity of illness, in terms of present 
symptomatology and inflammation. This finding has important implications for the 
management of all auto immune illnesses including asthma, eczema, rheumatoid arthritis 
and COPD. Should corticosteroid medication in and of itself lead to depression, its long-term 
prescription should be considered carefully in the management of chronic illness. This 













7.2 Methodology and Limitations 
 
7.2.1 Strengths of study 
 
The study was able to gain a large sample size; larger than any similar study of IBD. This 
made predictors of depression and anxiety possible for which many other social and clinical 
variables could be controlled. There were some aspects of data for which the number of 
samples was low such as faecal Calprotectin and prescription of inflixamab for which only up 
to 50 samples existed. However, overall statistically significant results were found when 
corrected for multiple comparison tests. 
 
It can be argued that there was little in the way of selection bias from the sample. Some 
76% of clinic attenders responded to the study. When looking at those in the original cohort 
compared to those captured up to 10 years later, there were no significant differences in 
terms of clinical or demographic data. This would suggest that those entering the study 
were a fair representation of an out-patient clinic population. 
 
The study gained from having both a prospective and cross-sectional arm. This has not been 
done in other studies of psychiatric phenotype in IBD. Unlike other IBD studies all subjects 
had a histological diagnosis of IBD. This study is unique in having biological, psychological 
and sociodemographic data from this patient population. 
 
Three areas which have been ignored in this study are personality measurements, perceived 
stress scales and life events recording. There is an existing literature on both of these and 
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while they may have added more to explain the variance of depression or anxiety in this 
group, they were omitted due the practicalities of extending the demand on subjects to 
participate. 
 







As outlined in the methodology section of the thesis, patients recruited to the ISA study 
were those with a histological diagnosis of IBD, aged 18-65, fluent English speakers and 
were attending a routine outpatient appointment at the gastroenterology department of 
the Western General Hospital, Edinburgh. 
 
The likely omissions in this group were those who had quiescent IBD and required no 
routine appointments during the sampling timeframe or those with severe illness such that 
they were inpatients in the above or another hospital. There exists a small private health 
sector in Edinburgh which may have seen some IBD patients, but the number is unknown 
though likely to have been small. The importance of this relates to whether a representative 
sample of patients according to social class, smoking, employment and alcohol usage was 
recruited in the study. Those who were very well or very unwell may have skewed the 
sample in both directions. However, given that 77% of the potential sample were recruited, 
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it may be fair to assume that this was representative. Following previous work, it may be 
deduced that those in remission/relapse would be likely to demonstrate altered levels of 
psychopathology though this could push the results in both directions, but the magnitude of 
this effect is unknown. In terms of general demographics, only four patients were 
approached who were unable to participate in the study due to problems with language; 
two of these did not have English as a first language, one was illiterate, and one had a 
learning disability. These patients are unlikely to have affected any results significantly and 
were ignored from the results and discussion. 
 
The prevalence of IBD varies internationally and Scotland may have higher levels than other 
countries. (204) The rates of depression in Scotland may also be higher than other countries, 
thus this sample could either represent potentially higher levels of psychiatric illness than 
that which may be seen elsewhere.  
 
In comparison with other work, the ISA has one of the largest sample sizes for this 
population. As has been described in the introduction, work in this field has either centred 
on a community sample which may not have histological diagnoses of IBD or hospital 
samples which are much smaller. It can be concluded that the ISA sample is likely to be 
representative of an out-patient population in a developed country and the psychiatric 







7.2.2.2 Coeliac disease 
 
Coeliac disease was chosen to be a comparator group for several reasons outlined in the 
introduction. Patients with coeliac experience chronic gastroenterological illness with 
similar symptoms to IBD, need for hospital out-patient appointments, contact with the same 
gastroenterologists as those who would see the IBD population. However, Coeliac disease 
patients would not exhibit clear inflammatory disturbance, although inflammation can be 
detected in the small intestine, use anti-inflammatory medication, use corticosteroids 
(except in extreme cases), surgery, in-patient admissions. Coeliac disease is unlikely to have 
impacted on patients’ lives including being able to maintain a job or a relationship in the 
way that IBD may do. 
 
Thus, the use of coeliac may have allowed a comparison of the experience of illness but 
without inflammation, steroid use and disability secondary to illness and intervention. 
Coeliac disease was also used to be able to control for the rates of depression by socio 
demographic variable. As can be noted from the results the number of coeliac patients is 
significantly smaller than the IBD group, however this has not affected the ability to power 
the main comparisons needed for the above questions. A question does arise as to the 
representativeness of the coeliac group recruited. As described in the introduction, patients 
with coeliac, when they get a diagnosis, need simply to adhere to a dietary plan. There is 
little in the way of medical intervention which is required. Coeliac can therefore be 
managed in a primary care setting. However, patients in this study all attended a secondary 
care coeliac disease clinic. This may suggest that they had complicated disease or exhibited 
comorbidity which was not able to be managed in primary care. As will be discussed below, 
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this group showed similar levels of psychiatric illness as the IBD group which may reflect 
how they were atypical coeliac patients.  
 
7.2.2.3 Prospective data 
 
Data for the ISA study comes from both the prospective and cross-sectional components. 
The prospective work was carried out between 2001 and 2005 and recruited sequential 
referrals to the IBD clinics for clinical phenotyping and genotyping. Patients were recruited 
based on diagnosis and willingness to participate. It is not known how many patients 
refused to participate in these rounds of data collection. However, for the purposes of 
gastroenterology research, participation in research is unlikely to be subject to sample bias 
in the same way as in psychiatric research. Personality and social class are unlikely to affect 
understanding pathogenesis of IBD in this work. Over many years the IBD group recruited 
2000 patients. However only some of these consented to specific aspects of the research 
and therefore there will exist some sampling bias where psychiatric phenotype is looked at 
latterly. 
 
Initially the study design aimed to recruit all those who were registered with the IBD 
database, however this excluded many new patients and furthermore many of the original 
patients were not attending outpatient appointments in the timeframe of the cross-
sectional arm of the ISA study. 
 
As can be seen, of 1160 patients with data, some 490 had deceased, moved area or were 
not due to attend clinic in the cross-sectional arm timeframe. However, when we compare 
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those in the cross sectional who were in the original cohort with those who were not, there 
are no significant differences in these groups with respect to age, age at diagnosis, family 
history, Vienna classification at diagnosis, number of surgical procedures and smoking 
status. These comparators, while not exhaustive, reflect a general appraisal that disease 
type, disease severity and socio demographic variables were not significantly different. This 
suggests that those patients who were initially recruited were not significantly different 
from those who were seen in the cross-sectional component of the study. 
 
 
There remains an important question as to why over 10 years some 490 patients were not 
captured in the cross-sectional component of the study. The possible clinical course of IBD 
allows for remission, remission following surgery or time between relapses lasting several 
years.  Although not measured in this study, the ethnicity of the ISA cohort was anecdotally 
largely white Scottish and did not present with the same level of migratory population as 
may have been seen in other illnesses or locations. The mortality rate in IBD is not very high 
such that it is unlikely that a large proportion of patients will have died over the 10-year 
period. The implications for psychiatric phenotyping are that, a proportion of patients 
entered into the study may have had mild disease and did not need to attend clinic which 
may have been associated with lower levels of psychopathology. Thus, the rate of 
psychiatric symptoms in IBD may be slightly higher in ISA sample. Alternatively, those who 
did not attend clinic during this time may have done so because of extreme social adversity. 
Importantly those who were/were not recruited to the initial cohort showed no differences 




7.2.2.4 Measurement used in the ISA study 
 
 
The following section will look at the measures used in the ISA study to identify any 
methodological flaws which may be as a consequence of choice of measures used. This will 
be divided into sociodemographic data, medication data, IBD disease data and psychiatric 
measures. 
 
In terms of sociodemographic data, much of the acquired data has relied on self-reporting 
measures. Here it is likely that subjects will under report smoking and alcohol usage. It is 
also possible that subjects may under estimate reliance on incapacity benefits and level of 
employment. Social class estimates have been based on self-report of occupation and 
extrapolation to I-VI social class definitions. Many patients in the study were students and 
were excluded from this definition. There are many ways in which social class can be 
defined and there exist more recent and accurate definitions. The system used here, while 
imperfect, simply represents a traditional and well used model. 
 
The use of self-reporting of medication prescription is open to some discussion. Patients 
may frequently forget or be unaware of the name, type and dose of their medication. Here 
both generic and brand name was used to try and cover most treatments. It is true that a 
better account of medication would have been a cross reference with GP records and 
pharmacy records. However, this was out with the scope of the study and not completed. 
Patients with a chronic severe illness such as Crohn’s or Colitis are often very likely to have 
great awareness of their medication. Of most importance was the prescription of steroids. 
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Evidence suggests that patients are very aware of being on steroids due to side effects and 
can often describe dose accurately. 
 
As discussed in the methodology section, much attention was paid to the use of the HADS 
scale as the primary measure of psychiatric phenotype. There were clear disadvantages in 
its use as this was a self-reported scale and could primarily give dimensional rather than 
categorical descriptions of psychopathology. Given that the HADS has been used extensively 
over the PHQ, Zung and Beck in IBD populations, it was deemed the best one to use so that 
results could be easily compared with other studies. In this study the HADS scale has been 
used as a dimensional scale with separate anxiety and depression arms rather than with cut 
offs. The main reason for this is that the cut offs are often arbitrary, and it was important to 
try and pick out patients with subclinical levels of depression and anxiety symptoms. Some 
of the main hypotheses were that steroid levels and inflammation levels were associated 
with mood. In this case it would be important to measure all variables as continuous rather 
than categorical data as in theory, small increments could cause subtle changes in mood. A 
further question relates to the division between anxiety and depression subscales. Much of 
the interest in co morbid mental and physical health relates to depression, and on this basis, 
it was important to get a pure depression scale. Furthermore, the available evidence 
suggests that depression, but not anxiety is likely to relate to corticosteroid usage. As the 
study was sufficiently powered to study this, most of the analysis was conducted with 
separate depression and anxiety outcomes. 
There exists an extensive literature on screening for depressive illness. There are already a 
number of tools available for this purpose and there have been several reviews assessing 




Pooled data on specific instruments is available for the Centre of Epidemiology Studies-
Depression scale (CES-D), General Health Questionnaire (GHQ), Medical Outcomes Study 
Depression Screen, and the Symptom Driven Diagnostic System-Primary Care scales.  More 
recent literature exists on bivariate meta-analysis of Patient Health Questionnaire-9 item 
(PHQ-9) and 2 item (PHQ-2) instruments. (208)  However, these scales were not compared 
with the other depression identification tools in clinical practice. 
 
The Cochrane Collaboration (208) published a meta-analysis of depression screening tools 
with bivariate outcomes. Importantly most of these analyses were not carried out in 
medically ill populations. 
 
Evidence was taken from the NICE guideline review group looking at the optimum scale for 
measurement in a medically ill population. This review was limited to identification tools 
used in UK clinical practice, that is, the BDI, PHQ, GHQ, CES-D, Geriatric Depression Scale 
(GDS), Hospital Anxiety and Depression Scale (HADS), Zung Self-Rating Depression Scale, and 
any 1- or 2-item measures of depression in primary care, hospital and community settings. 
‘Gold standard’ diagnoses were defined here as DSM-IV or ICD-10 diagnosis of depression. 
Studies were excluded if they did not clearly state that the comparator was DSM-IV or ICD-
10, used a scale with more than 28 items. (208) 
 
Of 129 studies, 77 studies were conducted in primary care or general medical settings and 
52 were on people with a chronic physical health problem.  16 were on the PHQ-9, five on 
the PHQ-2, seven on the Whooley, 18 on the BDI, five on the BDI short form, five on the BDI 
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fast screen, 28 on the GHQ-12, 17 on the CES-D, 27 on the GDS, 26 on the GDS-15, 24 on the 
HADS-D.  
 
Of the above scales only the HADS and the ZUNG have validated measurements of mild, 
moderate and severe depression.  
 
The Patient Health Questionnaire (PHQ) (211) in both consultation and chronic physical 
health problem populations was found to have good sensitivity and specificity.  
 
The Beck Depression Inventory (BDI) (210) and subsequently the cognitive–affective 
subscale of the BDI has often been used to identify depression (210).  The BDI appeared to 
perform relatively well in terms of sensitivity (0.85, 95% CI, 0.79, 0.90) and specificity (0.83, 
95% CI, 0.70, 0.91). However comparable sensitivity (0.85, 95% CI, 0.79, 0.89) but lower 
specificity (0.73, 95% CI, 0.65, 0.79) was found for this scale in people with a chronic 
physical health problem. 
 
Data from the BDI-fast screen (210) were combined to assess the impact of removing 
somatic items since data from both scales were relatively sparse. There was sufficient, 
although relatively low, consistency between studies to assess these scales (BDI: non-
somatic) in consultation populations and those with a chronic physical health problem. In 
populations with a chronic physical health problem, the BDI non-somatic scales performed 
relatively similarly. The instruments were associated with relatively high sensitivity (0.87, 




The General Health Questionnaire (GHQ) (211) was developed as a general measure of 
psychiatric distress and measures a variety of constructs such as depression and anxiety.  
There were only two trials of the GHQ-28 in patients with a physical health problem. There 
was relatively high sensitivity (0.84, 95% CI, 0.59, 0.95) but less specificity (0.75, 95% CI, 
0.70, 0.79) found for this scale in people with a chronic physical health problem. 
 
The Hospital Anxiety and Depression Scale (HADS) (213) is a measure of depression and 
anxiety developed for people with physical health problems. The depression subscale has 
seven items and the cut-off is 8 to 10 points. A total of 21 studies have been conducted, 
however meta-analysis could not be conducted due to very high heterogeneity for all 
subgroups including consultation populations and older adults. Notably this scale has been 
used extensively for patients with Crohn’s disease and Ulcerative Colitis. (See chapter 3) 
 
In view of the many possible available scales, the decision was made to use the HADS as:  
1. Sensitivity and specificity compared favourably with all other scales 
2. Both sensitivity and specificity became lower in other scales when used on a 
medically ill population 
3. The HADS has been extensively used in populations with Crohn’s Disease and 
Ulcerative Colitis 
4. The HADS has been used on other English-speaking Scottish populations of similar 
demographic  
 
Little literature exists as to measurement of manic symptomatology in a medically ill 
population. As discussed in the methodology, most scales looking at mania are either a 
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categorical diagnosis or severity based in patients with known illness. It is likely that ASRM 
was insufficient to detect new cases of bipolar illness – if anything scores correlated well 
with HADS scores which may mean, at best, they are another measure of affective illness.  
 
 
The use of self-reported measures of past psychiatric history may also be questioned. An 
improved way of doing this would have been to cross check self-reports with GP data and 
psychiatric records. This was beyond the scope of the ISA study but based on result which 
patients provided, past psychiatric history appeared to be reported in a range expected by 
epidemiological data.  
 
 
The gastroenterological scores used (CAI, HBI) are well validated tools used in many similar 
studies. Of note, some of the symptoms in these scales could apply to both physical and 
psychiatric symptom scores such as general malaise. Before the actual study the IBDQ was 
trialled in a pilot but it was clear that to gain an optimal sized sample a shorter 
questionnaire would be best. The advantage of the prospective element of this study is that 
all data relating to disease staging and typing and all surgical history was collected blind to 
future psychiatric assessments. Here both Vienna and Montreal classification systems are 
well validated systems of classifying IBD.  
 
Many of the original hypotheses for this study had been predicated on the idea that specific 
inflammatory changes notable IL-2, IL-6, IL-10 and TNF alpha were abnormal in both 
depression and IBD. As can be noted these were not measured in the patient group due to 
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the study design. Measurements of inflammation used were CRP, ESR, WCC and faecal 
calprotectin. The correlation between these markers and the above cytokines may not be 
ideal but may have represented a rough measure of inflammatory process. Of note Hs CRP 
has been the measure used in many of the depression studies in this area. The choice of 
these markers was based mainly on their easy availability in a clinic setting and the fact they 
would have been routinely done on the patients.  Work on cytokines in depression has 
mostly been conducted in psychiatric populations who are medically well. Thus, this 
represents an early piece of work in looking at patients with known inflammation and 
psychiatric phenotype. Of note not all patients underwent inflammatory markers collection. 
Those who did would be patients needing closer monitoring of their illness which may 
reflect a deterioration or improvement in their condition. Patients with long term stable 
illness would not have been investigated. This does not diminish the relationship between 
psychiatric phenotype and inflammation however as patients were not selected because of 
known levels of psychiatric phenotype or known inflammatory levels. Those who gave 
samples for faecal Calprotectin levels were likely to have more severe disease and are 











7.3 Discussion: Implications of the main findings and future research 
 
7.3.1 Prevalence of psychiatric illness in IBD 
 
A first and consistent finding from this study is that depression and anxiety remain high in 
the target population. While this finding is not new it supports other literature that this is 
the case and it remains worrying that a large number of patients with IBD not only have high 
levels of depression and anxiety, but a significant proportion are undiagnosed and 
untreated. These findings support the development of liaison psychiatry services in 
gastroenterological illness. Awareness that comorbid depression does lead to increased 
health service usage highlights the strong argument for integrated care in this area. 
 
7.3.2 Disease predictors of Depression 
 
In the univariate analysis, we see that patients who have strong surgical histories, have a 
stoma and who have oral disease are more likely to have a depressive illness. Such findings 
support the idea of targeted screening in such patients.  
 
7.3.3 Socio demographic predictors of depression 
 
The strongest predictors of psychiatric phenotype in this population were unemployment 
and incapacity benefit status. There are two implications from such findings. Firstly, as 
above it can be argued that the group of those on ICB or unemployed could be high risk 
groups who should be screened for depression. The second implication is that, beyond 
238 
 
severity of illness, it is loss of role or lack of meaningful activity which is closely associated 
with mental health. These themes are often taken up in Interpersonal therapy and to a 
lesser degree in Cognitive Behavioural Therapy. This tells us that specific therapeutic targets 
such as cognitions around usefulness and purpose may be the key to understanding 
depression in this population. It also implies that there may be a role for supporting patients 
back to employment may be useful in managing long term medical conditions in ensuring 
patients are able to work or be active in some way.  
 
7.3.4 Physical symptoms and psychiatric symptoms 
 
The finding that there is a close and independent relationship between physical symptoms 
and psychiatric symptoms is not new. However, given the available data in this study of 
inflammatory markers it adds new implications to the literature. Having an objective 
measure of disease severity in this study shows that mood is a far stronger driver than 
inflammation in expression of physical symptoms. While the patient’s history should never 
be ignored, an interesting question is to what degree physician’s decision to investigate a 
patient or treat a patient is based on history rather than objective findings. That is not to say 
that symptom management is not a reason for not treating or operating but to highlight the 
possible role of psychology or psychiatric illness where there is a significant disparity 
between reported symptoms and quantitative disease. Highlighting such a finding to 
gastroenterologists may reduce the need for unnecessary investigations and surgery. The 
literature around medically unexplained symptoms become complicated when patients 
have an actual physical disease and their symptoms can, in part, potentially be explained by 
that disease. In IBD this study can show that mood and anxiety drive symptoms considerably 
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more than disease which would be useful information for a gastroenterologist to take in to 
clinic. 
 
7.3.5 Corticosteroids as predictors of depression 
 
Arguably the most important finding from this work is that corticosteroids represent an 
independent risk factor for depression – independent from severity of disease or physical 
symptoms. It is not surprising that this is the case given what has already been discussed but 
this is the first study to show this. Patients on long term steroids should be screened for 
depression. It can be stated that their depression is not just a product of chronic disease but 
the steroids themselves. This has clear implications for almost every medical specialty and 
the chronic disease management of asthma, eczema, COPD, arthritis etc. The importance of 
this finding is also that it can argue for a change in the role of Liaison psychiatry. Hitherto it 
has been the role of liaison psychiatrists to advise medical teams on the psychiatric 
management of their patients. This finding would support the idea that the decision to 
initiate/continue/discontinue different immunotherapies (including corticosteroids) for a 
physical illness could be as much a psychiatric as a medical decision. 
 
7.3.6 Corticosteroid dose does not predict mania 
 
The available literature suggests that dose increase of corticosteroids leads to a 
manic/psychotic reaction. This study refutes this idea as there appears to be no relationship 
between steroid dose and affective symptoms across a large population. This study suggests 
that a manic or psychotic reaction to steroids is an idiosyncratic reaction and that those who 
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experience this must have some genetic predisposition to this. This may be comparable to 
puerperal psychosis or drug induced psychosis.  
 
7.3.7 Anti TNF medications increases mood 
 
Consistent with other literature, this study shows that anti TNF medications increase mood. 
While a prospective study would be able to demonstrate causality better, here we are able 
to show cross-sectionally that the increase in mood does not correspond to differential 
inflammation levels, symptom scores or severity of past illness. This finding may not have 
direct applicability to a gastroenterological environment as it would be hard to argue that in 
this group, such agents should be used principally for its antidepressant action however it 





7.3.9 Future research 
 
There exist several lines of future research which hopefully can emanate from this study. 
 
7.3.9.1 Untreated depression in the outpatient population 
 
It would be interesting to further research the factors which lead to poor detection and 
treatment of depression in this patient group. While obvious answers would include the lack 
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of resources and skills to do so, other ideas such as stigma about mental health or how to 
improve access to psychiatric case notes may aid this. 
 
7.3.9.2 Cognitive schema of those with depression in the medically ill 
 
What are the underlying common features of those who have IBD and are depressed? Do 
those with either depression or anxiety have negative thoughts about appearance, social 
anxiety with regards to bowel frequency or urgency or generalised feelings of failure? 
 
7.3.9.3 Immunological basis of depression in medical illness 
 
The ISA study was unable to look at specific immune markers such as TNF alpha, IL 2,6,10 
which have shown to be elevated in depression. The study has shown that inflammatory 
markers measured do not vary significantly with mood. However, it may be that more 
sensitive measures are needed to show this. 
 
7.3.9.4 What predicts corticosteroid induced psychiatric illness.  
 
This study has shown that long term corticosteroid use is associated with depression but 
that there is no dose relationship between corticosteroids and mania. What are the genetic 
or endocrinological predisposing factors which mediate these associations? Genes such as 





7.3.9.5 Where can anti TNF immunoglobulins be used in psychiatric practice 
 
Given the emerging literature demonstrating the antidepressant action of these 

























The ISA study sought to look at the complex relationships between physical illness, 
medications and psychiatric phenotype. It has shown that socio demographic factors, 
disease factors and medication all exist as independent risk factors for depression and 
anxiety in this group. The study has been powered to demonstrate the independence of 
these factors and as such has achieved its main aims. The findings call for a more substantial 
role of psychiatric involvement in the care of patients with physical illness. Importantly 
there are key target areas such as corticosteroid medication which psychiatrists may 
consider as methods of improving patient care. Disappointingly the study was not consistent 
with the emerging area of psycho immunology. As stated above this may be due to the lack 
of sensitive measures but may also be due to either a ceiling effect of other factors or that 
the variance accounted for by immunology is in fact small. 
 
The study hopes to support and develop the role of liaison psychiatry as a clinical specialty. 
The skills of a psychiatrist lie, in part, in gaining a good history from the patient. That 
physical symptoms and psychiatric symptoms are closely related, suggest that a 
comprehensive medical history may eliminate the need for increased and unnecessary 
investigations and hopefully unnecessary treatments. A liaison psychiatrist is well placed to 
coordinate the biological, psychological and social elements of a patients care. Thus, the 
importance of social predictors of depression and the need to understand the importance of 
loss of role is a function which psychiatry or indeed psychology can help with.  It was hoped 
that psychoimmunology could allow psychiatrists a greater role in understanding depression 
in IBD as the cerebral component of a multisystemic illness. While this has not happened in 
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this study, the finding that anti TNF immunoglobulins can have antidepressant action is a 
starting point. Along with the findings about corticosteroids, this suggests that psychiatry 
(and not just psychology) may have an active role in the management of chronic medical 
illness.  
 
If the gastroenterological teams of the future can be comprised of psychiatrists and 
psychologists, this may lead firstly to the better detection and treatment of mental health 
but the subsequent improvement in physical health care. The recent call for parity of 
esteem between physical and mental health care and the call for increased liaison 
psychiatry services in general hospitals are both consistent with the findings of this thesis.  
 
Such development of services has commenced in oncology and diabetes and this work 
hopefully supports the need for commensurate services in IBD.  Studies in oncology and 
diabetes have shown that therapeutic interventions are feasible and conclusively lead to not 
only improved mental but also physical health care outcomes.  
 
In conclusion, it is hoped that the ISA study will add to existing literature on 
psychoimmunology, support the role of liaison psychiatry in medical teams and ultimately 
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